{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "e886e453",
   "metadata": {},
   "source": [
    "# Web Scraping"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "2d6840ba",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Libs for web scraping\n",
    "import os\n",
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "from urllib.parse import urljoin\n",
    "import re\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "2b17e41c",
   "metadata": {},
   "outputs": [],
   "source": [
    "url = \"https://sheffield.ac.uk/nice-dsu/tsds/full-list\"\n",
    "folder_name = \"NICE_TSD_PDFs\"\n",
    "\n",
    "# Create the folder if it doesn't exist\n",
    "if not os.path.exists(folder_name):\n",
    "    os.makedirs(folder_name)\n",
    "    print(f\"Created folder: {folder_name}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "bd426bb1",
   "metadata": {},
   "outputs": [],
   "source": [
    "response = requests.get(url)\n",
    "response.raise_for_status()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "7eeac947",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<!DOCTYPE html>\n",
       "\n",
       "<html class=\"no-js\" dir=\"ltr\" lang=\"en\" prefix=\"og: https://ogp.me/ns#\">\n",
       "<head>\n",
       "<!-- OneTrust Cookies Consent Notice start for sheffield.ac.uk -->\n",
       "<script src=\"https://cdn-ukwest.onetrust.com/consent/a3110129-5f04-4e81-9c5e-b494a7836315/OtAutoBlock.js\" type=\"text/javascript\"></script>\n",
       "<script charset=\"UTF-8\" data-domain-script=\"a3110129-5f04-4e81-9c5e-b494a7836315\" src=\"https://cdn-ukwest.onetrust.com/scripttemplates/otSDKStub.js\" type=\"text/javascript\"></script>\n",
       "<script type=\"text/javascript\">\n",
       "function OptanonWrapper() { }\n",
       "</script>\n",
       "<!-- OneTrust Cookies Consent Notice end for sheffield.ac.uk -->\n",
       "<meta charset=\"utf-8\"/>\n",
       "<meta content=\"All the technical support documents produced by the Nice DSU. The TSDs have the aim of providing further information about how to implement the approaches described in the current Guide to the Methods of Technology Appraisal (2022).\" name=\"description\"/>\n",
       "<link href=\"https://sheffield.ac.uk/nice-dsu/tsds/full-list\" rel=\"canonical\"/>\n",
       "<meta content=\"NICE Decision and Technical Support Unit\" name=\"group_name_short\"/>\n",
       "<meta content=\"Basic\" name=\"content_type\"/>\n",
       "<meta content=\"41502\" name=\"node_id\"/>\n",
       "<meta content=\"The University of Sheffield\" property=\"og:site_name\"/>\n",
       "<meta content=\"Full list of technical support documents (TSDs)\" property=\"og:title\"/>\n",
       "<meta content=\"All the technical support documents produced by the Nice DSU. The TSDs have the aim of providing further information about how to implement the approaches described in the current Guide to the Methods of Technology Appraisal (2022).\" property=\"og:description\"/>\n",
       "<meta content=\"2025-07-16T10:09:55+0100\" property=\"og:updated_time\"/>\n",
       "<meta content=\"The University of Sheffield, Western Bank, Sheffield\" property=\"og:street_address\"/>\n",
       "<meta content=\"S10 2TN\" property=\"og:postal_code\"/>\n",
       "<meta content=\"UK\" property=\"og:country_name\"/>\n",
       "<meta content=\"0114 222 2000\" property=\"og:phone_number\"/>\n",
       "<meta content=\"en_GB\" property=\"og:locale\"/>\n",
       "<meta content=\"Full list of technical support documents (TSDs)\" name=\"dcterms.title\"/>\n",
       "<meta content=\"2025-07-16\" name=\"dcterms.date\"/>\n",
       "<meta content=\"summary_large_image\" name=\"twitter:card\"/>\n",
       "<meta content=\"@SheffieldUni\" name=\"twitter:site\"/>\n",
       "<meta content=\"Full list of technical support documents (TSDs)\" name=\"twitter:title\"/>\n",
       "<meta content=\"All the technical support documents produced by the Nice DSU. The TSDs have the aim of providing further information about how to implement the approaches described in the current Guide to the Methods of Technology Appraisal (2022).\" name=\"twitter:description\"/>\n",
       "<meta content=\"Drupal 10 (https://www.drupal.org)\" name=\"Generator\"/>\n",
       "<meta content=\"width\" name=\"MobileOptimized\"/>\n",
       "<meta content=\"true\" name=\"HandheldFriendly\"/>\n",
       "<meta content=\"width=device-width, initial-scale=1.0\" name=\"viewport\"/>\n",
       "<meta content=\"false\" http-equiv=\"ImageToolbar\"/>\n",
       "<script defer=\"\" src=\"//cdn.sheffield.ac.uk/sites/default/files/google_tag/primary/google_tag.script.js?t9ba4o\"></script>\n",
       "<title>Full list of technical support documents (TSDs) | NICE Decision and Technical Support Unit | The University of Sheffield</title>\n",
       "<link href=\"//cdn.sheffield.ac.uk/sites/default/files/css/css_9EaxU3dvkfpOw76xoU8JaRITk81KIOhmuThnJMfJSFM.css?delta=0&amp;language=en&amp;theme=uos_public&amp;include=eJxNj2tuwzAMgy_kxkcSZFtptTmWq0eG7PRLg2HdH4H6SAlg_aTGLgpYq2hjGflPLavKcBot0XD2A2gr1HLF6aebPp5BekAwYLhU2WYnp_x_SR0PCYfGVmU_01kGVelpouJdcT4sN42JfXmTJcaM0tke1JKSTRnGO4Fj6QQrdyfNb367eLLDnLZc0CiFGFwvar53KdjTzvRl-ZrLJi3Og-_QAqvEaPiq85v8AQBhbFs\" media=\"all\" rel=\"stylesheet\"/>\n",
       "<link href=\"//cdn.sheffield.ac.uk/sites/default/files/css/css_pQN7DEryLhTbQ8I6jCEm3mbpvu0OLmsCcUzhinHEMyw.css?delta=1&amp;language=en&amp;theme=uos_public&amp;include=eJxNj2tuwzAMgy_kxkcSZFtptTmWq0eG7PRLg2HdH4H6SAlg_aTGLgpYq2hjGflPLavKcBot0XD2A2gr1HLF6aebPp5BekAwYLhU2WYnp_x_SR0PCYfGVmU_01kGVelpouJdcT4sN42JfXmTJcaM0tke1JKSTRnGO4Fj6QQrdyfNb367eLLDnLZc0CiFGFwvar53KdjTzvRl-ZrLJi3Og-_QAqvEaPiq85v8AQBhbFs\" media=\"all\" rel=\"stylesheet\"/>\n",
       "<meta content=\"#440099\" name=\"theme-color\"/>\n",
       "<link href=\"/themes/custom/uos_public/favicon.ico\" rel=\"icon\" sizes=\"any\"/>\n",
       "<link href=\"/themes/custom/uos_public/favicon.svg\" rel=\"icon\" type=\"image/svg+xml\">\n",
       "</link></head>\n",
       "<body class=\"public lang-en section-nice-dsu path-node node--type-page whitecontent\">\n",
       "<a class=\"visually-hidden focusable skip-link\" href=\"#main-content\">\n",
       "    Skip to main content\n",
       "  </a>\n",
       "<div class=\"muse-bar-container\">\n",
       "<div class=\"muse-bar smooth-criminal\">\n",
       "<nav aria-label=\"MUSE menu\" class=\"muse\">\n",
       "<ul class=\"muse-nav\">\n",
       "<li class=\"switcher-container\"><a class=\"switcher-button\" href=\"/\"><i class=\"fas fa-home fa-lg\" title=\"Home\"></i></a>\n",
       "</li>\n",
       "</ul>\n",
       "</nav>\n",
       "<div class=\"site-search\" role=\"search\">\n",
       "<div class=\"site-search-wrapper search-autocomplete\">\n",
       "<form action=\"/find\" method=\"get\">\n",
       "<label class=\"show-for-sr\" for=\"site-search-box\">Search sheffield.ac.uk</label>\n",
       "<div class=\"search-autocomplete__inputs\">\n",
       "<input aria-autocomplete=\"list\" aria-haspopup=\"true\" aria-label=\"Search our site\" autocomplete=\"off\" class=\"site-search-input\" id=\"site-search-box\" name=\"query\" placeholder=\"Search our site\" required=\"\" type=\"search\"/>\n",
       "<input name=\"f.Tabs|AllDocumentsFill\" type=\"hidden\" value=\"All results\"/>\n",
       "</div>\n",
       "<button aria-label=\"Site search\" type=\"submit\">\n",
       "<i class=\"fas fa-search\"></i>\n",
       "</button>\n",
       "</form>\n",
       "</div>\n",
       "<button aria-label=\"Open site search dropdown\" class=\"site-search-toggle hide-for-medium\" type=\"button\">\n",
       "<i class=\"fas fa-search\"></i>\n",
       "<i class=\"fas fa-times\"></i>\n",
       "</button>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "<noscript><iframe height=\"0\" src=\"https://www.googletagmanager.com/ns.html?id=GTM-W5K7W4T\" style=\"display:none;visibility:hidden\" width=\"0\"></iframe></noscript>\n",
       "<div class=\"dialog-off-canvas-main-canvas\" data-off-canvas-main-canvas=\"\">\n",
       "<div class=\"off-canvas-wrapper\">\n",
       "<div class=\"inner-wrap off-canvas-wrapper-inner\" data-off-canvas-wrapper=\"\" id=\"inner-wrap\">\n",
       "<aside class=\"off-canvas left-off-canvas-menu position-left\" data-off-canvas=\"\" data-transition=\"overlap\" id=\"left-off-canvas-menu\" role=\"complementary\">\n",
       "<div class=\"region region-left_off_canvas\">\n",
       "<button aria-label=\"Close menu\" class=\"close-button\" data-close=\"\" type=\"button\">\n",
       "<span aria-hidden=\"true\">Close menu ×</span>\n",
       "</button>\n",
       "<div class=\"views-element-container block-views-block-section-navigation-block-2 block block-views block-views-blocksection-navigation-block-2\" id=\"block-views-block-section-navigation-block-2\">\n",
       "<div><div class=\"section-navigation js-view-dom-id-152d854909fa3af472ac2af683fd6797d66e9b8f5da5df68f0969f850852b0b7\">\n",
       "<div><div class=\"views-field views-field-label\"><div class=\"field-content section-title row\"><div class=\"section-title-holder\"><h4 class=\"off-canv\"><a href=\"/nice-dsu\" hreflang=\"en\">NICE Decision and Technical Support Unit</a></h4></div></div></div><div class=\"views-field views-field-field-section-navigation\"><div class=\"field-content\"> <div class=\"block block-layout-builder block-field-blockparagraphfrom-libraryfield-reusable-paragraph\">\n",
       "<!-- <h1>Library item label woz ere</H1> -->\n",
       "<div class=\"paragraph paragraph--type--para-section-nav paragraph--view-mode--default\">\n",
       "<nav class=\"desktop-section-navigation\" role=\"navigation\">\n",
       "<ul>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"3f838072-78a1-4493-ae41-d61ff34a43c3\" href=\"/nice-dsu/training\" title=\"Training\">Training</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"b5209d4b-a1bf-4090-8aca-e1b66a0596ab\" href=\"/nice-dsu/appraisal-specific-projects\" title=\"Appraisal specific projects\">Appraisal specific</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"24b1fcc1-e481-4062-9f5a-bb127be627e7\" href=\"/nice-dsu/methods-development\" title=\"Methods development\">Methods development</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"669ba4af-5d7b-457a-9382-32ff65e95262\" href=\"/nice-dsu/tsds\" title=\"Technical support documents\">TSDs</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"7bf4d3f0-1392-4252-b3cd-d7a4db08b626\" href=\"/nice-dsu/publications\" title=\"Publications\">Publications</a></li>\n",
       "<li>About\n",
       "\t<ul>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"97273bcc-450d-4c27-91b6-c775b3405802\" href=\"/nice-dsu/about\" title=\"About the Decision and Technical Support Unit\">About us</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"49b7082b-4f1f-4845-91fb-d6068e7efc63\" href=\"/nice-dsu/members\" title=\"Staff and members\">Staff and members</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"baeb586e-6316-4f2d-b732-bfbac3a0bf99\" href=\"/nice-dsu/contact\" title=\"Contact\">Contact</a></li>\n",
       "</ul>\n",
       "</li>\n",
       "</ul>\n",
       "</nav>\n",
       "</div>\n",
       "</div>\n",
       "</div></div></div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</aside>\n",
       "<aside class=\"off-canvas right-off-canvas-menu position-right\" data-off-canvas=\"\" data-transition=\"overlap\" id=\"right-off-canvas-menu\" role=\"complementary\">\n",
       "</aside>\n",
       "<div class=\"off-canvas-content\" data-off-canvas-content=\"\">\n",
       "<div class=\"region region-meta_header\">\n",
       "<section class=\"block-alertbanner block block-fixed-block-content block-fixed-block-contentalert-banner\" id=\"block-alertbanner\">\n",
       "</section>\n",
       "</div>\n",
       "<header aria-label=\"Site header\" class=\"site-header\" role=\"banner\">\n",
       "<div class=\"header row\">\n",
       "<div class=\"logo\">\n",
       "<a href=\"/?home\">\n",
       "<picture>\n",
       "<source media=\"(min-width: 768px)\" srcset=\"/themes/custom/uos_public/images/logos/uos-crest.svg\"/>\n",
       "<img alt=\"University of Sheffield homepage\" class=\"resp\" src=\"/themes/custom/uos_public/images/logos/uos-crest.svg\"/>\n",
       "</picture>\n",
       "</a>\n",
       "</div>\n",
       "<div class=\"meganav\">\n",
       "<div class=\"region region-header\">\n",
       "<div class=\"block-globalnav block block-fixed-block-content block-fixed-block-contentglobal-nav\" id=\"block-globalnav\">\n",
       "<nav aria-label=\"Global menu\" class=\"block-uos-globalnav\" role=\"navigation\">\n",
       "<ul><li>Study<ul><li><a href=\"/courses\">Courses</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"8327793a-08ba-4aad-9956-d7081aa675e1\" href=\"/undergraduate/home\" title=\"Undergraduate study\">Undergraduate courses</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"8a54b37d-5fb8-45aa-b33f-edcd9db92b21\" href=\"/postgraduate/taught\" title=\"Postgraduate taught courses\">Postgraduate taught courses</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"8d659779-254b-4740-bc96-1e2c90a83a87\" href=\"/postgraduate/phd\" title=\"PhD study\">PhD study</a></li><li><a href=\"/apprenticeships\">Apprenticeships</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"653b4a42-407e-4603-8933-72d70bd9d00a\" href=\"/mature/home\" title=\"Mature students\">Mature students</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"3920766d-f654-43a9-9208-0977468921aa\" href=\"/online-learning/home\" title=\"Online learning\">Online learning</a></li><li><a href=\"/eltc\">TEFL and English as a second language</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"d3212e99-b5f9-4706-9866-5c7f61c1ce34\" href=\"/study/home\" title=\"Study at Sheffield\">Studying at Sheffield</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"777c17a2-9bc9-420c-bc7b-14d387be10db\" href=\"/study/teaching\" title=\"Teaching\">Teaching</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"83ac4e5f-e2ba-4a88-8bb0-121953863176\" href=\"/study/facilities\" title=\"Facilities\">Facilities</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"bff9a1be-d813-46ef-86a7-574b2aea6f60\" href=\"/study/ranking\" title=\"Ranking, reputation and history\">Ranking, reputation and history</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"3e144cba-be9b-4a34-af85-50e88cded274\" href=\"/study/career\" title=\"Your career prospects\">Your career prospects</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"be0a4f1a-57d9-4cc4-9b22-796a786eed04\" href=\"/contact/study\" title=\"Contact us: course, application and study enquiries \">Contact us</a></li></ul></li><li><a class=\"uoslink\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"d3212e99-b5f9-4706-9866-5c7f61c1ce34\" href=\"/study/home\" title=\"Study at Sheffield\">Student life</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"202ff932-2070-4845-90d0-9efb9add0802\" href=\"/study/su\" title=\"Students' Union\">Students' Union - the UK's no. 1</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"f770e211-7226-4f1b-88ba-5081d8d4cc83\" href=\"/study/clubs-societies-sport\" title=\"Clubs, societies and sport\">Clubs, societies and sport</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"0b189b2d-4672-4f63-9fa0-25f582f60e6e\" href=\"/sheffield-guide/home\" title=\"Guide to Sheffield\">Guide to Sheffield</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"950c20e4-3adc-41b0-86ed-9fe50ff64904\" href=\"/study/support\" title=\"Support\">Support</a></li><li><a class=\"uoslink\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"fba602b7-8bf1-4b0b-80b9-90ecc1d87727\" href=\"/inclusion/race/bame-students\" title=\"Black, Asian and Minority Ethnic (BAME) students\">Black, Asian and Minority Ethnic (BAME) students</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"e9c9cde5-9ecb-4cc3-a29c-aff4ba731236\" href=\"/accommodation/home\" title=\"Accommodation at the University of Sheffield\">Accommodation</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"e9c9cde5-9ecb-4cc3-a29c-aff4ba731236\" href=\"/accommodation/home\" title=\"Accommodation at the University of Sheffield\">University residences</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"166e8b8d-7c06-4cd4-924f-30c0a9a9d21b\" href=\"/accommodation/rents\" title=\"Rents - 2025/26\">Rent</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"bc547446-f348-4687-b9e4-7c2e10c49b1a\" href=\"/accommodation/apply\" title=\"How to apply\">Apply for accommodation</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"f5fb9a71-133d-49df-8849-85636141559c\" href=\"/visit-us/home\" title=\"Visit us\">Visit</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"4ee6b0c1-d044-4ec1-ab9e-ec66a23e3e70\" href=\"/undergraduate/visit/open-days\" title=\"Open days\">Undergraduate open days</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"392dbe74-acb2-4ef0-bb14-08d8cf6b9663\" href=\"/postgraduate/visit\" title=\"Visit\">Postgraduate visits</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"4285a653-10eb-4179-be20-3fbd937c3305\" href=\"/international/visits\" title=\"Events in your region\">International visits to your region</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"8d73b80d-f3d7-4402-9724-38fffd58fe9f\" href=\"/study/online-events\" title=\"Sheffield Live online events\">Sheffield Live online events</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"e9e3fa8c-18e2-4a5d-8518-823a81072417\" href=\"/undergraduate/visit/subject-tasters\" title=\"Subject tasters\">Subject taster sessions for Y12 and Y13 students</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"574c41da-41a4-4432-a74c-83cf95a97dc1\" href=\"/apply/home\" title=\"Visit us\">Apply</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"b796fc95-abe2-4d1a-a80f-6d32a03b7615\" href=\"/undergraduate/apply\" title=\"Applying essentials\">Undergraduate applications</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"0f629527-a85a-4949-adac-78719373cc2f\" href=\"/postgraduate/taught/apply\" title=\"Applying essentials\">Postgraduate taught applications</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"22be776e-87ae-4c2c-87f8-571a2d4d0454\" href=\"/postgraduate/phd/apply\" title=\"Applying essentials – PhD study\">PhD applications</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"0478ebe6-6688-4f98-8c11-48f5cfa49657\" href=\"/international/applying\" title=\"How to apply\">Applying as an international student</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"7d4dfc9a-305e-40da-a67b-8d8921168e72\" href=\"/student-visas-immigration/home\" title=\"Student visas and immigration\">Visas and immigration</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"88a97d58-fca2-417e-a0b2-2cf13005a660\" href=\"/international/home\" title=\"International students\">International students</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"ebf25e08-4726-4c50-b531-e1a130afe689\" href=\"/international/after-you-apply/arriving-sheffield\" title=\"Arriving in Sheffield\">Our international community</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"574c41da-41a4-4432-a74c-83cf95a97dc1\" href=\"/apply/home\" title=\"Apply\">How to apply</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"7d4dfc9a-305e-40da-a67b-8d8921168e72\" href=\"/student-visas-immigration/home\" title=\"Student visas and immigration\">Visas and immigration</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"b89e0aba-e3f1-4bc7-8c62-7a8eba17a1dd\" href=\"/international-summer-school/home\" title=\"International Summer School 2026\">International Summer School</a></li><li><a class=\"uoslink\" href=\"https://usic.sheffield.ac.uk/programmes\">Pathway programmes</a></li></ul></li><li>Fees and funding<ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"2f7b477e-10b6-4ab1-96e0-bb8479491dcc\" href=\"/undergraduate/fees-funding\" title=\"Undergraduate fees and funding\">Undergraduate fees and funding</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"a74fa62a-0464-489a-91b0-7b9f8e8bbd7c\" href=\"/postgraduate/taught/fees\" title=\"Postgraduate taught course tuition fees\">Postgraduate taught fees</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"d4b28a44-e3a2-4a74-9fa8-7084053b7766\" href=\"/postgraduate/taught/funding\" title=\"Funding for postgraduate taught courses\">Postgraduate taught funding</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"075aa099-dbec-4ec3-a9db-b428b488f3ce\" href=\"/postgraduate/phd/fees\" title=\"PhD fees\">PhD fees</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"1ea5ad56-f87b-4232-aae6-fcca969c122b\" href=\"/postgraduate/phd/scholarships\" title=\"PhD scholarships\">PhD scholarships</a></li><li><a class=\"uoslink\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"bf0a3f94-e203-4d39-b0f2-14df61792bef\" href=\"/money-matters/home\" title=\"Cost of living and money resources\">Cost of living and money resources</a></li></ul></li></ul></li><li>Research<ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"6b0f842a-2778-4eb5-baa4-c9b3c7457027\" href=\"/research/home\" title=\"Research\">Research at Sheffield</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"85cf5d90-052b-46ce-b0db-62a127ebe87f\" href=\"/vision/our-pillars/research\" title=\"Research\">Our strategic priorities</a></li><li><a href=\"/research/people\">Our people</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"ea063c3e-492d-4021-b5fb-f83428529e0e\" href=\"/research/ref-2021\" title=\"Research Excellence Framework 2021\">Research Excellence Framework 2021</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"a215929b-ecd0-42f7-baff-49c957710597\" href=\"/rpi/home\" title=\"Research, Partnerships and Innovation\">Researcher support</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"2393e685-679d-4edd-9955-53532da3b810\" href=\"/research/culture\" title=\"Our research culture\">Research environment and culture</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"69997ad5-91fc-4418-a85c-854fdb67b17b\" href=\"/openresearch/home\" title=\"Open Research\">Open Research</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"8d659779-254b-4740-bc96-1e2c90a83a87\" href=\"/postgraduate/phd\" title=\"PhD study\">Postgraduate research</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"42c03535-144e-46c5-b5e6-aaca19eb0edf\" href=\"/postgraduate/phd/search\" title=\"Find a PhD\">Find a PhD</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"3926eb8c-ac63-4c9d-8230-6c7ef70764b7\" href=\"/postgraduate/phd/projects\" title=\"PhD project directory\">PhD projects directory</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"1ea5ad56-f87b-4232-aae6-fcca969c122b\" href=\"/postgraduate/phd/scholarships\" title=\"PhD scholarships\">PhD scholarships</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"8a36da72-1d12-4830-9315-34a3bc3b459e\" href=\"/research/centres\" title=\"Research centres and facilities\">Expertise</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"fb3e5a81-525b-4950-8eb4-a7cfb127bcdf\" href=\"/research/centres/cross-faculty\" title=\"Centres of excellence\">Centres of excellence</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"84f7e341-3366-40be-9b3c-5e4312d4e732\" href=\"/collaborate/support-industry/access-facilities\" title=\"Access to equipment and facilities\">Facilities</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"b18e5aa3-9cae-4885-8402-4387f2c05d66\" href=\"/library/research\" title=\"Researchers\">Library</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"7023e013-944e-4771-8347-373f043de04e\" href=\"/about/impact\" title=\"At Sheffield, we make an impact\">Our impact</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"3f126d86-4e16-4b90-b796-ae39f60e3b11\" href=\"/research/features\" title=\"Research features\">Research features</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"1faeda10-46e0-4a9a-9e56-eb2525aaa475\" href=\"/research/features/sdg\" title=\"UN Sustainable Development Goals\">UN sustainable development goals</a></li><li><a href=\"https://player.sheffield.ac.uk/\">University Player</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"3b5d81fa-c698-4f72-ab46-542cf45ac056\" href=\"/research/people/nobel-laureates\" title=\"Nobel Laureates\">Nobel Prizes</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"e44f4791-8693-467f-b1e3-dcb3e0b38a2b\" href=\"/about/queens-prize\" title=\"Queen's Anniversary Prizes \">Queen's Anniversary Prizes</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"bf2518c6-7ee7-4115-bfc5-a9ad46313fb6\" href=\"/research/contact\" title=\"Contact us\">Contact</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"bf2518c6-7ee7-4115-bfc5-a9ad46313fb6\" href=\"/research/contact\" title=\"Contact us\">Research partnerships and people</a></li></ul></li></ul></li><li>Collaborate<ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"2c515bfa-a42c-480c-a12b-9bad4ea6c606\" href=\"/collaborate/home\" title=\"Partnerships\">Partnerships</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"0f222498-1686-46f9-a14e-3494bc3d3f73\" href=\"/collaborate/support-industry\" title=\"Collaboration\">How we support business</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"ef2ff403-9a7e-46b2-867d-c3e7ea0d4aee\" href=\"/collaborate/partners\" title=\"Partners and collaborators\">Examples of business partners</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"8a36da72-1d12-4830-9315-34a3bc3b459e\" href=\"/research/centres\" title=\"Research centres and facilities\">Research centres, institutes and networks</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"0330d3ba-bbfd-4548-85de-b7d059433e9a\" href=\"/city-region/home\" title=\"Ambitious Plans. Made Together.\">Our role in the city and region</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"9232b6a8-20e3-4f70-8507-9ea63130285d\" href=\"/internationalpartnerships/home\" title=\"International partnerships\">International</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"f9b49d13-d650-4d5f-b448-45463f37f211\" href=\"/internationalpartnerships/global-networks\" title=\"Our global networks\">Our global networks</a></li><li><a href=\"/global/we-are-international\">We Are International campaign</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"0a82542e-e013-47a9-a479-48cb13d21c9c\" href=\"/globalopps/home\" title=\"Global Opportunities\">Global opportunities and exchanges</a></li></ul></li><li><a href=\"/alumni\">Alumni</a><ul><li><a href=\"/alumni/update \">Update your details</a></li><li><a href=\"/giving\">Support us</a></li><li><a href=\"/alumni/our-alumni\">Our alumni</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"c0cae2be-8f1f-4b20-9e47-f3ed3fa122af\" href=\"/alumni/volunteer\" title=\"Alumni volunteering\">Alumni volunteering</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"af7e760b-c977-460d-bda5-79417c03f6a5\" href=\"/giving/home\" title=\"Giving\">Philanthropy</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"8c8d63e0-f957-4d68-80b0-4eb3295e8d2c\" href=\"/forged/home\" title=\"Forged in Sheffield, Shaping the Future\">Forged in Sheffield, Shaping the Future campaign</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"a6aa633f-458b-49b0-9e0a-14a69c3ff010\" href=\"/forged/get-involved\" title=\"Get involved\">Get involved</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"ec7952a5-47a1-4639-b9af-0c566541ae23\" href=\"/giving/donate/online\" title=\"My gift to Sheffield\">Donate now</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"4bace1e6-21f6-40ae-bc65-8054c220ac79\" href=\"/giving/causes/mnd\" title=\"Accelerating neuroscience research\">MND appeal</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"4684b249-44eb-43d8-b357-d3a31fd437a9\" href=\"/schools/home\" title=\"Schools and colleges\">Schools and colleges</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"705481ce-31b2-4bd8-9bb6-d962a4be8856\" href=\"/schools/teachers-advisors\" title=\"Teachers and advisors\">Resources for teachers and advisors</a></li><li><a class=\"uoslink\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"65041535-7253-4376-8c40-f92185cf4095\" href=\"/schools/activities\" title=\"Activities and events\">Activities and events</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"290dca41-102b-42d4-becb-1cd2e721ec89\" href=\"/schools/programmes\" title=\"Access to Sheffield Programmes\">Sustained programmes</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"a04be6eb-ece0-4af8-83a8-ff50264cf302\" href=\"/schools/partnerships\" title=\"Partnerships\">Education partnerships</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"bf2518c6-7ee7-4115-bfc5-a9ad46313fb6\" href=\"/research/contact\" title=\"Contact us\">Contact us</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"bf2518c6-7ee7-4115-bfc5-a9ad46313fb6\" href=\"/research/contact\" title=\"Contact us\">Research partnerships and people</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"c6b2a34e-0729-4428-89dc-3cb10cf94846\" href=\"/global/contact\" title=\"Contact us\">Global Engagement team</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"c2125d5a-ddc9-4807-9922-72df03af4f97\" href=\"/schools/contact\" title=\"Contact the Schools and Colleges Liaison Team\">Schools and Colleges Liaison team</a></li></ul></li><li><a href=\"https://withus.com/\">Hospitality</a><ul><li><a href=\"https://withus.com/\">Conferences, events, visitor accommodation and weddings</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"cb93b7ce-6c04-41f1-85ef-ecc26266f1a4\" href=\"/cafesandbars/home\" title=\"Cafes and Bars\">Cafes and bars</a></li></ul></li></ul></li><li>About<ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"9b6c8b60-1037-47fa-8213-1e65d64edd7f\" href=\"/about/home\" title=\"About us\">About the University</a><ul><li><a href=\"/news\">News</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"95c59e5c-deef-4e2b-b40a-77de8ec5d5e7\" href=\"/whatson/home\" title=\"What's on\">Events</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"da31559c-e214-4de9-ad9d-30438e6e22ba\" href=\"/jobs/home\" title=\"Jobs\">Jobs</a></li><li><a class=\"uoslink\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"497783e7-40c0-43ef-82e3-d25cf8534391\" href=\"/ambition/home\" title=\"Independent thinking. Shared ambition\">Who we are</a></li><li><a class=\"uoslink\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"e7405607-b7b6-4444-8ffe-280cc271f142\" href=\"/our-education/home\" title=\"Education at Sheffield\">Education at Sheffield</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"c967e894-6b47-4b6a-a200-f56292edb035\" href=\"/sustainability/home\" title=\"Sustainability at Sheffield\">Sustainability at Sheffield</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"753d66ef-68d4-4cdc-8405-e84e6a458bde\" href=\"/inclusion/home\" title=\"Inclusion at Sheffield\">Inclusion at Sheffield</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"04d910a8-eee0-4cd4-a85b-600acec01ec8\" href=\"/about/supporting-sanctuary\" title=\"Support for students and scholars seeking sanctuary\">Support for refugee students and scholars</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"313a35bf-2c39-4be8-bf34-f4c59a9a8049\" href=\"/vision/home\" title=\"Our vision and strategic plan\">Our vision and strategic plan</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"0330d3ba-bbfd-4548-85de-b7d059433e9a\" href=\"/city-region/home\" title=\"Ambitious Plans. Made Together.\">Our role in the city and region</a></li><li><a href=\"/govern\">Governance and management</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"112035ff-56eb-4844-b97c-61c3cdd11fc0\" href=\"/about/rankings\" title=\"Rankings \">Rankings</a></li><li><a class=\"uoslink\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"5c687a4b-703c-4bde-a5cf-f27db2784daa\" href=\"/about/world-top-100\" title=\"A world top-100 university\">A world top-100 university</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"e44f4791-8693-467f-b1e3-dcb3e0b38a2b\" href=\"/about/queens-prize\" title=\"Queen's Anniversary Prizes \">Queen's Anniversary Prizes</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"3b5d81fa-c698-4f72-ab46-542cf45ac056\" href=\"/research/people/nobel-laureates\" title=\"Nobel Laureates\">Nobel Prize winners</a></li></ul></li><li><a href=\"/departments\">Schools, departments and services</a><ul><li><a href=\"/departments/academic\">Schools</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"d9d787fb-4d2a-421a-a45b-45173e81396e\" href=\"/departments/faculties\" title=\"Faculties\">Faculties</a></li><li><a href=\"/departments/professional-services\">Professional services</a></li></ul></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"d3212e99-b5f9-4706-9866-5c7f61c1ce34\" href=\"/study/home\" title=\"Study at Sheffield\">Studying at Sheffield</a><ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"0b189b2d-4672-4f63-9fa0-25f582f60e6e\" href=\"/sheffield-guide/home\" title=\"Guide to Sheffield\">Guide to Sheffield</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"5a436f60-f893-4f34-9089-be3dee0ca6cd\" href=\"/courses/home\" title=\"Courses\">Courses</a></li></ul></li><li><a href=\"https://withus.com/\">Hospitality</a><ul><li><a href=\"https://withus.com/\">Conferences, events, visitor accommodation and weddings</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"cb93b7ce-6c04-41f1-85ef-ecc26266f1a4\" href=\"/cafesandbars/home\" title=\"Cafes and Bars\">Cafes and bars</a></li></ul></li></ul></li></ul>\n",
       "</nav>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</header>\n",
       "<div class=\"region region-banner\">\n",
       "<div class=\"views-element-container block-views-block-section-navigation-block-1 block block-views block-views-blocksection-navigation-block-1\" id=\"block-views-block-section-navigation-block-1\">\n",
       "<div><div class=\"section-navigation js-view-dom-id-38c33eca484b9467da9e6c1767250ff0255ff8d3385cc33609cf04198e718927\">\n",
       "<div><div class=\"views-field views-field-label\"><div class=\"field-content section-title row\"><div class=\"section-title-wrapper\"><h2 class=\"section-title-holder\"><a href=\"/nice-dsu\" hreflang=\"en\">NICE Decision and Technical Support Unit</a></h2>\n",
       "<a aria-controls=\"left-off-canvas-menu\" aria-expanded=\"false\" class=\"button menu\" data-toggle=\"left-off-canvas-menu\" role=\"button\" tabindex=\"0\">Menu <span aria-hidden=\"true\" class=\"section-title-burger\"></span></a></div></div></div><div class=\"views-field views-field-field-section-navigation\"><div class=\"field-content\"> <div class=\"block block-layout-builder block-field-blockparagraphfrom-libraryfield-reusable-paragraph\">\n",
       "<!-- <h1>Library item label woz ere</H1> -->\n",
       "<div class=\"paragraph paragraph--type--para-section-nav paragraph--view-mode--default\">\n",
       "<nav class=\"desktop-section-navigation\" role=\"navigation\">\n",
       "<ul>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"3f838072-78a1-4493-ae41-d61ff34a43c3\" href=\"/nice-dsu/training\" title=\"Training\">Training</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"b5209d4b-a1bf-4090-8aca-e1b66a0596ab\" href=\"/nice-dsu/appraisal-specific-projects\" title=\"Appraisal specific projects\">Appraisal specific</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"24b1fcc1-e481-4062-9f5a-bb127be627e7\" href=\"/nice-dsu/methods-development\" title=\"Methods development\">Methods development</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"669ba4af-5d7b-457a-9382-32ff65e95262\" href=\"/nice-dsu/tsds\" title=\"Technical support documents\">TSDs</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"7bf4d3f0-1392-4252-b3cd-d7a4db08b626\" href=\"/nice-dsu/publications\" title=\"Publications\">Publications</a></li>\n",
       "<li>About\n",
       "\t<ul>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"97273bcc-450d-4c27-91b6-c775b3405802\" href=\"/nice-dsu/about\" title=\"About the Decision and Technical Support Unit\">About us</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"49b7082b-4f1f-4845-91fb-d6068e7efc63\" href=\"/nice-dsu/members\" title=\"Staff and members\">Staff and members</a></li>\n",
       "<li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"baeb586e-6316-4f2d-b732-bfbac3a0bf99\" href=\"/nice-dsu/contact\" title=\"Contact\">Contact</a></li>\n",
       "</ul>\n",
       "</li>\n",
       "</ul>\n",
       "</nav>\n",
       "</div>\n",
       "</div>\n",
       "</div></div></div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "<div aria-hidden=\"true\" class=\"nav-overlay\"> </div>\n",
       "<div class=\"row\">\n",
       "</div>\n",
       "<div class=\"row\">\n",
       "<main class=\"cell columns\" id=\"main\" role=\"main\">\n",
       "<div class=\"region region-highlighted\"><div class=\"hidden\" data-drupal-messages-fallback=\"\"></div></div> <a id=\"main-content\"></a>\n",
       "<section>\n",
       "<div class=\"region region-breadcrumbs\">\n",
       "<div class=\"block-uos-public-breadcrumbs block block-system block-system-breadcrumb-block\" id=\"block-uos-public-breadcrumbs\">\n",
       "<nav aria-labelledby=\"system-breadcrumb\" role=\"navigation\">\n",
       "<h2 class=\"visually-hidden hideonmobile\" id=\"system-breadcrumb\">You are here</h2>\n",
       "<ul class=\"breadcrumbs\">\n",
       "<li>\n",
       "<a href=\"/\">Home</a>\n",
       "</li>\n",
       "<li>\n",
       "<a href=\"/nice-dsu/home\">NICE Decision and Technical Support Unit</a>\n",
       "</li>\n",
       "<li>\n",
       "<a href=\"/nice-dsu/tsds\">Technical support documents</a>\n",
       "</li>\n",
       "<li class=\"current\">Full list of technical support documents (TSDs)</li>\n",
       "</ul>\n",
       "</nav>\n",
       "</div>\n",
       "</div>\n",
       "<div class=\"region region-content\">\n",
       "<div class=\"block-uos-public-content block block-system block-system-main-block\" id=\"block-uos-public-content\">\n",
       "<article>\n",
       "<div class=\"view-mode-full\">\n",
       "<div class=\"row\">\n",
       "<div class=\"columns large-8\">\n",
       "<div class=\"block block-layout-builder block-field-blocknodepagetitle\">\n",
       "<div class=\"block-uos-page-title\">\n",
       "<h1>Full list of technical support documents (TSDs)</h1>\n",
       "</div>\n",
       "</div>\n",
       "<div class=\"block block-layout-builder block-field-blocknodepagefield-this-is-a-meeting-page\">\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "<div class=\"row page-body\">\n",
       "<div class=\"columns large-8\">\n",
       "<div class=\"block block-layout-builder block-field-blocknodepagefield-b-intro\">\n",
       "<p class=\"leadintro\">All the technical support documents produced by the Nice DSU. The TSDs have the aim of providing further information about how to implement the approaches described in the current Guide to the Methods of Technology Appraisal (2022).   </p>\n",
       "</div>\n",
       "<div class=\"block block-layout-builder block-field-blocknodepagefield-show-onpage-anchors\">\n",
       "  \n",
       "    \n",
       "\n",
       "  \n",
       "                  Off\n",
       "    \n",
       "    \n",
       "    \n",
       "</div>\n",
       "<div class=\"block block-layout-builder block-field-blocknodepagefield-atoz-rollup\">\n",
       "<div data-atozrollup=\"false\"></div>\n",
       "</div>\n",
       "<div class=\"block block-layout-builder block-field-blocknodepagebody\">\n",
       "<div class=\"uosblock grey\"><div class=\"uosblock-content\"><p>One-page technical support document (TSD) summaries that have been produced so far.</p><p><a class=\"uosbutton\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"a191fe63-6d06-4d62-ad26-518d79946665\" href=\"/nice-dsu/tsds/summaries\" title=\"TSD summaries\">One-page summaries</a></p></div></div><p>TSD 27: <a class=\"uoslink\" data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"edf8dcab-0b02-4f69-94dd-d07a898b7785\" href=\"/media/99966/download?attachment\" title=\"TSD 27\">Prioritising studies and outcomes for consideration in NICE HealthTech literature reviews</a> (PDF, 719KB)</p><p>TSD 26: <a class=\"uoslink\" data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"87656a69-d711-4a1c-b723-195e2d5cab27\" href=\"/media/94031/download?attachment\" title=\"TSD26\">Expert elicitation for long-term survival outcomes</a> (PDF, 1.56MB)</p><p>TSD 25: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"c12c8af9-1d09-4b4a-83dc-36b03b08bf5f\" href=\"/media/83861/download?attachment\" title=\"TSD 25: Evidence Synthesis of Diagnostic Test Accuracy for Decision Making\">Evidence Synthesis of Diagnostic Test Accuracy for Decision Making</a> (PDF, 1740KB)</p><p>TSD 24: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"93b93149-53b5-4764-8bf1-8a9913adcc77\" href=\"/media/65536/download?attachment\" title=\"TSD 24 Adjusting survival time estimates in the presence of treatment switching\">Adjusting survival time estimates in the presence of treatment switching [Update of TSD16]</a> (PDF, 700KB)</p><p>TSD 23: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"c539ac6e-c5ee-49f2-a57d-d7d396ec906b\" href=\"/media/57671/download?attachment\" title=\"TSD23: Severity shortfall \">A guide to calculating severity shortfall for nice evaluations</a> (PDF, 317KB)</p><p>TSD 22: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"2b8c816b-b4d8-4325-9167-eea6489dd270\" href=\"/media/42422/download?attachment\" title=\"TSD22 Mapping\">Mapping to estimate health state utilities</a> (PDF, 484KB)</p><p>TSD 21: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"36ac7da4-8e11-40ae-9fed-8d11efab98b0\" href=\"/media/34188/download?attachment\" title=\"DSU NICE DSU Flex Surv TSD 21_Final_alt_text_updated\">Flexible methods for survival analysis</a> (PDF, 5.7MB)</p><p dir=\"ltr\">TSD 20: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"76cc077b-9849-4a09-8c66-70b36e2c4f7c\" href=\"/media/34200/download?attachment\" title=\"DSU TSD20 Version2\">Multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints</a> (PDF, 1.2MB)</p><p dir=\"ltr\">TSD 19: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"96bc8e0f-702f-4398-90ee-805c9cdc760a\" href=\"/media/34205/download?attachment\" title=\"DSU TSD19-Partitioned-Survival-Analysis-final-report\">Partitioned survival analysis as a decision modelling tool</a> (PDF, 529KB)</p><p dir=\"ltr\">TSD 18: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"0f7ff767-30e8-4cef-8b54-38d44eefd343\" href=\"/media/34216/download?attachment\" title=\"DSU TSD18 Population-adjustment-TSD-FINAL\">Methods for population-adjusted indirect comparisons in submissions to NICE</a> (PDF, 1.5MB)</p><p dir=\"ltr\">TSD 17: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"115a94aa-c823-4786-95d5-22e562faae08\" href=\"/media/34204/download?attachment\" title=\"DSU TSD17-DSU-Observational-data-FINAL\">The use of observational data to inform estimates of treatment effectiveness in technology appraisal: Methods for comparative individual patient data</a> (PDF, 604KB)</p><p dir=\"ltr\">TSD 16: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"7c3f42d4-a47f-46a7-86f6-9c75f324beb2\" href=\"/media/34229/download?attachment\" title=\"DSU TSD16_Treatment_Switching\">Adjusting survival time estimates in the presence of treatment switching</a> (PDF, 450KB)</p><p dir=\"ltr\">TSD 15: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"0d7effb9-345c-4379-a7ad-5c9e1cfb9a3c\" href=\"/media/34206/download?attachment\" title=\"DSU TSD15_Patient-level_simulation\">Cost-effectiveness modelling using patient-level simulation</a> (PDF, 494KB)</p><p dir=\"ltr\">TSD 14: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"a5e5c954-1dcd-4103-91bf-e1d58897e378\" href=\"/media/34225/download?attachment\" title=\"DSU TSD14-Survival-analysis.updated-March-2013.v2\">Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data</a> (PDF, 395KB)</p><p dir=\"ltr\">TSD 13: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"7c88c6ae-18dc-45e7-a046-9c1903050921\" href=\"/media/34222/download?attachment\" title=\"DSU TSD13-model-parameters\">Identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models</a> (PDF, 376KB)</p><p dir=\"ltr\">TSD 12: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"3dfd9a6b-7888-4fab-ab47-25c0b40954a7\" href=\"/media/34240/download?attachment\" title=\"DSU TSD12-Utilities-in-modelling-FINAL\">The use of health state utility values in decision models</a> (PDF, 164KB)</p><p dir=\"ltr\">TSD 11: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"f0c54038-4f70-4872-91a5-b5c856ccb01e\" href=\"/media/34238/download?attachment\" title=\"DSU TSD11-Alternatives-to-EQ-5D_final\">Alternatives to EQ-5D for generating health state utility values</a> (PDF, 157KB)</p><p dir=\"ltr\">TSD 10: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"6f4f79c3-cf9c-4466-847b-61b2f5595dbd\" href=\"/media/34237/download?attachment\" title=\"DSU TSD10-mapping-FINAL\">The use of mapping methods to estimate health state utility values</a> (PDF, 144KB)</p><p dir=\"ltr\">TSD 9: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"7cf369bf-87be-4a90-ae3c-9061ee5e53c8\" href=\"/media/34236/download?attachment\" title=\"DSU TSD9-HSUV-values_FINAL\">The identification, review and synthesis of health state utility values from the literature</a> (PDF, 304KB)</p><p dir=\"ltr\">TSD 8: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"d4dcba01-4aa7-45da-85f3-71697c306b1e\" href=\"/media/34235/download?attachment\" title=\"DSU TSD8-Introduction-to-MVH_final\">An introduction to the measurement and valuation of health for NICE submissions</a> (PDF, 136KB)</p><p dir=\"ltr\">TSD 7: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"103c0d2d-9cbd-4973-a0a3-1dc99c86cebc\" href=\"/media/34186/download?attachment\" title=\"DSU TSD7-reviewer-checklist.final_.08.05.12\">Evidence synthesis of treatment efficacy in decision making: a reviewer’s checklist</a> (PDF, 147KB)</p><p dir=\"ltr\">TSD 6: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"6a9f7a41-773d-4f9d-a002-8ca06ef915a9\" href=\"/media/34185/download?attachment\" title=\"DSU TSD6-Software.final_.08.05.12\">Embedding evidence synthesis in probabilistic cost effectiveness analysis: Software choices</a> (PDF, 122KB)</p><p dir=\"ltr\">TSD 5: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"42f687a2-7155-4a6d-8766-24ab60db3f3a\" href=\"/media/34183/download?attachment\" title=\"DSU TSD5-Baseline.final-report.08.05.12\">Evidence synthesis in the baseline natural history model</a> (PDF, 178KB)</p><p dir=\"ltr\">TSD 4: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"aa221e93-eb9b-4e7f-b1b2-8922fa5bebb6\" href=\"/media/34181/download?attachment\" title=\"DSU TSD4-Inconsistency.final_.15April2014\">Inconsistency in networks of evidence based on randomised controlled trials</a> (PDF, 429KB)</p><p dir=\"ltr\">TSD 3: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"c4f59c60-1dc6-4221-b154-fab8402a0cea\" href=\"/media/34179/download?attachment\" title=\"DSU TSD3-Heterogeneity.final-report.08.05.12\">Heterogeneity: subgroups, meta-regression, bias and bias-adjustment</a> (PDF, 492KB)</p><p dir=\"ltr\">TSD 2: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"d026f634-a01f-4463-ab34-85a397f87378\" href=\"/media/34176/download?attachment\" title=\"DSU TSD2-General-meta-analysis-corrected-2Sep2016v2\">A general linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials</a> (PDF, 1.6MB)</p><p dir=\"ltr\">TSD 1: <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"ccda9572-c753-4aa3-995f-a22fc0b6f108\" href=\"/media/34175/download?attachment\" title=\"DSU TSD1-Introduction.final_.08.05.12\">Introduction to evidence synthesis for decision making</a> (PDF, 106KB)</p>\n",
       "</div>\n",
       "<div class=\"block block-layout-builder block-field-blocknodepagefield-b-related-title\">\n",
       "<hr class=\"related\"/>\n",
       "<h2>Related information</h2>\n",
       "</div>\n",
       "<div class=\"block block-layout-builder block-field-blocknodepagefield-b-related-links\">\n",
       "<ul>\n",
       "<li><p><a href=\"/nice-dsu/tsds\">Technical support documents</a></p></li>\n",
       "<li><p><a href=\"/nice-dsu/tsds/summaries\">One page TSD summaries</a></p></li>\n",
       "</ul>\n",
       "</div>\n",
       "</div>\n",
       "<div class=\"columns large-4\">\n",
       "<div class=\"views-element-container block block-views block-views-blockgroup-promo-block-1\">\n",
       "<div><div class=\"js-view-dom-id-c98ebcda98c1fbd34572af80fc443744c282e331594bb50c50fb1cb2a31d6cfb\">\n",
       "<div class=\"views-row\"><div class=\"views-field views-field-field-group-promotion\"><div class=\"field-content\">\n",
       "</div></div></div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "<div class=\"views-element-container block block-views block-views-blockcentral-promo-block-1\">\n",
       "<div><div class=\"js-view-dom-id-b0e826428d6dcae695d454b9231f0386e2eb71439732e1c819ede7a9011c8e0d\">\n",
       "<div class=\"views-row\"><div class=\"views-field views-field-field-b-central-promo\"><div class=\"field-content\"><div>\n",
       "<div class=\"block block-layout-builder block-field-blockparagraphfrom-libraryfield-reusable-paragraph\">\n",
       "<!-- <h1>Library item label woz ere</H1> -->\n",
       "<div class=\"paragraph paragraph--type--para-promotion blue-bar\">\n",
       "<div>\n",
       "<h2>A global reputation</h2>\n",
       "<p>Sheffield is a world top-100 research university with a global reputation for excellence. We're a member of the Russell Group: one of the 24 leading UK universities for research and teaching.</p>\n",
       "<div class=\"promo-link\">\n",
       "<a href=\"/about/home\">About the University</a>\n",
       "<br/>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div></div></div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</article>\n",
       "</div>\n",
       "</div>\n",
       "</section>\n",
       "</main>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "<footer>\n",
       "<div class=\"row pad\">\n",
       "<div class=\"large-9 columns\">\n",
       "<h4 class=\"footer-heading\">The University of Sheffield</h4>\n",
       "<div class=\"quicklinks\">\n",
       "<nav aria-label=\"Footer navigation\">\n",
       "<div class=\"region region-quicklinks\">\n",
       "<div class=\"block-footerlinkcolumns block block-fixed-block-content block-fixed-block-contentfooter-link-columns\" id=\"block-footerlinkcolumns\">\n",
       "<ul><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"8327793a-08ba-4aad-9956-d7081aa675e1\" href=\"/undergraduate/home\">Undergraduate courses</a></li><li><a href=\"/postgraduate/taught\">Postgraduate taught courses</a></li><li><a href=\"/postgraduate/phd\">PhD study</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"e9c9cde5-9ecb-4cc3-a29c-aff4ba731236\" href=\"/accommodation/home\">Accommodation</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"88a97d58-fca2-417e-a0b2-2cf13005a660\" href=\"/international/home\">International students</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"da31559c-e214-4de9-ad9d-30438e6e22ba\" href=\"/jobs/home\">Jobs</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"3b63a1b5-bee2-4a76-9c8a-b3dcdc6c950e\" href=\"/giving/donate\">Support us</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"47c06071-ad5e-4c73-8ede-81f3066cc271\" href=\"/visitors/home\">Visitor information</a></li><li><a href=\"https://player.sheffield.ac.uk/\">Player</a></li><li><a href=\"https://staff.sheffield.ac.uk\">Staff hub</a></li><li><a href=\"https://students.sheffield.ac.uk\">Student hub</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"e1a8382c-63ca-4f45-a29c-f31aca3a863b\" href=\"/payments/home\">Make an online payment</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"6dd88cda-ab31-43ce-ae2e-13012e10c5b2\" href=\"/study/policies\">Student policies and protection plan</a></li><li><a class=\"uoslink\" data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"46e1e43a-9524-403e-a3b4-562574dc4dcd\" href=\"/harassment-sexual-misconduct/home\">Harassment and sexual misconduct information</a></li><li><a href=\"/departments\">Schools, departments and services</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"9443c151-21b4-4f63-862e-6c7d4a99f9d6\" href=\"/alumni/home\">Alumni</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"6f8015b0-2a83-4237-8bf5-c1532bdaf4ad\" href=\"/library/home\">Library</a></li><li><a href=\"https://su.sheffield.ac.uk/\">Students' Union</a></li><li><a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"ff9fa13e-433b-4920-ae7a-4ba4bbb04832\" href=\"/contact/home\">Contact</a></li></ul>\n",
       "</div>\n",
       "</div>\n",
       "</nav>\n",
       "</div>\n",
       "</div>\n",
       "<div class=\"large-3 columns\">\n",
       "<br>\n",
       "<address>\n",
       "    The University of Sheffield<br/>\n",
       "    Western Bank<br/>\n",
       "    Sheffield<br/>\n",
       "    S10 2TN<br/>\n",
       "    +44 114 222 2000\n",
       "    </address>\n",
       "</br></div>\n",
       "</div>\n",
       "<div class=\"row\">\n",
       "<div class=\"footicons\">\n",
       "<div class=\"awards\">\n",
       "<a href=\"//www.sheffield.ac.uk/about/rankings\"><img alt=\"A World Top 100 University\" loading=\"lazy\" src=\"/themes/custom/common/uos/images/WORLD100_stamp_white.png\"/></a>\n",
       "<a href=\"//www.sheffield.ac.uk/about/rankings\"><img alt=\"Russell Group\" loading=\"lazy\" src=\"/themes/custom/common/uos/images/russell.png\"/></a>\n",
       "<a href=\"//www.sheffield.ac.uk/about/queens-prize\"><img alt=\"Five Queen's Anniversary Prizes\" loading=\"lazy\" src=\"/themes/custom/common/uos/images/QAP.png\"/></a>\n",
       "</div>\n",
       "<div class=\"region region-footer_last\">\n",
       "<div class=\"social\">\n",
       "<div class=\"block block-layout-builder block-field-blockblock-contentbasicbody\">\n",
       "<a href=\"https://instagram.com/theuniversityofsheffield\"><div class=\"embedded-entity\" data-embed-button=\"media\" data-entity-embed-display=\"view_mode:media.original\" data-entity-embed-display-settings=\"[]\" data-entity-type=\"media\" data-entity-uuid=\"1a3ee92b-d30e-4feb-9e9f-0fabc985dca8\" data-langcode=\"en\"><div class=\"media--image--figure\">\n",
       "<figure class=\"imgcapt\">\n",
       "<img alt=\"Instagram logo\" height=\"34\" loading=\"lazy\" src=\"//cdn.sheffield.ac.uk/sites/default/files/styles/original/public/2022-10/social-in.png?itok=UpurzD83\" width=\"34\"/>\n",
       "</figure>\n",
       "</div>\n",
       "</div>\n",
       "</a><a href=\"https://www.linkedin.com/school/university-of-sheffield/\"><div class=\"embedded-entity\" data-embed-button=\"media\" data-entity-embed-display=\"view_mode:media.original\" data-entity-embed-display-settings=\"[]\" data-entity-type=\"media\" data-entity-uuid=\"1a08f0ed-8737-46c6-858c-d6df4aa8bdb0\" data-langcode=\"en\"><div class=\"media--image--figure\">\n",
       "<figure class=\"imgcapt\">\n",
       "<img alt=\"LinkedIn\" height=\"34\" loading=\"lazy\" src=\"//cdn.sheffield.ac.uk/sites/default/files/styles/original/public/2022-10/social-li.png?itok=pBCn-VE3\" width=\"34\"/>\n",
       "</figure>\n",
       "</div>\n",
       "</div>\n",
       "</a><a href=\"https://www.tiktok.com/@sheffielduni\"><div class=\"embedded-entity\" data-embed-button=\"media\" data-entity-embed-display=\"view_mode:media.original\" data-entity-embed-display-settings=\"[]\" data-entity-type=\"media\" data-entity-uuid=\"7e6b1eb8-eb3a-4521-af36-f0fff11b5ed1\" data-langcode=\"en\"><div class=\"media--image--figure\">\n",
       "<figure class=\"imgcapt\">\n",
       "<img alt=\"TikTok\" height=\"34\" loading=\"lazy\" src=\"//cdn.sheffield.ac.uk/sites/default/files/styles/original/public/2022-10/social-tt.png?itok=G8v7iLhy\" width=\"34\"/>\n",
       "</figure>\n",
       "</div>\n",
       "</div>\n",
       "</a><a href=\"https://bsky.app/profile/sheffielduni.bsky.social\"><div class=\"embedded-entity\" data-embed-button=\"media\" data-entity-embed-display=\"view_mode:media.original\" data-entity-embed-display-settings=\"[]\" data-entity-type=\"media\" data-entity-uuid=\"90cddbdf-ba0b-43c2-82e1-4ff0cde18809\" data-langcode=\"en\"><div class=\"media--image--figure\">\n",
       "<figure class=\"imgcapt\">\n",
       "<img alt=\"Bluesky butterfly logo\" height=\"34\" loading=\"lazy\" src=\"/sites/default/files/styles/original/public/2025-10/social-icon-bluesky2.png?h=ebc76fda&amp;itok=vfSDiDHf\" width=\"34\"/>\n",
       "</figure>\n",
       "</div>\n",
       "</div>\n",
       "</a><a href=\"https://www.threads.com/@theuniversityofsheffield\"><div class=\"embedded-entity\" data-embed-button=\"media\" data-entity-embed-display=\"view_mode:media.original\" data-entity-embed-display-settings=\"[]\" data-entity-type=\"media\" data-entity-uuid=\"8d20c927-8161-43f1-88b9-6d575e0d6517\" data-langcode=\"en\"><div class=\"media--image--figure\">\n",
       "<figure class=\"imgcapt\">\n",
       "<img alt=\"Threads logo\" height=\"34\" loading=\"lazy\" src=\"/sites/default/files/styles/original/public/2025-10/social-icon-threads.png?h=ebc76fda&amp;itok=TswsZn-u\" width=\"34\"/>\n",
       "</figure>\n",
       "</div>\n",
       "</div>\n",
       "</a><a href=\"https://www.weibo.com/sheffielduni\"><div class=\"embedded-entity\" data-embed-button=\"media\" data-entity-embed-display=\"view_mode:media.original\" data-entity-embed-display-settings=\"[]\" data-entity-type=\"media\" data-entity-uuid=\"4d85bf8f-1c5f-41e9-b5ba-4ecf21d45026\" data-langcode=\"en\"><div class=\"media--image--figure\">\n",
       "<figure class=\"imgcapt\">\n",
       "<img alt=\"Weibo\" height=\"34\" loading=\"lazy\" src=\"//cdn.sheffield.ac.uk/sites/default/files/styles/original/public/2022-10/social-wb.png?itok=c0RLZdQP\" width=\"34\"/>\n",
       "</figure>\n",
       "</div>\n",
       "</div>\n",
       "</a>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "</div>\n",
       "<div class=\"bottom-bar panel\">\n",
       "<div class=\"row\">\n",
       "<div class=\"large-7 columns\">\n",
       "<div class=\"region region-footer_first\">\n",
       "<nav aria-labelledby=\"block-uos-public-footer-menu\" class=\"block-uos-public-footer\" id=\"block-uos-public-footer\" role=\"navigation\">\n",
       "<h2 class=\"block-title visually-hidden\" id=\"block-uos-public-footer-menu\">Footer menu</h2>\n",
       "<ul class=\"menu\">\n",
       "<li>\n",
       "<a href=\"https://www.sheffield.ac.uk/contact/comments\">Feedback</a>\n",
       "</li>\n",
       "<li>\n",
       "<a href=\"https://www.sheffield.ac.uk/privacy\">Privacy</a>\n",
       "</li>\n",
       "<li>\n",
       "<a href=\"https://www.sheffield.ac.uk/accessibility\">Accessibility</a>\n",
       "</li>\n",
       "<li>\n",
       "<a href=\"https://www.sheffield.ac.uk/foi\">FOI</a>\n",
       "</li>\n",
       "<li>\n",
       "<a href=\"https://www.sheffield.ac.uk/procurement/modern-slavery\">Modern slavery statement</a>\n",
       "</li>\n",
       "</ul>\n",
       "</nav>\n",
       "</div>\n",
       "</div>\n",
       "<div class=\"large-5 columns copyright\">\n",
       "      © 2026 The University of Sheffield\n",
       "      </div>\n",
       "</div>\n",
       "</div>\n",
       "</footer>\n",
       "</div>\n",
       "</div>\n",
       "<button aria-label=\"Scroll to top of page\" class=\"backtotop\">\n",
       "<i aria-hidden=\"true\" class=\"fas fa-angle-up fa-2x\"></i>\n",
       "</button>\n",
       "<script data-drupal-selector=\"drupal-settings-json\" type=\"application/json\">{\"path\":{\"baseUrl\":\"\\/\",\"pathPrefix\":\"\",\"currentPath\":\"node\\/41502\",\"currentPathIsAdmin\":false,\"isFront\":false,\"currentLanguage\":\"en\"},\"pluralDelimiter\":\"\\u0003\",\"suppressDeprecationErrors\":true,\"cms\":{\"name\":\"public\",\"muse_url\":\"https:\\/\\/www.sheffield.ac.uk\"},\"search_autocomplete\":{\"related_links_programmatic\":{\"source\":\"\\/callback\\/pages\",\"selector\":\".node-form:not(\\u0022[class*=\\u0027node-course\\u0027],[class*=\\u0027node-student-profile\\u0027],[class*=\\u0027node-pgt-course-coupler\\u0027],[class*=\\u0027node-news-link\\u0027],[class*=\\u0027node-event\\u0027],[class*=\\u0027node-event-link\\u0027],[class*=\\u0027node-subject-area\\u0027],[class*=\\u0027node-programme\\u0027]\\u0022) [data-autocomplete-path^=\\u0027\\/entity_reference_autocomplete\\/node\\u0027]\",\"minChars\":3,\"maxSuggestions\":25,\"autoSubmit\":false,\"autoRedirect\":false,\"theme\":\"minimal\",\"filters\":[\"q\",\"combine\"],\"noResult\":{\"group\":{\"group_id\":\"no_results\"},\"label\":\"No results found for [search-phrase].\",\"value\":\"[search-phrase]\",\"link\":\"\"},\"moreResults\":{\"group\":{\"group_id\":\"more_results\"},\"label\":\"\",\"value\":\"\",\"link\":\"\"}}},\"ckeditorAccordion\":{\"accordionStyle\":{\"collapseAll\":1,\"keepRowsOpen\":1,\"animateAccordionOpenAndClose\":1,\"openTabsWithHash\":1,\"allowHtmlInTitles\":0}},\"csp\":{\"nonce\":\"b2QG0VdaQSskNjxonyxYTw\"},\"user\":{\"uid\":0,\"permissionsHash\":\"2955e7a5b922838f5883d0eac436ac44b4eef028a873170b7ce2722155bce7af\"}}</script>\n",
       "<script src=\"//cdn.sheffield.ac.uk/sites/default/files/js/js_OCH5IjjFOJjDDbsbtst5iYlI8hsXVKvXgWNwV9POI_4.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=uos_public&amp;include=eJxNjEEKgDAMBD9U7JNCm0ap1q7G5KCvFxHE28wchhcp1aCUmKGlosePhlHRTXoJ8-6iJ3ml5AbGujUxiX8JjoM2z61ynBpyauFyzTTCe0n2jN98A0vELbc\"></script>\n",
       "</body>\n",
       "</html>"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "soup = BeautifulSoup(response.text, 'html.parser')\n",
    "soup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "6b38c454",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<a class=\"uoslink\" data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"edf8dcab-0b02-4f69-94dd-d07a898b7785\" href=\"/media/99966/download?attachment\" title=\"TSD 27\">Prioritising studies and outcomes for consideration in NICE HealthTech literature reviews</a>,\n",
       " <a class=\"uoslink\" data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"87656a69-d711-4a1c-b723-195e2d5cab27\" href=\"/media/94031/download?attachment\" title=\"TSD26\">Expert elicitation for long-term survival outcomes</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"c12c8af9-1d09-4b4a-83dc-36b03b08bf5f\" href=\"/media/83861/download?attachment\" title=\"TSD 25: Evidence Synthesis of Diagnostic Test Accuracy for Decision Making\">Evidence Synthesis of Diagnostic Test Accuracy for Decision Making</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"93b93149-53b5-4764-8bf1-8a9913adcc77\" href=\"/media/65536/download?attachment\" title=\"TSD 24 Adjusting survival time estimates in the presence of treatment switching\">Adjusting survival time estimates in the presence of treatment switching [Update of TSD16]</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"c539ac6e-c5ee-49f2-a57d-d7d396ec906b\" href=\"/media/57671/download?attachment\" title=\"TSD23: Severity shortfall \">A guide to calculating severity shortfall for nice evaluations</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"2b8c816b-b4d8-4325-9167-eea6489dd270\" href=\"/media/42422/download?attachment\" title=\"TSD22 Mapping\">Mapping to estimate health state utilities</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"36ac7da4-8e11-40ae-9fed-8d11efab98b0\" href=\"/media/34188/download?attachment\" title=\"DSU NICE DSU Flex Surv TSD 21_Final_alt_text_updated\">Flexible methods for survival analysis</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"76cc077b-9849-4a09-8c66-70b36e2c4f7c\" href=\"/media/34200/download?attachment\" title=\"DSU TSD20 Version2\">Multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"96bc8e0f-702f-4398-90ee-805c9cdc760a\" href=\"/media/34205/download?attachment\" title=\"DSU TSD19-Partitioned-Survival-Analysis-final-report\">Partitioned survival analysis as a decision modelling tool</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"0f7ff767-30e8-4cef-8b54-38d44eefd343\" href=\"/media/34216/download?attachment\" title=\"DSU TSD18 Population-adjustment-TSD-FINAL\">Methods for population-adjusted indirect comparisons in submissions to NICE</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"115a94aa-c823-4786-95d5-22e562faae08\" href=\"/media/34204/download?attachment\" title=\"DSU TSD17-DSU-Observational-data-FINAL\">The use of observational data to inform estimates of treatment effectiveness in technology appraisal: Methods for comparative individual patient data</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"7c3f42d4-a47f-46a7-86f6-9c75f324beb2\" href=\"/media/34229/download?attachment\" title=\"DSU TSD16_Treatment_Switching\">Adjusting survival time estimates in the presence of treatment switching</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"0d7effb9-345c-4379-a7ad-5c9e1cfb9a3c\" href=\"/media/34206/download?attachment\" title=\"DSU TSD15_Patient-level_simulation\">Cost-effectiveness modelling using patient-level simulation</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"a5e5c954-1dcd-4103-91bf-e1d58897e378\" href=\"/media/34225/download?attachment\" title=\"DSU TSD14-Survival-analysis.updated-March-2013.v2\">Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"7c88c6ae-18dc-45e7-a046-9c1903050921\" href=\"/media/34222/download?attachment\" title=\"DSU TSD13-model-parameters\">Identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"3dfd9a6b-7888-4fab-ab47-25c0b40954a7\" href=\"/media/34240/download?attachment\" title=\"DSU TSD12-Utilities-in-modelling-FINAL\">The use of health state utility values in decision models</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"f0c54038-4f70-4872-91a5-b5c856ccb01e\" href=\"/media/34238/download?attachment\" title=\"DSU TSD11-Alternatives-to-EQ-5D_final\">Alternatives to EQ-5D for generating health state utility values</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"6f4f79c3-cf9c-4466-847b-61b2f5595dbd\" href=\"/media/34237/download?attachment\" title=\"DSU TSD10-mapping-FINAL\">The use of mapping methods to estimate health state utility values</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"7cf369bf-87be-4a90-ae3c-9061ee5e53c8\" href=\"/media/34236/download?attachment\" title=\"DSU TSD9-HSUV-values_FINAL\">The identification, review and synthesis of health state utility values from the literature</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"d4dcba01-4aa7-45da-85f3-71697c306b1e\" href=\"/media/34235/download?attachment\" title=\"DSU TSD8-Introduction-to-MVH_final\">An introduction to the measurement and valuation of health for NICE submissions</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"103c0d2d-9cbd-4973-a0a3-1dc99c86cebc\" href=\"/media/34186/download?attachment\" title=\"DSU TSD7-reviewer-checklist.final_.08.05.12\">Evidence synthesis of treatment efficacy in decision making: a reviewer’s checklist</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"6a9f7a41-773d-4f9d-a002-8ca06ef915a9\" href=\"/media/34185/download?attachment\" title=\"DSU TSD6-Software.final_.08.05.12\">Embedding evidence synthesis in probabilistic cost effectiveness analysis: Software choices</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"42f687a2-7155-4a6d-8766-24ab60db3f3a\" href=\"/media/34183/download?attachment\" title=\"DSU TSD5-Baseline.final-report.08.05.12\">Evidence synthesis in the baseline natural history model</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"aa221e93-eb9b-4e7f-b1b2-8922fa5bebb6\" href=\"/media/34181/download?attachment\" title=\"DSU TSD4-Inconsistency.final_.15April2014\">Inconsistency in networks of evidence based on randomised controlled trials</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"c4f59c60-1dc6-4221-b154-fab8402a0cea\" href=\"/media/34179/download?attachment\" title=\"DSU TSD3-Heterogeneity.final-report.08.05.12\">Heterogeneity: subgroups, meta-regression, bias and bias-adjustment</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"d026f634-a01f-4463-ab34-85a397f87378\" href=\"/media/34176/download?attachment\" title=\"DSU TSD2-General-meta-analysis-corrected-2Sep2016v2\">A general linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials</a>,\n",
       " <a data-entity-substitution=\"media_download\" data-entity-type=\"media\" data-entity-uuid=\"ccda9572-c753-4aa3-995f-a22fc0b6f108\" href=\"/media/34175/download?attachment\" title=\"DSU TSD1-Introduction.final_.08.05.12\">Introduction to evidence synthesis for decision making</a>]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "links = soup.find_all('a', href=re.compile(r'/download\\?attachment', re.IGNORECASE))\n",
    "links"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "36c2e6e4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "27"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(links)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "57bc2656",
   "metadata": {},
   "outputs": [],
   "source": [
    "def clean_filename(text):\n",
    "    \"\"\"Removes illegal characters and technical suffixes from filenames.\"\"\"\n",
    "    # Remove the (PDF, XXXKB) part often found in the link text\n",
    "    text = re.sub(r'\\(PDF,.*?\\)', '', text, flags=re.IGNORECASE)\n",
    "    # Remove characters that aren't allowed in filenames\n",
    "    text = re.sub(r'[\\\\/*?:\"<>|]', \"\", text)\n",
    "    return text.strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b5391e94",
   "metadata": {},
   "outputs": [],
   "source": [
    "def download_pdfs():\n",
    "    print(f\"Connecting to {url}...\")\n",
    "    try:\n",
    "        response = requests.get(url)\n",
    "        response.raise_for_status()\n",
    "    except requests.exceptions.RequestException as e:\n",
    "        print(f\"Error fetching the page: {e}\")\n",
    "        return\n",
    "\n",
    "    soup = BeautifulSoup(response.text, 'html.parser')\n",
    "    \n",
    "    # Find all anchor tags that link to TSD document download\n",
    "    links = soup.find_all('a', href=re.compile(r'/download\\?attachment', re.IGNORECASE))\n",
    "    \n",
    "    print(f\"Found {len(links)} PDF links. Starting download...\")\n",
    "\n",
    "    for link in links:\n",
    "        pdf_url = urljoin(url, link['href'])\n",
    "        \n",
    "        # Use the link text as the filename for better metadata/organization\n",
    "        raw_name = link.get_text() or pdf_url.split('/')[-1]\n",
    "        filename = clean_filename(raw_name) + \".pdf\"\n",
    "        filepath = os.path.join(folder_name, filename)\n",
    "\n",
    "        try:\n",
    "            print(f\"Downloading: {filename}...\")\n",
    "            pdf_data = requests.get(pdf_url)\n",
    "            pdf_data.raise_for_status()\n",
    "\n",
    "            with open(filepath, 'wb') as f:\n",
    "                f.write(pdf_data.content)\n",
    "        except Exception as e:\n",
    "            print(f\"Failed to download {pdf_url}: {e}\")\n",
    "\n",
    "    print(\"\\nDownload complete. Check the 'NICE_TSD_PDFs' folder.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "6520e750",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Connecting to https://sheffield.ac.uk/nice-dsu/tsds/full-list...\n",
      "Found 27 PDF links. Starting download...\n",
      "Downloading: Prioritising studies and outcomes for consideration in NICE HealthTech literature reviews.pdf...\n",
      "Downloading: Expert elicitation for long-term survival outcomes.pdf...\n",
      "Downloading: Evidence Synthesis of Diagnostic Test Accuracy for Decision Making.pdf...\n",
      "Downloading: Adjusting survival time estimates in the presence of treatment switching [Update of TSD16].pdf...\n",
      "Downloading: A guide to calculating severity shortfall for nice evaluations.pdf...\n",
      "Downloading: Mapping to estimate health state utilities.pdf...\n",
      "Downloading: Flexible methods for survival analysis.pdf...\n",
      "Downloading: Multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints.pdf...\n",
      "Downloading: Partitioned survival analysis as a decision modelling tool.pdf...\n",
      "Downloading: Methods for population-adjusted indirect comparisons in submissions to NICE.pdf...\n",
      "Downloading: The use of observational data to inform estimates of treatment effectiveness in technology appraisal Methods for comparative individual patient data.pdf...\n",
      "Downloading: Adjusting survival time estimates in the presence of treatment switching.pdf...\n",
      "Downloading: Cost-effectiveness modelling using patient-level simulation.pdf...\n",
      "Downloading: Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data.pdf...\n",
      "Downloading: Identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models.pdf...\n",
      "Downloading: The use of health state utility values in decision models.pdf...\n",
      "Downloading: Alternatives to EQ-5D for generating health state utility values.pdf...\n",
      "Downloading: The use of mapping methods to estimate health state utility values.pdf...\n",
      "Downloading: The identification, review and synthesis of health state utility values from the literature.pdf...\n",
      "Downloading: An introduction to the measurement and valuation of health for NICE submissions.pdf...\n",
      "Downloading: Evidence synthesis of treatment efficacy in decision making a reviewer’s checklist.pdf...\n",
      "Downloading: Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices.pdf...\n",
      "Downloading: Evidence synthesis in the baseline natural history model.pdf...\n",
      "Downloading: Inconsistency in networks of evidence based on randomised controlled trials.pdf...\n",
      "Downloading: Heterogeneity subgroups, meta-regression, bias and bias-adjustment.pdf...\n",
      "Downloading: A general linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials.pdf...\n",
      "Downloading: Introduction to evidence synthesis for decision making.pdf...\n",
      "\n",
      "Download complete. Check the 'NICE_TSD_PDFs' folder.\n"
     ]
    }
   ],
   "source": [
    "download_pdfs()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "334f365e",
   "metadata": {},
   "source": [
    "# Ingestion"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1a0db837",
   "metadata": {},
   "source": [
    "## PyMuPDF"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "f26f54bd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "WindowsPath('c:/Users/Public/Documents/MARIO/NICE_TSD_PDFs')"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import fitz  # PyMuPDF\n",
    "from pathlib import Path\n",
    "\n",
    "Path.joinpath(Path.cwd(), folder_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "66733bc2",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "<>:1: SyntaxWarning: invalid escape sequence '\\A'\n",
      "<>:1: SyntaxWarning: invalid escape sequence '\\A'\n",
      "C:\\Users\\DevanshUpadhyay\\AppData\\Local\\Temp\\ipykernel_2808\\2559908142.py:1: SyntaxWarning: invalid escape sequence '\\A'\n",
      "  file = \"NICE_TSD_PDFs\\A general linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials.pdf\"\n"
     ]
    }
   ],
   "source": [
    "file = \"NICE_TSD_PDFs\\A general linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials.pdf\"\n",
    "doc = fitz.open(file)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "aa4b263b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'format': 'PDF 1.5',\n",
       " 'title': 'Microsoft Word - TSD2 General meta analysis corrected 2Sep2016v2.docx',\n",
       " 'author': 'epsdsd',\n",
       " 'subject': '',\n",
       " 'keywords': '',\n",
       " 'creator': '',\n",
       " 'producer': 'PDF Writer - bioPDF / http://www.biopdf.com / CP / The University Of Bristol',\n",
       " 'creationDate': \"D:20160902140031+01'00'\",\n",
       " 'modDate': \"D:20160902140031+01'00'\",\n",
       " 'trapped': '',\n",
       " 'encryption': None}"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "doc.metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "c65bd901",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('11 \\n'\n",
      " ' \\n'\n",
      " '2 DEVELOPMENT OF THE CORE MODELS: BINOMIAL DATA \\n'\n",
      " 'WITH LOGIT LINK \\n'\n",
      " 'Consider a set of M trials comparing two treatments 1 and 2 in a '\n",
      " 'pre-specified target patient \\n'\n",
      " 'population, which are to be synthesised in a meta-analysis. A fixed effect '\n",
      " 'analysis would \\n'\n",
      " 'assume that each study i generates an estimate of the same parameter d12, '\n",
      " 'subject to sampling \\n'\n",
      " 'error. In a random effects model, each study i provides an estimate of the '\n",
      " 'study-specific \\n'\n",
      " 'treatment effects δi,12 which are assumed not to be equal but rather '\n",
      " 'exchangeable. This means \\n'\n",
      " 'that all δi,12 are ‘similar’ in a way which assumes that the trial labels, '\n",
      " 'i, attached to the treatment \\n'\n",
      " 'effects δi,12 are irrelevant. In other words, the information that the '\n",
      " 'trials provide is independent \\n'\n",
      " 'of the order in which they were carried out, over the population of '\n",
      " 'interest.30 The \\n'\n",
      " 'exchangeability assumption is equivalent to saying that the trial-specific '\n",
      " 'treatment effects come \\n'\n",
      " 'from a common distribution with mean d12 and variance \\n'\n",
      " '2\\n'\n",
      " '12\\n'\n",
      " 'σ\\n'\n",
      " '.  \\n'\n",
      " 'The common distribution is usually chosen to be a normal distribution, so '\n",
      " 'that \\n'\n",
      " ' \\n'\n",
      " '2\\n'\n",
      " ',12\\n'\n",
      " '12\\n'\n",
      " '12\\n'\n",
      " '~\\n'\n",
      " '(\\n'\n",
      " ',\\n'\n",
      " ')\\n'\n",
      " 'i\\n'\n",
      " 'N d\\n'\n",
      " 'δ\\n'\n",
      " 'σ\\n'\n",
      " ' \\n'\n",
      " '(1) \\n'\n",
      " 'It follows that the fixed effect model is a special case of this, obtained '\n",
      " 'by setting the variance \\n'\n",
      " 'to zero.   \\n'\n",
      " 'Note that in the case of a meta-analysis of only two treatments the '\n",
      " 'subscripts in d, δ and σ are \\n'\n",
      " 'redundant since only one treatment comparison is being made. We shall drop '\n",
      " 'the subscripts for \\n'\n",
      " 'σ, but will keep the subscripts for δ and d, to allow for extensions to '\n",
      " 'multiple treatments in \\n'\n",
      " 'Section 5.  \\n'\n",
      " ' \\n'\n",
      " '2.1 WORKED EXAMPLE: A LOGIT MODEL FOR A META-ANALYSIS OF BINOMIAL \\n'\n",
      " 'DATA \\n'\n",
      " 'Carlin31 and the WinBUGS user manual26 consider a meta-analysis of 22 trials '\n",
      " 'of beta-blockers \\n'\n",
      " 'to prevent mortality after myocardial infarction. The data available are the '\n",
      " 'number of deaths in \\n'\n",
      " 'the treated and control arms, out of the total number of patients in each '\n",
      " 'arm, for all 22 trials \\n'\n",
      " '(Table 1).  \\n'\n",
      " ' \\n'\n",
      " ' \\n')\n"
     ]
    }
   ],
   "source": [
    "from pprint import pprint\n",
    "pprint(doc.load_page(10).get_text())"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a75c58d7",
   "metadata": {},
   "source": [
    "## Docling"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "ab5d7bde",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:44,101 [RapidOCR] base.py:22: Using engine_name: torch\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:44,292 [RapidOCR] device_config.py:50: Using CPU device\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:44,311 [RapidOCR] download_file.py:68: Initiating download: https://www.modelscope.cn/models/RapidAI/RapidOCR/resolve/v3.5.0/torch/PP-OCRv4/det/ch_PP-OCRv4_det_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:46,746 [RapidOCR] download_file.py:82: Download size: 13.83MB\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:50,088 [RapidOCR] download_file.py:95: Successfully saved to: C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_det_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:50,094 [RapidOCR] main.py:50: Using C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_det_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:50,559 [RapidOCR] base.py:22: Using engine_name: torch\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:50,560 [RapidOCR] device_config.py:50: Using CPU device\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:50,561 [RapidOCR] download_file.py:68: Initiating download: https://www.modelscope.cn/models/RapidAI/RapidOCR/resolve/v3.5.0/torch/PP-OCRv4/cls/ch_ptocr_mobile_v2.0_cls_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:52,599 [RapidOCR] download_file.py:82: Download size: 0.56MB\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:53,015 [RapidOCR] download_file.py:95: Successfully saved to: C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_ptocr_mobile_v2.0_cls_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:53,018 [RapidOCR] main.py:50: Using C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_ptocr_mobile_v2.0_cls_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:53,107 [RapidOCR] base.py:22: Using engine_name: torch\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:53,108 [RapidOCR] device_config.py:50: Using CPU device\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:53,110 [RapidOCR] download_file.py:68: Initiating download: https://www.modelscope.cn/models/RapidAI/RapidOCR/resolve/v3.5.0/torch/PP-OCRv4/rec/ch_PP-OCRv4_rec_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:43:55,262 [RapidOCR] download_file.py:82: Download size: 25.67MB\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:44:01,215 [RapidOCR] download_file.py:95: Successfully saved to: C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_rec_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 19:44:01,218 [RapidOCR] main.py:50: Using C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_rec_infer.pth\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "from docling.datamodel.base_models import InputFormat\n",
    "from docling.document_converter import DocumentConverter\n",
    "\n",
    "converter = DocumentConverter()\n",
    "doc = converter.convert(file)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "f28f09d7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "## NICE DSU TECHNICAL SUPPORT DOCUMENT 2: A GENERALISED LINEAR MODELLING FRAMEWORK FOR PAIRWISE AND NETWORK META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS\n",
      "\n",
      "## R EPORT BY THE D ECISION S UPPORT U NIT\n",
      "\n",
      "August 2011 (last updated September 2016)\n",
      "\n",
      "Sofia Dias 1 , Nicky J Welton 1 , Alex J Sutton 2 , AE Ades 1\n",
      "\n",
      "1 School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK\n",
      "\n",
      "2 Department  of  Health  Sciences,  University  of  Leicester,  2nd  Floor  Adrian  Building, University Road, Leicester LE1 7RH, UK\n",
      "\n",
      "Decision Support Unit, ScHARR, University of Sheffield, Regent Court, 30 Regent Street Sheffield, S1 4DA;\n",
      "\n",
      "Tel (+44) (0)114 222 0734\n",
      "\n",
      "E-mail dsuadmin@sheffield.ac.uk\n",
      "\n",
      "## A BOUT THE D ECISION S UPPORT U NIT\n",
      "\n",
      "The Decision Support Unit (DSU) is a collaboration between the Universities of Sheffield, York and Leicester. We also have members at the University of Bristol, London School of Hygiene and Tropical Medicine and Brunel University.\n",
      "\n",
      "The DSU is commissioned by The National Institute for Health and Clinical Excellence (NICE) to  provide  a  research  and  training  resource  to  support  the  Institute's  Technology  Appraisal Programme. Please see our website for further information www.nicedsu.org.uk\n",
      "\n",
      "## A BOUT THE T ECHNICAL S UPPORT D OCUMENT SERIES\n",
      "\n",
      "The NICE Guide to the Methods of Technology Appraisal i is a regularly updated document that provides an overview of the key principles and methods of health technology assessment and appraisal for use in NICE appraisals. The Methods Guide does not provide detailed advice on how to implement and apply the methods it describes. This DSU series of Technical Support Documents  (TSDs)  is  intended  to  complement  the  Methods  Guide  by  providing  detailed information on how to implement specific methods.\n",
      "\n",
      "The TSDs provide a review of the current state of the art in each topic area, and make clear recommendations  on  the  implementation  of  methods  and  reporting  standards  where  it  is appropriate to do so. They aim to provide assistance to all those involved in submitting or critiquing evidence as part of  NICE  Technology  Appraisals,  whether  manufacturers, assessment groups or any other stakeholder type.\n",
      "\n",
      "We recognise that there are areas of uncertainty, controversy and rapid development. It is our intention that such areas are indicated in the TSDs. All TSDs are extensively peer reviewed prior to publication (the names of peer reviewers appear in the acknowledgements for each document). Nevertheless, the responsibility for each TSD lies with the authors and we welcome any constructive feedback on the content or suggestions for further guides.\n",
      "\n",
      "Please be aware that whilst the DSU is funded by NICE, these documents do not constitute formal NICE guidance or policy.\n",
      "\n",
      "## Dr Allan Wailoo\n",
      "\n",
      "Director of DSU and TSD series editor.\n",
      "\n",
      "i National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal, 2008 (updated June 2008), London.\n",
      "\n",
      "## Acknowledgements\n",
      "\n",
      "The DSU thanks Mike Campbell, Rachael Fleurence, Julian Higgins, Jeroen Jansen, Steve Palmer and the team at NICE, led by Zoe Garrett, for reviewing this document. The authors thank Gabriel Rogers and Marta Soares for useful comments on the Appendix. The editor for the TSD series is Allan Wailoo.\n",
      "\n",
      "The production of this document was funded by the National Institute for Health and Clinical Excellence (NICE) through its Decision Support Unit. The views, and any errors or omissions, expressed in this document are of the author only. NICE may take account of part or all of this document if it considers it appropriate, but it is not bound to do so.\n",
      "\n",
      "## This report should be referenced as follows:\n",
      "\n",
      "Dias, S., Welton, N.J., Sutton, A.J. &amp; Ades, A.E. NICE DSU Technical Support Document 2: A  Generalised  Linear  Modelling  Framework  for  Pairwise  and  Network  Meta-Analysis  of Randomised Controlled Trials. 2011; last updated September 2016; available from http://www.nicedsu.org.uk\n",
      "\n",
      "## EXECUTIVE SUMMARY\n",
      "\n",
      "This paper sets out a generalised linear model (GLM) framework for the synthesis of data from randomised controlled trials (RCTs). We describe a common model taking the form of a linear regression for both fixed and random effects synthesis, that can be implemented with Normal, Binomial, Poisson, and Multinomial data. The familiar logistic model for meta-analysis with Binomial  data  is  a  GLM  with  a  logit  link  function,  which  is  appropriate  for  probability outcomes. The same linear regression framework can be applied to continuous outcomes, rate models, competing risks, or ordered category outcomes, by using other link functions, such as identity, log, complementary log-log, and probit link functions. The common core model for the linear predictor can be applied to pair-wise meta-analysis, indirect comparisons, synthesis of multi-arm trials, and mixed treatment comparisons, also known as network meta-analysis, without distinction.\n",
      "\n",
      "We  take  a  Bayesian  approach  to  estimation  and  provide  WinBUGS  program  code  for  a Bayesian analysis using Markov chain Monte Carlo (MCMC) simulation. An advantage of this approach is that it is straightforward to extend to shared parameter models where different RCTs report outcomes in different formats but from a common underlying model. Use of the GLM framework allows us to present a unified account of how models can be compared using the Deviance Information Criterion (DIC), and how goodness of fit can be assessed using the residual deviance. WinBUGS code for model critique is provided. Our approach is illustrated through  a  range  of  worked  examples  for  the  commonly  encountered  evidence  formats, including shared parameter models.\n",
      "\n",
      "We  give  suggestions  on  computational  issues  that  sometimes  arise  in  MCMC  evidence synthesis, and comment briefly on alternative software.\n",
      "\n",
      "## CONTENTS\n",
      "\n",
      "| 1                                                                                                                                                                                                                                                                                                                                    | INTRODUCTION TO PAIRWISE &NETWORKMETA-ANALYSIS..................9                                                                                                                                                                                                                                                                    | INTRODUCTION TO PAIRWISE &NETWORKMETA-ANALYSIS..................9                                                                                                                                                                                                                                                                    | INTRODUCTION TO PAIRWISE &NETWORKMETA-ANALYSIS..................9                                                                                                                                                                                                                                                                    |\n",
      "|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n",
      "| 2 DEVELOPMENT OF THE CORE MODELS: BINOMIAL DATA WITH LOGIT                                                                                                                                                                                                                                                                           | 2 DEVELOPMENT OF THE CORE MODELS: BINOMIAL DATA WITH LOGIT                                                                                                                                                                                                                                                                           | 2 DEVELOPMENT OF THE CORE MODELS: BINOMIAL DATA WITH LOGIT                                                                                                                                                                                                                                                                           | 2 DEVELOPMENT OF THE CORE MODELS: BINOMIAL DATA WITH LOGIT                                                                                                                                                                                                                                                                           |\n",
      "| LINK.......................................................................................................................................11                                                                                                                                                                                        | LINK.......................................................................................................................................11                                                                                                                                                                                        | LINK.......................................................................................................................................11                                                                                                                                                                                        | LINK.......................................................................................................................................11                                                                                                                                                                                        |\n",
      "| 2.1 W ORKED EXAMPLE : A LOGIT MODEL FOR A META - ANALYSIS OF BINOMIAL DATA .....11                                                                                                                                                                                                                                                   | 2.1 W ORKED EXAMPLE : A LOGIT MODEL FOR A META - ANALYSIS OF BINOMIAL DATA .....11                                                                                                                                                                                                                                                   | 2.1 W ORKED EXAMPLE : A LOGIT MODEL FOR A META - ANALYSIS OF BINOMIAL DATA .....11                                                                                                                                                                                                                                                   | 2.1 W ORKED EXAMPLE : A LOGIT MODEL FOR A META - ANALYSIS OF BINOMIAL DATA .....11                                                                                                                                                                                                                                                   |\n",
      "| 2.1.1 Model specification............................................................................................12                                                                                                                                                                                                              | 2.1.1 Model specification............................................................................................12                                                                                                                                                                                                              | 2.1.1 Model specification............................................................................................12                                                                                                                                                                                                              | 2.1.1 Model specification............................................................................................12                                                                                                                                                                                                              |\n",
      "| 2.1.2 Model fit and model comparison .......................................................................13 2.1.3 WinBUGS implementation and illustrative results............................................16 GENERALISED LINEAR MODELS .........................................................................19             | 2.1.2 Model fit and model comparison .......................................................................13 2.1.3 WinBUGS implementation and illustrative results............................................16 GENERALISED LINEAR MODELS .........................................................................19             | 2.1.2 Model fit and model comparison .......................................................................13 2.1.3 WinBUGS implementation and illustrative results............................................16 GENERALISED LINEAR MODELS .........................................................................19             | 2.1.2 Model fit and model comparison .......................................................................13 2.1.3 WinBUGS implementation and illustrative results............................................16 GENERALISED LINEAR MODELS .........................................................................19             |\n",
      "| 3.1 R ATE DATA : P OISSON LIKELIHOOD AND LOG LINK ....................................................20                                                                                                                                                                                                                             | 3.1 R ATE DATA : P OISSON LIKELIHOOD AND LOG LINK ....................................................20                                                                                                                                                                                                                             | 3.1 R ATE DATA : P OISSON LIKELIHOOD AND LOG LINK ....................................................20                                                                                                                                                                                                                             | 3.1 R ATE DATA : P OISSON LIKELIHOOD AND LOG LINK ....................................................20                                                                                                                                                                                                                             |\n",
      "| 3.2 R ATE DATA :B INOMIAL LIKELIHOOD AND CLOGLOG LINK .........................................21                                                                                                                                                                                                                                    | 3.2 R ATE DATA :B INOMIAL LIKELIHOOD AND CLOGLOG LINK .........................................21                                                                                                                                                                                                                                    | 3.2 R ATE DATA :B INOMIAL LIKELIHOOD AND CLOGLOG LINK .........................................21                                                                                                                                                                                                                                    | 3.2 R ATE DATA :B INOMIAL LIKELIHOOD AND CLOGLOG LINK .........................................21                                                                                                                                                                                                                                    |\n",
      "| 3.3 C OMPETING R ISKS :M ULTINOMIAL LIKELIHOOD AND LOG LINK ...............................23                                                                                                                                                                                                                                        | 3.3 C OMPETING R ISKS :M ULTINOMIAL LIKELIHOOD AND LOG LINK ...............................23                                                                                                                                                                                                                                        | 3.3 C OMPETING R ISKS :M ULTINOMIAL LIKELIHOOD AND LOG LINK ...............................23                                                                                                                                                                                                                                        | 3.3 C OMPETING R ISKS :M ULTINOMIAL LIKELIHOOD AND LOG LINK ...............................23                                                                                                                                                                                                                                        |\n",
      "| 3.4 C ONTINUOUS DATA :N ORMAL LIKELIHOOD AND IDENTITY LINK ...............................25 3.4.1 Before/after studies: change from baseline measures .......................................25                                                                                                                                     | 3.4 C ONTINUOUS DATA :N ORMAL LIKELIHOOD AND IDENTITY LINK ...............................25 3.4.1 Before/after studies: change from baseline measures .......................................25                                                                                                                                     | 3.4 C ONTINUOUS DATA :N ORMAL LIKELIHOOD AND IDENTITY LINK ...............................25 3.4.1 Before/after studies: change from baseline measures .......................................25                                                                                                                                     | 3.4 C ONTINUOUS DATA :N ORMAL LIKELIHOOD AND IDENTITY LINK ...............................25 3.4.1 Before/after studies: change from baseline measures .......................................25                                                                                                                                     |\n",
      "| REATMENT DIFFERENCES                                                                                                                                                                                                                                                                                                                 | REATMENT DIFFERENCES                                                                                                                                                                                                                                                                                                                 | REATMENT DIFFERENCES                                                                                                                                                                                                                                                                                                                 | REATMENT DIFFERENCES                                                                                                                                                                                                                                                                                                                 |\n",
      "| 3.5 T ........................................................................................26                                                                                                                                                                                                                                     | 3.5 T ........................................................................................26                                                                                                                                                                                                                                     | 3.5 T ........................................................................................26                                                                                                                                                                                                                                     | 3.5 T ........................................................................................26                                                                                                                                                                                                                                     |\n",
      "| 3.5.1 Standardised mean differences ..........................................................................27 3.6 O RDERED C ATEGORICAL D ATA :M ULTINOMIAL LIKELIHOOD AND PROBIT LINK .......29                                                                                                                                  | 3.5.1 Standardised mean differences ..........................................................................27 3.6 O RDERED C ATEGORICAL D ATA :M ULTINOMIAL LIKELIHOOD AND PROBIT LINK .......29                                                                                                                                  | 3.5.1 Standardised mean differences ..........................................................................27 3.6 O RDERED C ATEGORICAL D ATA :M ULTINOMIAL LIKELIHOOD AND PROBIT LINK .......29                                                                                                                                  | 3.5.1 Standardised mean differences ..........................................................................27 3.6 O RDERED C ATEGORICAL D ATA :M ULTINOMIAL LIKELIHOOD AND PROBIT LINK .......29                                                                                                                                  |\n",
      "| 3.7 A DDITIVE AND MULTIPLICATIVE EFFECTS WITH B INOMIAL D ATA , AND OTHER N ON -                                                                                                                                                                                                                                                     | 3.7 A DDITIVE AND MULTIPLICATIVE EFFECTS WITH B INOMIAL D ATA , AND OTHER N ON -                                                                                                                                                                                                                                                     | 3.7 A DDITIVE AND MULTIPLICATIVE EFFECTS WITH B INOMIAL D ATA , AND OTHER N ON -                                                                                                                                                                                                                                                     | 3.7 A DDITIVE AND MULTIPLICATIVE EFFECTS WITH B INOMIAL D ATA , AND OTHER N ON -                                                                                                                                                                                                                                                     |\n",
      "| C ANONICAL LINKS ................................................................................................................30                                                                                                                                                                                                  | C ANONICAL LINKS ................................................................................................................30                                                                                                                                                                                                  | C ANONICAL LINKS ................................................................................................................30                                                                                                                                                                                                  | C ANONICAL LINKS ................................................................................................................30                                                                                                                                                                                                  |\n",
      "| SHARED PARAMETER MODELS............................................................................31                                                                                                                                                                                                                                | SHARED PARAMETER MODELS............................................................................31                                                                                                                                                                                                                                | SHARED PARAMETER MODELS............................................................................31                                                                                                                                                                                                                                | SHARED PARAMETER MODELS............................................................................31                                                                                                                                                                                                                                |\n",
      "| EXTENSION TO INDIRECT COMPARISONS AND NETWORK META-                                                                                                                                                                                                                                                                                  | EXTENSION TO INDIRECT COMPARISONS AND NETWORK META-                                                                                                                                                                                                                                                                                  | EXTENSION TO INDIRECT COMPARISONS AND NETWORK META-                                                                                                                                                                                                                                                                                  | EXTENSION TO INDIRECT COMPARISONS AND NETWORK META-                                                                                                                                                                                                                                                                                  |\n",
      "| ANALYSIS.............................................................................................................................33                                                                                                                                                                                              | ANALYSIS.............................................................................................................................33                                                                                                                                                                                              | ANALYSIS.............................................................................................................................33                                                                                                                                                                                              | ANALYSIS.............................................................................................................................33                                                                                                                                                                                              |\n",
      "| 5.1 I NCORPORATING MULTI -A RM TRIALS ........................................................................35                                                                                                                                                                                                                     | 5.1 I NCORPORATING MULTI -A RM TRIALS ........................................................................35                                                                                                                                                                                                                     | 5.1 I NCORPORATING MULTI -A RM TRIALS ........................................................................35                                                                                                                                                                                                                     | 5.1 I NCORPORATING MULTI -A RM TRIALS ........................................................................35                                                                                                                                                                                                                     |\n",
      "| 5.1.1 Multi-arm trials with treatment differences (trial-based summaries) ...............36 TECHNICAL ISSUES IN BAYESIAN MCMC.........................................................38                                                                                                                                             | 5.1.1 Multi-arm trials with treatment differences (trial-based summaries) ...............36 TECHNICAL ISSUES IN BAYESIAN MCMC.........................................................38                                                                                                                                             | 5.1.1 Multi-arm trials with treatment differences (trial-based summaries) ...............36 TECHNICAL ISSUES IN BAYESIAN MCMC.........................................................38                                                                                                                                             | 5.1.1 Multi-arm trials with treatment differences (trial-based summaries) ...............36 TECHNICAL ISSUES IN BAYESIAN MCMC.........................................................38                                                                                                                                             |\n",
      "| 6.1 C HOICE OF REFERENCE TREATMENT .........................................................................38 6.2 C ....................................................................................................39                                                                                                          | 6.1 C HOICE OF REFERENCE TREATMENT .........................................................................38 6.2 C ....................................................................................................39                                                                                                          | 6.1 C HOICE OF REFERENCE TREATMENT .........................................................................38 6.2 C ....................................................................................................39                                                                                                          | 6.1 C HOICE OF REFERENCE TREATMENT .........................................................................38 6.2 C ....................................................................................................39                                                                                                          |\n",
      "| 6.3 Z ERO CELLS ..............................................................................................................40 NON-BAYESIAN APPROACHES AND COMPUTATIONAL ISSUES................41                                                                                                                                  | 6.3 Z ERO CELLS ..............................................................................................................40 NON-BAYESIAN APPROACHES AND COMPUTATIONAL ISSUES................41                                                                                                                                  | 6.3 Z ERO CELLS ..............................................................................................................40 NON-BAYESIAN APPROACHES AND COMPUTATIONAL ISSUES................41                                                                                                                                  | 6.3 Z ERO CELLS ..............................................................................................................40 NON-BAYESIAN APPROACHES AND COMPUTATIONAL ISSUES................41                                                                                                                                  |\n",
      "| 7.1B AYESIAN VERSUS FREQUENTIST APPROACHES IN THE CONTEXT OF DECISION MAKING ..41                                                                                                                                                                                                                                                    | 7.1B AYESIAN VERSUS FREQUENTIST APPROACHES IN THE CONTEXT OF DECISION MAKING ..41                                                                                                                                                                                                                                                    | 7.1B AYESIAN VERSUS FREQUENTIST APPROACHES IN THE CONTEXT OF DECISION MAKING ..41                                                                                                                                                                                                                                                    | 7.1B AYESIAN VERSUS FREQUENTIST APPROACHES IN THE CONTEXT OF DECISION MAKING ..41                                                                                                                                                                                                                                                    |\n",
      "| 7.2. C OMPARISON OF META - ANALYTIC METHODS ............................................................42 7.3. C OMPARISON OF EVIDENCE SYNTHESIS SOFTWARE ...................................................43 FURTHER READING..................................................................................................44 | 7.2. C OMPARISON OF META - ANALYTIC METHODS ............................................................42 7.3. C OMPARISON OF EVIDENCE SYNTHESIS SOFTWARE ...................................................43 FURTHER READING..................................................................................................44 | 7.2. C OMPARISON OF META - ANALYTIC METHODS ............................................................42 7.3. C OMPARISON OF EVIDENCE SYNTHESIS SOFTWARE ...................................................43 FURTHER READING..................................................................................................44 | 7.2. C OMPARISON OF META - ANALYTIC METHODS ............................................................42 7.3. C OMPARISON OF EVIDENCE SYNTHESIS SOFTWARE ...................................................43 FURTHER READING..................................................................................................44 |\n",
      "| 9. DISCUSSION.................................................................................................................45                                                                                                                                                                                                     | 9. DISCUSSION.................................................................................................................45                                                                                                                                                                                                     | 9. DISCUSSION.................................................................................................................45                                                                                                                                                                                                     | 9. DISCUSSION.................................................................................................................45                                                                                                                                                                                                     |\n",
      "| 10. REFERENCES...............................................................................................................48 APPENDIX: ILLUSTRATIVE EXAMPLES AND WINBUGS CODE ..........................56                                                                                                                        | 10. REFERENCES...............................................................................................................48 APPENDIX: ILLUSTRATIVE EXAMPLES AND WINBUGS CODE ..........................56                                                                                                                        | 10. REFERENCES...............................................................................................................48 APPENDIX: ILLUSTRATIVE EXAMPLES AND WINBUGS CODE ..........................56                                                                                                                        | 10. REFERENCES...............................................................................................................48 APPENDIX: ILLUSTRATIVE EXAMPLES AND WINBUGS CODE ..........................56                                                                                                                        |\n",
      "| EXAMPLE 1. B LOCKER ....................................................................................................57                                                                                                                                                                                                           | EXAMPLE 1. B LOCKER ....................................................................................................57                                                                                                                                                                                                           | EXAMPLE 1. B LOCKER ....................................................................................................57                                                                                                                                                                                                           | EXAMPLE 1. B LOCKER ....................................................................................................57                                                                                                                                                                                                           |\n",
      "| IETARY FAT                                                                                                                                                                                                                                                                                                                           | IETARY FAT                                                                                                                                                                                                                                                                                                                           | IETARY FAT                                                                                                                                                                                                                                                                                                                           | IETARY FAT                                                                                                                                                                                                                                                                                                                           |\n",
      "| EXAMPLE 2. D ..............................................................................................62 R ESULTS 65 EXAMPLE 3. D IABETES ...................................................................................................66                                                                                 | EXAMPLE 2. D ..............................................................................................62 R ESULTS 65 EXAMPLE 3. D IABETES ...................................................................................................66                                                                                 | EXAMPLE 2. D ..............................................................................................62 R ESULTS 65 EXAMPLE 3. D IABETES ...................................................................................................66                                                                                 | EXAMPLE 2. D ..............................................................................................62 R ESULTS 65 EXAMPLE 3. D IABETES ...................................................................................................66                                                                                 |\n",
      "| R ESULTS 70                                                                                                                                                                                                                                                                                                                          | R ESULTS 70                                                                                                                                                                                                                                                                                                                          | R ESULTS 70                                                                                                                                                                                                                                                                                                                          | R ESULTS 70                                                                                                                                                                                                                                                                                                                          |\n",
      "| CHIZOPHRENIA                                                                                                                                                                                                                                                                                                                         | CHIZOPHRENIA                                                                                                                                                                                                                                                                                                                         | CHIZOPHRENIA                                                                                                                                                                                                                                                                                                                         | CHIZOPHRENIA                                                                                                                                                                                                                                                                                                                         |\n",
      "| EXAMPLE 4. S .........................................................................................72                                                                                                                                                                                                                             | EXAMPLE 4. S .........................................................................................72                                                                                                                                                                                                                             | EXAMPLE 4. S .........................................................................................72                                                                                                                                                                                                                             | EXAMPLE 4. S .........................................................................................72                                                                                                                                                                                                                             |\n",
      "\n",
      "| R ESULTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 77                                                                                                                 |       |    |\n",
      "|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------|----|\n",
      "| EXAMPLE 5. R ESULTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | P ARKINSON ' S .............................................................................................78 81  |       |    |\n",
      "| EXAMPLE 6.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | P SORIASIS ...................................................................................................83   |       |    |\n",
      "| R ESULTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 91 P ARKINSON ' S D IFFERENCE ( TREATMENT DIFFERENCES AS DATA ) ..............92                                   |       |    |\n",
      "| EXAMPLE 7.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                    |       |    |\n",
      "| R ESULTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 95                                                                                                                 |       |    |\n",
      "| EXAMPLE 8.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | ARKINSON ' S SHARED PARAMETERS ( MIXED TREATMENT DIFFERENCE AND                                                    |       | P  |\n",
      "| ARM - LEVEL DATA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | ................................................................................................................96 |       |    |\n",
      "| R ESULTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ) 98                                                                                                               |       |    |\n",
      "| TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                    |       |    |\n",
      "| Table 1 Blocker example: number of events and total number of patients in the control and beta-blocker groups for the 22 trials. 31 .........................................................................................................................................12                                                                                                                                                                                                                                                                                                               |                                                                                                                    |       |    |\n",
      "| Table 2 Blocker example: posterior mean, standard deviation (sd), median and 95% Credible interval (CrI) for both the fixed and random effects models for the treatment effect d 12 , absolute effects of the placebo ( T 1 ) and beta-blocker ( T 2 ) for a mean mortality of -2.2 and precision 3.3 on the logit scale; heterogeneity parameter σ and model fit statistics.............................................................................................................16                                                                                                   |                                                                                                                    |       |    |\n",
      "| Table 3 Commonly used link functions and their inverse with reference to which likelihoods they can be applied                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                    |       |    |\n",
      "| to. ................................................................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                    |       |    |\n",
      "| Table A1 Index of WinBUGS code with details of examples and sections where they are described. ................56                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                    |       |    |\n",
      "| Table A2 Dietary fat example: Study names and treatment codes for the 10 included studies and person-years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                    |       |    |\n",
      "| and total mortality observed in each study..................................................................................................62 Table A3 Dietary fat example: posterior mean, standard deviation (sd), median and 95% Credible interval (CrI) for both the fixed and random effects models for the treatment effect d 12 , absolute effects of the control                                                                                                                                                                                                                     |                                                                                                                    |       |    |\n",
      "| diet ( T 1 ) and the reduced fat diet ( T 2 ) for a log-rate of mortality on the control diet with mean -3 and precision 1.77, heterogeneity parameter τ and model fit statistics. .............................................................66 A4 Diabetes example: study names, follow-up time in years, treatments compared, total number of new cases of diabetes and number of patients in each trial arm, where Diuretic = treatment 1, Placebo = treatment 2, β blocker = treatment 3, CCB = treatment 4, ACE inhibitor = treatment 5 and ARB = 105                                 |                                                                                                                    |       |    |\n",
      "| Table treatment 6. ..............................................................................................................................................67 Table A5 Diabetes example: posterior mean, standard deviation (sd), median and 95% Credible interval (CrI)                                                                                                                                                                                                                                                                                                                |                                                                                                                    |       |    |\n",
      "| for both the fixed and random effects models for the treatment effects of Placebo ( d 12 ), β blocker ( d 13 ), CCB ( d 14 ), ACE inhibitor ( d 15 ) and ARB ( d 16 ) relative to Diuretic; absolute effects of diuretic ( T 1 ) Placebo                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                    |       |    |\n",
      "| ( T 2 ), β blocker ( T 3 ), CCB ( T 4 ), ACE inhibitor ( T 5 ) and ARB ( T 6 ); heterogeneity parameter τ and model fit statistics.......................................................................................................................................................71 A6 Schizophrenia example: study names, follow-up time in weeks, treatments compared, total number of events for each of the four states and total number of patients in each trial arm, where Placebo = treatment                                                                                 |                                                                                                                    |       |    |\n",
      "| 1, Olanzapine = 2, Amisulpride = 3, Zotepine = 4, Aripripazole = 5, Ziprasidone = 6, Paliperidone = 7, 45                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                    |       |    |\n",
      "| Haloperidol = 8, Risperidone = 9. ............................................................................................................72 A7 Schizophrenia example: posterior mean, standard deviation (sd), median and 95% Credible interval                                                                                                                                                                                                                                                                                                                                          |                                                                                                                    |       |    |\n",
      "| (CrI) for both the fixed and random effects models for the treatment effects of Olanzapine ( d 12 ), Amisulpride ( d 13 ), Zotepine ( d 14 ), Aripripazole ( d 15 ), Ziprasidone ( d 16 ), Paliperidone ( d 17 ), Haloperidol ( d 18 ) and Risperidone ( d 19 ) relative to Placebo, absolute probabilities of reaching each of the outcomes for Placebo ( Pr 1 ), Olanzapine ( Pr 2 ), Amisulpride ( Pr 3 ), Zotepine ( Pr 4 ), Aripripazole ( Pr 5 ), Ziprasidone ( Pr 6 ), Paliperidone ( Pr 7 ), Haloperidol ( Pr 8 ) and Risperidone ( Pr 9 ); heterogeneity parameter τ for each of the |                                                                                                                    |       |    |\n",
      "| three outcomes, and model fit statistics for the fixed and random effects models......................................77                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                    |       |    |\n",
      "| A8 Parkinson's example: study names, treatments compared, mean off-time reduction with its standard deviation, total number of patients in each trial arm; treatment differences and standard error of the                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                    |       |    |\n",
      "| Table                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                    |       |    |\n",
      "| differences; where treatment 1 is a placebo and treatments 2-5 are active drugs........................................79                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                    |       |    |\n",
      "| Table A9 Parkinson example: posterior mean, standard deviation (sd), median and 95% Credible interval (CrI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                    |       |    |\n",
      "| Table                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                    | Table |    |\n",
      "\n",
      "| Table A10 Psoriasis example: study names, treatments compared, total number of patients with different percentage improvement and total number of patients in each trial arm, where Supportive Care = treatment 1, Etanercept 25mg = 2, Etanercept 50 mg = 3, Efalizumab = 4, Ciclosporin = 5, Fumaderm = 6, Infliximab = 7, Methotreaxate = 8. 52 ...........................................................................................................86 Table A11 Psoriasis example: posterior mean, standard deviation (sd), median and 95% Credible interval (CrI)                     |\n",
      "|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n",
      "| for the fixed and random effects models for the treatment effects, on the probit scale, of Etanercept 25 mg ( d 12 ), Etanercept 50 mg ( d 13 ), Efalizumab ( d 14 ), Ciclosporin ( d 15 ) , Fumaderm ( d 16 ) , Infliximab ( d 17 ), and Methotrexate ( d 18 ) relative to Supportive Care; absolute probabilities of achieving at least 50, 70 or 90% relief in symptoms for each treatment; heterogeneity parameter τ and model fit statistics. ........................91                                                                                                                     |\n",
      "| Figure 1 Blocker example: Plot of leverage versus Bayesian deviance residual w ik for each data point, with curves of the form x 2 + y = c , with c =1 (solid), c=2 (dashed), c=3 (dotted) and c=4 (dot-dashed), for the fixed effect model. ......................................................................................................................................17                                                                                                                                                                                                             |\n",
      "| Figure 2 Blocker example: Plot of leverage versus Bayesian deviance residual w ik for each data point, with curves of the form x 2 + y = c , with c =1 (solid), c=2 (dashed), c=3 (dotted) and c=4 (dot-dashed), for the random effects model..................................................................................................................................18                                                                                                                                                                                                                 |\n",
      "| which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison and the numbers by the treatment names are the treatment codes used in the modelling. ...................................................................................................................................................68 Figure A4 Schizophrenia network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the |\n",
      "| numbers of trials making that comparison and the numbers by the treatment names are the treatment codes used in the modelling. .................................................................................................................................73 Figure A5 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison and the numbers by the treatment names are the treatment codes used in the |\n",
      "| modelling. ...................................................................................................................................................79 A6 Psoriasis network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison and the numbers by the treatment names are the treatment codes used in the                                                                                                          |\n",
      "| Figure modelling. One trial compared two arms of Ciclosporin with Placebo and another compared two arms of Infliximab with placebo - these comparisons are not represented in the network......................................83                                                                                                                                                                                                                                                                                                                                                                 |\n",
      "\n",
      "## Abbreviations and Definitions\n",
      "\n",
      "ACR\n",
      "\n",
      "American College of Rheumatology\n",
      "\n",
      "ANCOVA\n",
      "\n",
      "Analysis of covariance\n",
      "\n",
      "CEA\n",
      "\n",
      "cost-effectiveness analysis\n",
      "\n",
      "cloglog\n",
      "\n",
      "complementary log-log\n",
      "\n",
      "DIC\n",
      "\n",
      "Deviance information criterion\n",
      "\n",
      "Φ\n",
      "\n",
      "Normal cumulative distribution function\n",
      "\n",
      "GLM\n",
      "\n",
      "Generalised linear models\n",
      "\n",
      "LRR\n",
      "\n",
      "log-relative risk\n",
      "\n",
      "MAR\n",
      "\n",
      "missing at random\n",
      "\n",
      "MC\n",
      "\n",
      "Monte Carlo\n",
      "\n",
      "MCMC\n",
      "\n",
      "Markov chain Monte Carlo\n",
      "\n",
      "ML\n",
      "\n",
      "maximum likelihood\n",
      "\n",
      "MTC\n",
      "\n",
      "Mixed treatment comparisons\n",
      "\n",
      "N\n",
      "\n",
      "normal distribution\n",
      "\n",
      "NNT\n",
      "\n",
      "numbers needed to treat\n",
      "\n",
      "PASI\n",
      "\n",
      "Psoriasis area severity score\n",
      "\n",
      "RCT\n",
      "\n",
      "Randomised controlled trial\n",
      "\n",
      "RD\n",
      "\n",
      "risk difference\n",
      "\n",
      "RR\n",
      "\n",
      "relative risk\n",
      "\n",
      "SMD\n",
      "\n",
      "Standardised mean difference\n",
      "\n",
      "## 1 INTRODUCTION TO PAIRWISE &amp; NETWORK META-ANALYSIS\n",
      "\n",
      "Meta-analysis,  the  pooling  of  evidence  from  independent  sources,  especially  randomised controlled  trials  (RCTs)  is  now  common  in  the  medical  research  literature.  There  is  a substantial  literature  on  statistical  methods  for  meta-analysis,  going  back  to  methods  for combination of results from two-by-two tables, 1 with the introduction of random effects metaanalysis 2 a  second  important  benchmark  in  the  development  of  the  field.  Over  the  years methodological and software advances have contributed to the widespread use of meta-analytic techniques.  A  series  of  instructional  texts  and  reviews  have  appeared, 3-7 and  Sutton  and Higgins 8 provide a review of recent developments.\n",
      "\n",
      "With some exceptions, 9,10 there have been few attempts to systematise the field. A wide range of alternative methods are employed, mostly relevant to binary and continuous outcomes. Our purpose here is to present a single unified account of evidence synthesis of aggregate data from RCTs, specifically, but not exclusively, for use in probabilistic decision making. 11 In order to cover the variety of outcomes reported in trials and the range of data transformations required to achieve linearity, we adopt the framework of generalised linear modelling. 12 This provides for  Normal,  Binomial,  Poisson  and  Multinomial  likelihoods,  with  identity,  logit,  log, complementary log-log,  and  probit  link  functions,  and  common  core  models  for  the  linear predictor in both fixed effects and random effects settings.\n",
      "\n",
      "Indirect  and  mixed  treatment  comparisons  (MTC),  also  known  as  network  meta-analysis, represent  a  recent  development  in  evidence  synthesis,  particularly  in  decision  making contexts. 13-23 Rather than pooling information on trials comparing treatments A and B, network meta-analysis combines data from randomised comparisons, A vs B, A vs C, A vs D, B vs D, and so on, to deliver an internally consistent set of estimates while respecting the randomisation in the evidence. 24 Our common core models are designed for network meta-analysis, and can synthesise  data  from  pair-wise  meta-analysis,  multi-arm  trials,  indirect  comparisons  and network  meta-analysis  without  distinction.  Indeed,  pair-wise  meta-analysis  and  indirect comparisons are special cases of network meta-analysis.\n",
      "\n",
      "The common Generalised Linear Model (GLM) framework can, of course, be applied in either frequentist or Bayesian contexts. However, Bayesian Markov Chain Monte Carlo (MCMC) has  for  many  years  been  the  mainstay  of  'comprehensive  decision  analysis', 25 because simulation  from  a  Bayesian  posterior  distribution  supplies  both  statistical  estimation  and inference,  and  a  platform  for  probabilistic  decision  making  under  uncertainty.  The  freely available WinBUGS 1.4.3 MCMC package 26 takes full advantage of the modularity afforded\n",
      "\n",
      "by a GLM approach to synthesis, allowing us to present a unified treatment of the fixed and random effects models for meta-analysis and model critique.\n",
      "\n",
      "In Section 2 we present the standard Bayesian MCMC approach to pair-wise meta-analysis for binomial data, based on Smith et al. 6 . We then develop our approach to assessment of goodness of  fit,  model  diagnostics  and  comparison based  on the residual deviance and the Deviance Information Criterion (DIC). 27 In Section 3 the GLM framework for continuous, Poisson, and Multinomial likelihoods is developed with identity, log, complementary log-log and probit link functions, with an introduction to competing risks and ordered probit models. Section 3.4, on continuous outcomes, describes methods for 'before-after' differences. All these models have a separate likelihood contribution for each trial arm: in Section 3.5 we develop a modified core model for forms of meta-analysis in which the likelihood is based on a summary treatment difference  and  its  variance.  Section  4  shows  how  different  trial  reporting  formats  can  be accommodated within the same synthesis in shared parameter models. In Section 5 the core linear predictor models for pair-wise meta-analysis are shown to be immediately applicable to indirect comparisons, multi-arm trials, and network meta-analysis, without further extension.\n",
      "\n",
      "An extensive appendix provides code to run a series of worked examples, and fully annotated WinBUGS  code  is  also  available  at  www.nicedsu.org.uk.  Section  6  provides  advice  on formulation of priors and a number of technical issues in MCMC computation.\n",
      "\n",
      "While  Bayesian  MCMC  is  surely  the  most  convenient  approach,  particularly  in  decision making, it is certainly not the only one, and there have been a series of recent developments in frequentist software for evidence synthesis. These are briefly reviewed in Section 7, where we also outline the key issues in using frequentist methods in the context of probabilistic decision making. Section 8 provides some pointers to further reading, and more advanced extensions, and we conclude with a brief discussion.\n",
      "\n",
      "This technical guide is the second in a series of technical support documents on methods for evidence synthesis in decision making. It focuses exclusively on synthesis of relative treatment effect data from randomised controlled trial (RCTs). Issues such as evidence consistency, and the construction of models for absolute treatment effects, are taken up in other guides in this series (see TSDs 4 28 and 5 29 ).\n",
      "\n",
      "## 2 DEVELOPMENT OF THE CORE MODELS: BINOMIAL DATA WITH LOGIT LINK\n",
      "\n",
      "Consider a set of M trials comparing two treatments 1 and 2 in a pre-specified target patient population,  which  are  to  be  synthesised  in  a  meta-analysis.  A  fixed  effect  analysis  would assume that each study i generates an estimate of the same parameter d 12 , subject to sampling error.  In  a  random  effects  model,  each  study i provides  an  estimate  of  the  study-specific treatment effects δ i, 12 which are assumed not to be equal but rather exchangeable . This means that all δ i, 12 are 'similar' in a way which assumes that the trial labels, i , attached to the treatment effects δ i, 12 are irrelevant. In other words, the information that the trials provide is independent of  the  order  in  which  they  were  carried  out,  over  the  population  of  interest. 30 The exchangeability assumption is equivalent to saying that the trial-specific treatment effects come from a common distribution with mean d 12 and variance 2 12 σ .\n",
      "\n",
      "The common distribution is usually chosen to be a normal distribution, so that\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "It follows that the fixed effect model is a special case of this, obtained by setting the variance to zero.\n",
      "\n",
      "Note that in the case of a meta-analysis of only two treatments the subscripts in d , δ and σ are redundant since only one treatment comparison is being made. We shall drop the subscripts for σ , but will keep the subscripts for δ and d , to allow for extensions to multiple treatments in Section 5.\n",
      "\n",
      "## 2.1 W ORKED EXAMPLE : A LOGIT MODEL FOR A META -ANALYSIS OF BINOMIAL DATA\n",
      "\n",
      "Carlin 31 and the WinBUGS user manual 26 consider a meta-analysis of 22 trials of beta-blockers to prevent mortality after myocardial infarction. The data available are the number of deaths in the treated and control arms, out of the total number of patients in each arm, for all 22 trials (Table 1).\n",
      "\n",
      "Table 1 Blocker example: number of events and total number of patients in the control and beta-blocker groups for the 22 trials. 31\n",
      "\n",
      "|         | Control                 | Control                   | Treatment               | Treatment                 |\n",
      "|---------|-------------------------|---------------------------|-------------------------|---------------------------|\n",
      "| study i | no. of events ( r i 1 ) | no. of patients ( n i 1 ) | no. of events ( r i 2 ) | no. of patients ( n i 2 ) |\n",
      "| 1       | 3                       | 39                        | 3                       | 38                        |\n",
      "| 2       | 14                      | 116                       | 7                       | 114                       |\n",
      "| 3       | 11                      | 93                        | 5                       | 69                        |\n",
      "| 4       | 127                     | 1520                      | 102                     | 1533                      |\n",
      "| 5       | 27                      | 365                       | 28                      | 355                       |\n",
      "| 6       | 6                       | 52                        | 4                       | 59                        |\n",
      "| 7       | 152                     | 939                       | 98                      | 945                       |\n",
      "| 8       | 48                      | 471                       | 60                      | 632                       |\n",
      "| 9       | 37                      | 282                       | 25                      | 278                       |\n",
      "| 10      | 188                     | 1921                      | 138                     | 1916                      |\n",
      "| 11      | 52                      | 583                       | 64                      | 873                       |\n",
      "| 12      | 47                      | 266                       | 45                      | 263                       |\n",
      "| 13      | 16                      | 293                       | 9                       | 291                       |\n",
      "| 14      | 45                      | 883                       | 57                      | 858                       |\n",
      "| 15      | 31                      | 147                       | 25                      | 154                       |\n",
      "| 16      | 38                      | 213                       | 33                      | 207                       |\n",
      "| 17      | 12                      | 122                       | 28                      | 251                       |\n",
      "| 18      | 6                       | 154                       | 8                       | 151                       |\n",
      "| 19      | 3                       | 134                       | 6                       | 174                       |\n",
      "| 20      | 40                      | 218                       | 32                      | 209                       |\n",
      "| 21      | 43                      | 364                       | 27                      | 391                       |\n",
      "| 22      | 39                      | 674                       | 22                      | 680                       |\n",
      "\n",
      "## 2.1.1 Model specification\n",
      "\n",
      "Defining r ik as the number of events (deaths), out of the total number of patients in each arm, n ik , for arm k of trial i , we assume that the data generation process follows a Binomial likelihood i.e.\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where p ik represents the probability of an event in arm k of trial i ( i =1,…,22; k =1,2).\n",
      "\n",
      "Since  the  parameters  of  interest, p ik ,  are  probabilities  and  therefore  can  only  take  values between 0 and 1, a transformation (link function) is used that maps these probabilities into a continuous  measure  between  plus  and  minus  infinity.  For  a  Binomial  likelihood  the  most commonly used link function is the logit link function (see Table 3). We model the probabilities of success p ik on the logit scale as\n",
      "\n",
      "where\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "In this setup, i µ are trial-specific baselines, representing the log-odds of the outcome in the 'control' treatment (i.e. the treatment indexed 1), , 12 i δ are the trial-specific log-odds ratios of success on the treatment group (2) compared to control (1). We can write equation (3) as\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where,  for  a  random  effects  model  the  trial-specific  log-odds  ratios  come  from  a  common distribution: 2 ,12 12 ~ ( , ) i N d δ σ . For a fixed effect model we replace equation (3) with\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "which  is  equivalent  to  setting  the  between-trial  heterogeneity σ 2 to  zero  thus  assuming homogeneity of the underlying true treatment effects.\n",
      "\n",
      "An important feature of all the meta-analytic models presented here is that no model is assumed for  the  trial-specific  baselines i µ .  They  are  regarded  as  nuisance  parameters  which  are estimated in the model.  An alternative is to place  a second hierarchical  model on the trial baselines, or to put a bivariate normal model on both. 32,33 However, unless this model is correct, the  estimated  relative  treatment  effects  will  be  biased.  Our  approach  is  therefore  more conservative, and in keeping with the widely used frequentist methods in which relative effect estimates  are  treated  as  data  (see  Section  3.5)  and  baselines  eliminated  entirely.  Baseline models are discussed in TSD5. 29\n",
      "\n",
      "## 2.1.2 Model fit and model comparison\n",
      "\n",
      "To check formally whether a model's fit is satisfactory, we will consider an absolute measure of fit: the overall residual deviance: res D . This is the posterior mean of the deviance under the current model, minus the deviance for the saturated model, 12 so that each data point should\n",
      "\n",
      "contribute about 1 to the posterior mean deviance. 27,34 We can then compare the value of res D to the number of independent data points to check if the model fit can be improved. For a Binomial  likelihood  each  trial  arm  contributes  1  independent  data  point  and  the  residual deviance is calculated as\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where r ik and n ik are the observed number of events and patients in each trial arm, ˆ ik ik ik r n p = is the expected number of events in each trial arm calculated at each iteration, based on the current model, and dev ik is the deviance residual for each data point calculated at each iteration. This is then summarised by the posterior mean: res D .\n",
      "\n",
      "Leverage statistics  are  familiar  from  frequentist  regression  analysis  where  they  are  used  to assess the influence that each data point has on the model parameters. The leverage for each data point, leverage ik , is calculated as the posterior mean of the residual deviance minus the deviance at the posterior mean of the fitted values. For a Binomial likelihood, letting ik r /tildenosp be the posterior mean of ˆ ik r , and ik dev the posterior mean of dev ik ,\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where /tildenosp4char ik dev is  the  posterior  mean  of  the  deviance  calculated  by  replacing ˆ ik r with ik r /tildenosp in equation (4).\n",
      "\n",
      "The Deviance Information Criterion (DIC) 27 is the sum of the posterior mean of the residual deviance, res D ,  and the leverage, p D ,  (also termed the effective number of parameters). The DIC provides a measure of model fit that penalises model complexity - lower values of the DIC  suggest  a  more  parsimonious  model.  The  DIC  is  particularly  useful  for  comparing different parameter models for the same likelihood and data, for example fixed and random effects models or fixed effect models with and without covariates.\n",
      "\n",
      "If the deviance residuals provide indications that the model does not fit the data well, leverage plots can give further information on whether poorly fitting data points are having a material effect  on  the  model  parameters.  Leverage  plots  show  each  data  point's  contribution  to p D\n",
      "\n",
      "( leverage ik ) plotted against their contribution to res D ( ik dev ) and can be used to check how each point is affecting the overall model fit and DIC. It is useful to display these summaries in a plot of leverage ik vs w ik for each data point, where ik ik w dev = ± , with sign given by the sign of ( ) ˆ ik ik r r -to indicate whether the data is over- or under-estimated by the model. Curves of the  form 2 x y c + = , c =1,2,3,…,  where x represents w ik and y represents  the  leverage,  are marked on the plots and points lying on such parabolas each contribute an amount c to  the DIC. 27 Points which lie outside the lines with c =3 can generally be identified as contributing to the model's poor fit. Points with a high leverage are influential, which means that they have a strong influence on the model parameters that generate their fitted values.\n",
      "\n",
      "Leverage plots for the fixed and random effects models are presented in Figure 1 and Figure 2, respectively. From these the random effects model appears to be more appropriate as points lie closer to the  centre of the plot. To further examine the model fit at individual data points, inspection of ik dev for all i and k will highlight points with a high residual deviance, over 2 say, as accounting for the lack of fit. This can help identify data points that fit poorly.\n",
      "\n",
      "WinBUGS will calculate p D and the posterior mean of the deviance for the current model D , but  will  not  output  the  contributions  of  the  individual  data  points  to  the  calculations. Furthermore, without subtracting the deviance for the saturated model, D is hard to interpret and can only be useful for model comparison purposes and not to assess the fit of a single model. Therefore users wishing to produce leverage plots such as those in Figure 1 and Figure 2  need  to  calculate  the  contributions  of  individual  studies  to res D and  to  the  leverage themselves. The latter needs to be calculated outside WinBUGS, for example in R or Microsoft Excel. The p D , and therefore the DIC, calculated in the way we suggest is not precisely the same as that calculated in WinBUGS, except in the case of a normal likelihood. This is because WinBUGS calculates the fit at the mean value of the parameter values, while we propose the fit at the mean value of the fitted values. The latter is more stable in highly non-linear models with high levels of parameter uncertainty.\n",
      "\n",
      "In this document we suggest that global DIC statistics and res D are consulted both to compare fixed and random effect models, and to ensure that overall fit is adequate. Leverage plots may be used to identify influential and/or poorly fitting observations. Guidance on choice of fixed or random effects model, an issue that is closely bound up with the impact of sparse data and choice of prior distributions, is given in Section 6. In network meta-analysis there are additional\n",
      "\n",
      "issues regarding consistency between evidence sources on different contrasts. This is discussed fully in TSD4. 28\n",
      "\n",
      "## 2.1.3 WinBUGS implementation and illustrative results\n",
      "\n",
      "Annotated WinBUGS 1.4.3 code is shown in the Appendix, for both a random effects model and a fixed effect model (Blocker Examples 1(c) and 1(d)). Included in the description of the code are some additional comments on alternative priors, and additional code that can be used when there are more than two treatments being compared, to rank the treatments, or compute the probability that each is the best treatment. We ran both fixed and random effects models, and some of the results, including the res D and DIC statistics, are shown in Table 2. All results are based on 20,000 iterations on 3 chains, after a burn-in of 10,000.\n",
      "\n",
      "Table 2 Blocker example: posterior mean, standard deviation (sd), median and 95% Credible interval (CrI) for both the fixed and random effects models for the treatment effect d 12 , absolute effects of the placebo ( T 1 ) and  beta-blocker  ( T 2 )  for  a  mean  mortality  of  -2.2  and  precision  3.3  on  the  logit  scale;  heterogeneity parameter σ and model fit statistics.\n",
      "\n",
      "|         | Fixed Effect model   | Fixed Effect model   | Fixed Effect model   | Fixed Effect model   | Random Effects model   | Random Effects model   | Random Effects model   | Random Effects model   |\n",
      "|---------|----------------------|----------------------|----------------------|----------------------|------------------------|------------------------|------------------------|------------------------|\n",
      "|         | mean                 | sd                   | median               | CrI                  | mean                   | sd                     | median                 | CrI                    |\n",
      "| d 12    | -0.26                | 0.050                | -0.26                | (-0.36,-0.16)        | -0.25                  | 0.066                  | -0.25                  | (-0.38,-0.12)          |\n",
      "| T 1     | 0.11                 | 0.055                | 0.10                 | (0.04,0.25)          | 0.11                   | 0.055                  | 0.10                   | (0.04,0.25)            |\n",
      "| T 2     | 0.09                 | 0.045                | 0.08                 | (0.03,0.20)          | 0.09                   | 0.046                  | 0.08                   | (0.03,0.20)            |\n",
      "| σ       | -                    | -                    | -                    | -                    | 0.14                   | 0.082                  | 0.13                   | (0.01,0.32)            |\n",
      "| res D * | 46.8                 |                      |                      |                      | 41.9                   |                        |                        |                        |\n",
      "| p D     | 23.0                 |                      |                      |                      | 28.1                   |                        |                        |                        |\n",
      "| DIC     | 69.8                 |                      |                      |                      | 70.0                   |                        |                        |                        |\n",
      "\n",
      "Comparing the  fit  of  both  these  models  using  the  posterior  mean  of  the  residual  deviance indicates that although the random effects models is a better fit to the data, with a posterior mean of the residual deviance of 41.9 against 46.8 for the fixed effect model, this is achieved at the expense of more parameters. This better fit can also be seen in the leverage plots for the fixed and random effects model (Figure 1 and Figure 2), where two extreme points can be seen in Figure 1, at either side of zero. These points refer to the two arms of study 14 (Table 1) but are no longer so extreme in Figure 2. We would suggest careful re-examination of the evidence and consideration of issues such as the existence of important covariates. These and other issues are covered in TSD3. 35 The DIC suggests that there is little to choose between the two models and the fixed effect model may be preferred since it is easier to interpret (Table 2). The posterior\n",
      "\n",
      "median of the pooled log odds ratio of beta-blockers compared to control in the fixed effect model is -0.26 with 95% Credible Interval (-0.36, -0.16) indicating a reduced mortality in the treatment  group.  The  posterior  medians  of  the  probability  of  mortality  on  the  control  and treatment groups are 0.10 and 0.08, respectively (with credible intervals in Table 2). Results for the random effects model are similar.\n",
      "\n",
      "Figure 1 Blocker example: Plot of leverage versus Bayesian deviance residual w ik for each data point, with curves of the form x 2 + y = c , with c =1 (solid), c=2 (dashed), c=3 (dotted) and c=4 (dot-dashed), for the fixed effect model.\n",
      "\n",
      "<!-- image -->\n",
      "\n",
      "Figure 2 Blocker example: Plot of leverage versus Bayesian deviance residual w ik for each data point, with curves of the form x 2 + y = c , with c =1 (solid), c=2 (dashed), c=3 (dotted) and c=4 (dot-dashed), for the random effects model.\n",
      "\n",
      "<!-- image -->\n",
      "\n",
      "The logit model assumes linearity of effects on the logit scale. A number of authors, notably Deeks, 36 have rightly emphasised the importance of using a scale in which effects are additive, as is required by the linear model. Choice of scale can be guided by goodness of fit, or by lower between-study heterogeneity, but there is seldom enough data to make this choice reliably, and logical considerations (see below) may play a larger role. Quite distinct from choice of scale for modelling, is the issue of how to report treatment effects. Thus, while one might assume linearity of effects on the logit scale, the investigator, given information on the absolute effect of one treatment, is free to derive treatment effects on other scales, such as Risk Difference (RD), Relative Risk (RR), or Numbers Needed to Treat (NNT). The computer code provided in  the  Appendix  shows  how  this  can  be  done.  An  advantage  of  Bayesian  MCMC  is  that appropriate distributions, and therefore credible intervals, are automatically generated for all these quantities.\n",
      "\n",
      "## 3 GENERALISED LINEAR MODELS\n",
      "\n",
      "We now extend our treatment to models other than the well-known logit link for data with a binomial likelihood. The essential idea is that the basic apparatus of the meta-analysis remains the same, but the likelihood and the link function can change to reflect the nature of the data (continuous, rate, categorical), and the sampling process that generated it (Normal, Poisson, Multinomial,  etc).  In  GLM  theory, 12 a  likelihood  is  defined  in  terms  of  some  unknown parameters γ (for example a Binomial likelihood as in Section 2), while a link function, g (·), maps the parameters of interest onto the plus/minus infinity range. Our meta-analysis model for the logit link in equation (3), now becomes a GLM taking the form\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where g is  an  appropriate  link  function  (for  example  the  logit  link),  and ik θ is  the  linear predictor, usually a continuous measure of the treatment effect in arm k of trial i (for example the log-odds). As before, µ i are the trial-specific baseline effects in a trial i , treated as unrelated nuisance parameters. The δ i,bk are the trial-specific treatment effect of the treatment in arm k relative to the control treatment in arm b ( b =1) in that trial, and\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "as in equation (1).\n",
      "\n",
      "Table 3 Commonly used link functions and their inverse with reference to which likelihoods they can be applied to.\n",
      "\n",
      "| Link                            | Link function ( ) g θ γ =   | Inverse link function 1 ( ) g γ θ - =   | Likelihood           |\n",
      "|---------------------------------|-----------------------------|-----------------------------------------|----------------------|\n",
      "| Identity                        | γ                           | θ                                       | Normal               |\n",
      "| Logit                           | ( ) ln (1 ) γ γ -           | exp( ) 1 exp( ) θ θ +                   | Binomial Multinomial |\n",
      "| Log                             | ln( ) γ                     | exp( ) θ                                | Poisson              |\n",
      "| Complementary log-log (cloglog) | { } ln ln(1 ) γ - -         | { } 1 exp exp( ) θ - -                  | Binomial Multinomial |\n",
      "| Reciprocal link                 | 1/ γ                        | 1/ θ                                    | Gamma                |\n",
      "| Probit                          | 1 ( ) γ - Φ                 | ( ) θ Φ                                 | Binomial Multinomial |\n",
      "\n",
      "We now turn to consider the different types of outcome data generated in trials, and the GLMs required to analyses them. In each case, the basic model for meta-analysis remains the same (equations (5) and (6)). What changes are the likelihood and the link function. In a Bayesian framework,  we  also  need  to  pay  careful  attention  to  the  specification  of  the  priors  for  the variance  parameter.  Table  3  has  details  of  the  most  commonly  used  likelihoods,  link  and inverse link functions. The formulae for the residual deviance and the predicted values needed to calculate p D for all the different likelihoods described are available in Table 4.\n",
      "\n",
      "Table 4  Formulae for the residual deviance and model predictors for common likelihoods\n",
      "\n",
      "| Likelihood                                                      | Model prediction     | Residual Deviance                                                                                                    |\n",
      "|-----------------------------------------------------------------|----------------------|----------------------------------------------------------------------------------------------------------------------|\n",
      "| ~ Binomial( , ) ik ik ik r p n                                  | ˆ ik ik ik r n p =   | 2 log ( )log ˆ ˆ ik ik ik ik ik ik i k ik ik ik r n r r n r r n r       - + -         -       ∑∑ |\n",
      "| ~ Poisson( ) ik ik ik r E λ                                     | ˆ ik ik ik r E λ =   | ( ) ˆ 2 log ˆ ik ik ik ik i k ik r r r r r     - +           ∑∑                                        |\n",
      "| ( ) 2 ~ , ik ik ik y N y se se ik assumed known                 | ik y                 | ( ) 2 2 ik ik i k ik y y se   -       ∑∑                                                                     |\n",
      "| , ,1 : , ,1: ,~ Multinomial( , ) i k J i k J ik r p n           | ˆ ikj ik ikj r n p = | 2 log ˆ ikj ikj i k j ikj r r r                 ∑∑ ∑                                                 |\n",
      "| Multivariate Normal ( ) ,1: ,1: ( ) ~ , i k k i k k k y N y × Σ | , 1: i k y           | 1 ,1 : ,1 : ,1 : ,1 : ( ) ( ) T i k i k i k i k i y y y y - - - ∑ Σ                                                  |\n",
      "\n",
      "## 3.1 R ATE DATA : P OISSON LIKELIHOOD AND LOG LINK\n",
      "\n",
      "When the data available for the RCTs included in the meta-analysis is in the form of counts over a certain time period (which may be different for each trial), a Poisson likelihood and a log link is used. Examples would be the number of deaths, or the number of patients in whom a device failed. But, rather than having a denominator number at risk, what is supplied is a total number of person-years at risk. For patients who do not reach the end event, the time at risk is the same as their follow-up time. For those that do, it is the time from the start of the trial to the event: in this way the method allows for censored observations.\n",
      "\n",
      "Defining r ik as  the  number of events occurring in arm k of trial i during the trial follow-up period, E ik as the exposure time in person-years and λ ik as the rate at which events occur in arm k of trial i , we can write the likelihood as\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "The parameter of interest is the hazard, the rate at which the events occur in each trial arm, and this is modelled on the log scale. The linear predictor in equation (5) is therefore on the lograte scale:\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "A key assumption of this model is that in each arm of each trial the hazard is constant over the follow-up period. This can only be the case in homogeneous populations where all patients have the same hazard rate. In populations with constant but heterogeneous rates, the average hazard must necessarily decrease over time, as those with higher hazard rates tend to reach their end-points earlier and exit from the risk set.\n",
      "\n",
      "These models are also useful for certain repeated event data. Examples would be the number of accidents, where each individual may have more than one accident. Here one would model the total number of accidents in each arm, that is, the average number of accidents multiplied by the number of patients. The Poisson model can also be used for observations repeated in space rather than time: for example the number of teeth requiring fillings. Using the Poisson model for repeated event data makes the additional assumption that the events are independent, so that, for example, an accident is no more likely in an individual who has already had an accident than in one who has not. Readers may consult previous work 37-39 for examples. Dietary Fat Examples 2(a) and 2(b) in the Appendix illustrate random and fixed effects meta-analyses of this sort.\n",
      "\n",
      "## 3.2 R ATE DATA : B INOMIAL LIKELIHOOD AND CLOGLOG LINK\n",
      "\n",
      "In some meta-analyses, each included trial reports the proportion of patients reaching an endpoint at a specified follow-up time, but the trials do not all have the same follow-up time. Defining r ik as the number of events in arm k of trial i , with follow-up time f i (measured in days, weeks etc), then the likelihood for the data generating process is Binomial, as in equation (2). Using a logit model implies one of the following assumptions: that all patients who reach the end-point  do  so  by  some  specific  follow-up  time,  and  further  follow-up  would  make  no difference; or that the proportional odds assumption holds. This assumption implies a complex form for the hazard rates. 40 If longer follow-up results in more events, the standard logit model\n",
      "\n",
      "is hard to interpret. The simplest way to account for the different length of follow-up in each trial, is to assume an underlying Poisson process for each trial arm, with a constant event rate λ ik , so that T ik , the time until an event occurs in arm k of trial i , has an exponential distribution\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "The probability that there are no events by time f i in arm k of trial i , the survival function, can be written as\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "Then, for each trial i , p ik , the probability of an event in arm k of trial i after follow-up time f i can be written as\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "which is time dependent.\n",
      "\n",
      "We now model the event rate λ ik , taking into account the different follow-up times f i . Since equation  (8)  is  a  non-linear  function  of  log( λ ik )  the  complementary  log-log  (cloglog)  link function 41 (Table  3)  is  used  to  obtain  a  generalised  linear  model  for  log( λ ik )  giving , cloglog( ) log( ) log( ) ik ik i i bk p f θ λ = = + , and log( λ ik ) is modelled as in equation (7):\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "with the treatment effects , i bk δ representing log-hazard ratios. The Diabetes Example, programs 3(a) and 3(b) in the Appendix, illustrates a cloglog meta-analysis.\n",
      "\n",
      "The assumptions made in this model are the same as those for the Poisson rate models, namely that the hazards are constant over the entire duration of follow-up. This implies homogeneity of the hazard across patients in each trial, a strong assumption, as noted above. Nonetheless, this assumption may be preferable to assuming that the follow-up time makes no difference to the number of events. The clinical plausibility of these assumptions should be discussed and supported by citing relevant literature, or by examination of evidence of changes in outcome rates over the follow-up period in the included trials.\n",
      "\n",
      "When the constant hazards assumption is not reasonable, but further follow-up time is believed to  result  in  more  events,  extensions  are  available  that  allow  for  time-varying  rates.  One\n",
      "\n",
      "approach is to adopt piece-wise constant hazards. These models can be fitted if there is data reported at multiple follow-up times within the same study. 42,43 An alternative is to fit a Weibull model, which involves an additional 'shape' parameter α :\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "Although no longer a GLM, since a non-linear predictor is used, these extensions lead to major liberalisation  of  modelling,  but  require  more  data.  The  additional  Weibull  parameter,  for example, can only be adequately identified if there is data on a wide range of follow-up times, and if investigators are content to assume the same shape parameter for all treatments.\n",
      "\n",
      "## 3.3 C OMPETING R ISKS : M ULTINOMIAL LIKELIHOOD AND LOG LINK\n",
      "\n",
      "A competing risk analysis is appropriate where multiple, mutually exclusive end-points have been defined, and patients leave the risk set if any one of them is reached. For example, in trials of  treatments  for  schizophrenia 44 observations  continued  until  patients  either  relapsed, discontinued  treatment  due  to  intolerable  side  effects,  or  discontinued  for  other  reasons. Patients who remain stable to the end of the study are censored. The statistical dependencies between  the  competing  outcomes  need  to  be  taken  into  account  in  the  model.  These dependencies are essentially within-trial, negative correlations between outcomes, applying in each arm of each trial. They arise because the occurrence of outcome events is a stochastic process, and if more patients should by chance reach one outcome, then fewer must reach the others.\n",
      "\n",
      "Trials  report r ikj ,  the  number  of  patients  in  arm k of  trial i reaching  each  of  the  mutually exclusive end-points j =1,2,… J , at the end of follow-up in trial i , f i . In this case the responses r ikj will follow a multinomial distribution:\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "which leads to:\n",
      "\n",
      "and the parameters of interest are the rates (hazards) at which patients move from their initial state  to  any  of  the  end-points j , λ ikj .  Note  that  the J th endpoint  represents  the  censored observations, i.e. patients who do not reach any of the other end-points before the end of followup.\n",
      "\n",
      "If we assume constant hazards λ ikj acting over the period of observation f i in years, weeks etc, the probability that outcome j has occurred by the end of the observation period for arm k in trial j is:\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "The probability of remaining in the initial state, that is the probability of being censored, is simply 1 minus the sum of the probabilities of arriving at any of the J -1 absorbing states, ie:\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "The parameters of interest are the hazards, λ ikj , and these are modelled on the log scale\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "The  trial-specific  treatment  effects δ i,bk,j of  the  treatment  in  arm k relative  to  the  control treatment in arm b of that trial for outcome j , are assumed to follow a normal distribution\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "The between-trials variance of the random effects distribution, 2 j σ , is specific to each outcome j .  Three  models  for  the  variance  can  be  considered:  a  fixed  effect  model,  where 2 j σ =0;  a Random Effects Single Variance model where the between-trial variance 2 j σ = 2 σ , reflecting the assumption that the between-trials variation is the same for each outcome; and a Random Effect Different Variances model where 2 j σ denotes a different between-trials variation for each outcome j . See the Schizophrenia Example 4 in the Appendix for an illustration.\n",
      "\n",
      "These competing risks models share the same assumptions as the cloglog models presented in Section 3.2 to which they are closely related: constant hazards over time, implying proportional hazards, for each outcome. A further assumption is that the ratios of the risks attaching to each\n",
      "\n",
      "outcome  must  also  remain  constant  over  time  (proportional  competing  risks).  Further extensions where the assumptions are relaxed are available. 45\n",
      "\n",
      "## 3.4 C ONTINUOUS DATA : N ORMAL LIKELIHOOD AND IDENTITY LINK\n",
      "\n",
      "With  continuous  outcome  data  the  meta-analysis  is  based  on  the  sample  means, y ik ,  with standard errors se ik . As long as the sample sizes are not too small, the Central Limit Theorem allows us to assume that, even in cases where the underlying data are skewed, the sample means are approximately normally distributed, so that the likelihood can be written as\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "The parameter of interest is the mean, ik θ , of this continuous measure which is unconstrained on the real line. The identity link is used (Table 3) and the linear model can be written on the natural scale as\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "See the Parkinson's Example, programs 5(a) and 5(b) in the Appendix, for WinBUGS code.\n",
      "\n",
      "## 3.4.1 Before/after studies: change from baseline measures\n",
      "\n",
      "In cases where the original trial outcome is continuous and measured at baseline and at a prespecified follow-up point the most common method is to base the meta-analysis on the mean change  from  baseline  for  each  patient  and  an  appropriate  measure  of  uncertainty  (e.g.  the variance or standard error) which takes into account any within-patient correlation. It should be noted that the most efficient and least biased statistic to use is the mean of the final reading, having adjusted for baseline via regression/ANCOVA. Although this is seldom reported, when available these should be the preferred outcome measures. 5\n",
      "\n",
      "The likelihood for the mean change from baseline in arm k of trial i , ik y ∆ , with change variance ik V ∆ can be assumed normal such that\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "The parameter of interest is the mean, ik θ , of this continuous measure which is unconstrained on the real line. The identity link is used (Table 3) and the linear model can be written on the natural scale as in equation (10).\n",
      "\n",
      "However, in practice many studies fail to report an adequate measure of the uncertainty for the before-after difference in outcome and instead report the mean and variance, ( ) b ik y and ( ) b ik V , (or other measure of uncertainty) at baseline (before), and at follow-up times (after), ( ) a ik y and ( ) a ik V , separately. While the mean change from baseline can be easily calculated as\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "to calculate ik V ∆ for such trials, information on the within-patient correlation ρ is required since\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "Information on the correlation ρ is seldom available. It may be possible to obtain information from a review of similar trials using the same outcome measures, or else a reasonable value for ρ ,  often  0.5  (which  is  considered  conservative)  or  0.7, 46 can  be  used  alongside  sensitivity analyses. 5,47 A more sophisticated approach, which takes into account the uncertainty in the correlation, is to use whatever information is available within the dataset, from trials that report both the before/after variances and the change variance (see Section 4), and possibly external trials  as  well,  to  obtain  an  evidence-based  prior  distribution  for  the  correlation,  or  even  to estimate the correlation and the treatment effect simultaneously within the same analysis. 48\n",
      "\n",
      "## 3.5 T REATMENT DIFFERENCES\n",
      "\n",
      "Trial  results  are  sometimes  only  available  as  overall,  trial-based  summary  measures,  for example as mean differences between treatments, log-odds ratios, log-risk ratios, log-hazard ratios, risk differences, or some other trial summary statistic and its sample variance. In this case we can assume a normal distribution for the continuous measure of treatment effect of arm k relative to arm 1 in trial i , ik y , with variance ik V , such that\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "The parameters of interest are the trial-specific mean treatment effects ik θ . An identity link is used and since no trial-specific effects of the baseline or control treatment can be estimated the linear predictor is reduced to , ik i bk θ δ = .  The trial baselines are eliminated and the , i bk δ are, exactly  as  in  all  previous  models,  assumed  to  come  from  a  random  effects  distribution 2 , 12 12 ~ ( , ) i N d δ σ or  to  be  fixed ,12 12 i d δ = .  Examples  7  (Parkinson's  Differences)  in  the Appendix can be consulted.\n",
      "\n",
      "Readers will recognise that this is overwhelmingly the most common form of meta-analysis, especially amongst the Frequentist methods. The case where the y ik are log-odds ratios, and an inverse-variance weighting is applied, with variance based on the normal theory approximation, remains a main-stay in applied meta-analytic studies. We refer to some of the key literature comparing different meta-analytic estimators and methods in the discussion.\n",
      "\n",
      "An important caveat about synthesis based on treatment differences relates to multi-arm trials. In Section 5 we show how the framework developed so far applies to syntheses that include multi-arm trials. However, trial-level data based on treatment differences present some special problems because, unlike data aggregated at the arm-level, there are correlations between the treatment differences that require adjustment to the likelihood . Details are given in Section 5.1. The WinBUGS coding we provide (Example 7) incorporates these adjustments. This point is also taken up in our discussion of alternative software (Section 7).\n",
      "\n",
      "## 3.5.1 Standardised mean differences\n",
      "\n",
      "There  are  a  series  of  standardised  mean  difference  (SMD)  measures  commonly  used  with psychological or neurological outcome measures. These can be synthesised in exactly the same way as any other treatment effect summary. We include some specific comments here relating to the special issues they raise.\n",
      "\n",
      "The main role of the SMD is to facilitate combining results from trials which have reported outcomes measured on different continuous scales. For example, some trials might use the Hamilton Depression scale, others the Montgomery-Asberg Depression Rating Scale. The idea is that the two scales are measuring essentially the same quantity, and that results can be placed on a common scale if the mean difference between the two arms in each trial is divided by its standard deviation. The best known SMD measures are Cohen's d 49 , and Hedges' adjusted g, 50 which differ only in how the pooled standard deviation is defined and the fact that Hedges' g is adjusted for small sample bias:\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where n 1 and n 2 represent the sample sizes and s 1 and s 2 the standard errors of the means in arms 1 and 2 of a given trial.\n",
      "\n",
      "However, dividing estimates through by the sample standard deviation introduces additional heterogeneity in two ways. First, standard deviations are themselves subject to sampling error, and secondly, the use of SMD opens the results to various kinds of distortion because trials vary in how narrowly defined the patient population is. For example we would expect trials with narrow inclusion criteria such as 'severe depression', to have smaller sample standard deviations, and thus larger SMDs, than trials on patients with 'severe to moderate depression'. A procedure that would produce more interpretable results would be to divide all estimates from a given test instrument by the standard deviation obtained in a representative population sample, external to the trial.\n",
      "\n",
      "The Cochrane Collaboration recommends the use of Hedges' g (equation (11)), while noting that interpretation of the overall intervention effect is difficult. 5 It recommends re-expressing the pooled SMD in terms of effect sizes as small, medium or large (according to some rules of thumb), transforming the pooled SMD into an Odds Ratio, or re-expressing the SMD in the units of one or more of the original measurement instruments, 5 although it is conceded none of these manoeuvres mitigates the drawbacks mentioned above.\n",
      "\n",
      "SMDs are sometimes used for non-continuous outcomes. For example in a review of topical fluoride therapies to reduce caries in children and adolescents, the outcomes were the number of  new  caries  observed  but  the  mean  number  of  caries  in  each  trial  arm  were  modelled  as SMD. 51 Where possible, it is preferable to use the appropriate GLM, in this case a Poisson likelihood and log link, as this is likely to reduce heterogeneity. 38\n",
      "\n",
      "## 3.6 O RDERED C ATEGORICAL D ATA : M ULTINOMIAL LIKELIHOOD AND PROBIT LINK\n",
      "\n",
      "In  some  applications,  the  data  generated  by  the  trial  may  be  continuous  but  the  outcome measure  categorised,  using one  or  more pre-defined  cut-offs.  Examples  include  the  PASI (Psoriasis Area Severity Index) and the ACR (American College of Rheumatology) scales, where it is common to report the percentage of patients who have improved by more than certain benchmark relative amounts. Thus ACR-20 would represent the proportion of patients who have improved by at least 20% on the ACR scale, PASI-75 the proportion who have improved by at least 75% on the PASI scale. Trials may report ACR-20, ACR-50 and ACR70, or only one or two of these end-points. We can provide a coherent model and make efficient use of such data by assuming that the treatment effect is the same regardless of the cut-off. This assumption can be checked informally by examining the relative treatment effects at different cut-offs in each trial and seeing if they are approximately the same. In particular, there should not be a systematic relationship between the relative effects at different cut-off points. The residual deviance check of model fit is also a useful guide.\n",
      "\n",
      "The likelihood is the same as in the competing risk analysis: trials report r ikj , the number of patients in arm k of trial i belonging to different, mutually exclusive categories j =1,2,… J , where these categories represent the different thresholds (e.g. 20%, 50% or 70% improvement), on a common underlying continuous scale. The responses for each arm k of trial i in category j will follow a multinomial distribution as defined in equation (9) and the parameters of interest are the probabilities, p ikj , that a patient in arm k of trial i belongs to category j . We may use the probit link function to map p ikj onto the real line. This is the inverse of the normal cumulative distribution function Φ (see Table 3). The model can be written as\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "In this setup, the pooled effect of taking the experimental treatment instead of the control is to change the probit score (or Z score) of the control arm, by δ i,bk standard deviations. This can be translated back into probabilities of events by noting that when the pooled treatment effect or equivalently\n",
      "\n",
      "12 0 d &gt; , then for a patient population with an underlying probability π j of an event in category j , the experimental treatment will increase this probability to ( ) 1 12 ( ) j d π -Φ Φ + .\n",
      "\n",
      "The model is set-up with the assumption that there is an underlying continuous variable which has been categorised by specifying different cut-offs, z ij , which correspond to the point at which an individual moves from one category to the next in trial i .  Several  options  are  available regarding the relationship between outcomes within each arm. Re-writing the model as\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "we can consider  the  terms z ij as  the  differences  on  the  standard  normal  scale  between  the response to category j and the response to category j1  in  all  the  arms  of  trial i. Different assumptions can be made. One option is to assume a 'fixed effect' z ij = z j for each of the J1 categories over all trials i , or a 'random effect' in which the trial-specific terms are drawn from a distribution, but are the same for each arm within a trial, taking care to ensure that the z j are increasing with category (i.e. are ordered). Choice of model can be made on the basis of DIC. Example 6 (Psoriasis) in the Appendix, illustrates fixed and random effects meta-analyses with fixed  effects z j .  Examples  of  very  similar  analyses  can  be  found  in  the  health  technology assessment literature on psoriasis, 52 psoriatic arthritis 53 and rheumatoid arthritis, 54 although in some  cases  random  effect  models  were  placed  on  baselines,  which  is  not  the  practice  we recommend. The model, and the WinBUGS coding, are appropriate in cases where different trials use different thresholds, or when different trials report different numbers of thresholds, as is the case in the Psoriasis Example 6. There is, in fact, no particular requirement for trials to even use the same underlying scale, in this case the PASI: this could however require an expansion of the number of categories.\n",
      "\n",
      "Unless the response probabilities are very extreme the probit model will be undistinguishable from the logit model in terms of model fit or DIC. Choosing which link function to use should therefore be based on the data generating process and on the interpretability of the results.\n",
      "\n",
      "## 3.7 A DDITIVE  AND  MULTIPLICATIVE  EFFECTS  WITH B INOMIAL D ATA , AND OTHER N ON -C ANONICAL LINKS\n",
      "\n",
      "It was mentioned earlier (Section 2.1) that the appropriate scale of measurement, and thus the appropriate link function, was the one in which effects were linear. It is common to see Log Relative  Risks  (LRR)  and  Risk  Differences  (RD)  modelled  using  the  treatment  difference\n",
      "\n",
      "approach  (Section  3.4),  but  there  are  advantages  to  adopting  an  arm-based  analysis  with Binomial likelihoods (see discussion). To perform an arm-based analysis using the RD or LRR requires  special  programming,  because,  unlike  the  'canonical' 12 logit  models,  there  is otherwise nothing to prevent the fitted probabilities in a risk difference or log risk model from being outside the natural zero-to-one range for probabilities. Suitable adjustments to coding have  been  published  for  Frequentist  software, 55 or  more  recently  for  WinBUGS. 56 A  Risk Difference model would be:\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "The effect of this construction is to guarantee that both the baseline probability i µ and , i i bk µ δ + remain in  the  interval  (0,1)  with δ i,bk interpreted  as  a  Risk  Difference.  For  a  Relative  Risk model:\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "Here, δ i,bk is a Log Relative Risk. Warn et al. 56 should be consulted for further details of the WinBUGS coding and considerations on prior distributions.\n",
      "\n",
      "Our experience with these models is that they can sometimes be less stable, and issues of convergence and starting values need especially close attention. One can readily avoid their use, of course, by using estimates of Relative Risk or Risk Difference as data. But this approach runs into difficulties when multi-arm trials are included (see Sections 5.1 and 7).\n",
      "\n",
      "## 4 SHARED PARAMETER MODELS\n",
      "\n",
      "Shared parameter models allow the user to generate a single coherent synthesis when trials report results in different formats. For example some trials may report binomial data for each arm, while others report only the estimated log odds ratios and their variances; or some may report numbers of events and time at risk, while others give binomial data at given follow-up times.  In  either  case  the  trial-specific  relative  effects δ i,bk represent  the  shared  parameters, which are generated from a common distribution regardless of which format trial i is reported in.\n",
      "\n",
      "So if in a meta-analysis of M trials, M 1 trials report the mean of a continuous outcome for each arm  of  the  trial,  and  the  remaining  trials  report  only  the  difference  in  the  means  of  each experimental  arm  relative  to  control,  a  shared  parameter  model  to  obtain  a  single  pooled estimate, can be written as a combination of the models presented in Section 3.4 such that\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "and a i represents the number of arms in trial i ( a i =2,3,…). The trial-specific treatment effects δ i,bk come from a common random effects distribution 2 , 12 12 ~ ( , ) i N d δ σ as before.\n",
      "\n",
      "Separate likelihood statements could also be defined, so for example in a meta-analysis with a binomial  outcome,  the M 1 trials  reporting  the  binomial  counts  in  each  trial  arm  could  be combined  with  the  trials  reporting  only  the  log-odds  ratio  of  each  experimental  treatment relative to control and its variance. In this case the binomial data would be modelled as in Section 2.1 and the continuous log-odds ratio data could be modelled as in Section 3.5, with the shared parameter being the trial-specific treatment effects δ i,bk as before. For a fixed effect model, δ i,12 can be replaced by d 12 in the model specification.\n",
      "\n",
      "These models can be easily coded in WinBUGS by having different loops for each of the data types, taking care to index the trial-specific treatment effects appropriately.\n",
      "\n",
      "Examples of shared parameter models will primarily include cases where some trials report results for each arm, whether proportions, rates, or continuous outcomes, and other trials report only the between-arm differences. A common model for log rates could be shared between trials with Poisson outcomes and time-at-risk and trials with Binomial data with a cloglog link; log rate ratios with identity link and normal approximation sample variance could form a third type of data for a shared log rate model. These models can be used to combine studies reporting outcomes as mean differences or as binomial data 57 and to combine data on survival endpoints which have been summarised either by using a hazard ratio or as number of events out of the total number of patients. 58 Another possibility would be to combine trials reporting test results at one or more cut-points using a probit link with binomial or multinomial likelihoods, with data on continuous outcomes transformed to a standard normal deviate scale.\n",
      "\n",
      "where\n",
      "\n",
      "To combine trials which report continuous outcome measures on different scales with trials reporting binary outcomes created by dichotomising the underlying continuous scale, authors have suggested converting the odds ratios calculated from the dichotomous response into a SMD, 5,59 or  converting  both  the  binary  and  continuous  measures  into  log-odds  ratios  for pooling. 60 These methods could be used within a shared parameter model.\n",
      "\n",
      "Examples 7 and 8 (Parkinson's differences and shared parameter) in the Appendix are shared parameter models.\n",
      "\n",
      "## 5 EXTENSION TO INDIRECT COMPARISONS AND NETWORK META-ANALYSIS\n",
      "\n",
      "In Section 2 we defined a set of M trials  over which the study-specific treatment effects of treatment 2 compared to treatment 1, δ i ,12 , were exchangeable with mean d 12 and variance 2 σ\n",
      "\n",
      "12\n",
      "\n",
      ". We now suppose that, within the same set of trials (i.e. trials which are relevant to the same research question), comparisons of treatments 1 and 3 are also made. To carry out a pairwise random effects meta-analysis of treatment 1 v 3, we would now assume that the study-specific treatment effects of treatment 3 compared to treatment 1, δ i ,13 , are also exchangeable such that ( ) 2 ,13 13 13 ~ , i N d δ σ .  If  so,  it  can  then  be  shown  that  the  study-specific  treatment  effects  of treatment 3 compared to 2, δ i ,23 , are also exchangeable:\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "This follows from the transitivity relation ,23 ,13 ,12 i i i δ δ δ = -. It can further be shown 61 that this implies\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where (1) 23 ρ represents the correlation between the relative effects of treatment 3 compared to treatment 1, and the relative effect of treatment 2 compared to treatment 1 within a trial (see Lu &amp; Ades 61 ). For simplicity we will assume equal variances in all subsequent methods, i.e.\n",
      "\n",
      "and\n",
      "\n",
      "2 2 2 2 12 13 23 σ σ σ σ = = = , and this implies that the correlation between any two treatment contrasts in a multi-arm trial is 0.5. 19 For heterogeneous variance models see Lu &amp; Ades. 61\n",
      "\n",
      "The exchangeability assumptions regarding the treatment effects ,12 i δ and ,13 i δ therefore make it possible to derive indirect comparisons of treatment 3 vs treatment 2, from trials of treatment 1 vs 2 and 1 vs 3, and also allow us to include trials of treatments 2 vs 3 in a coherent synthesis with the 1 vs 2 and 1 vs 3 trials.\n",
      "\n",
      "Note the relationship between the standard assumptions of pair-wise meta-analysis, and those required for indirect and mixed treatment comparisons. For a random effects pair-wise metaanalysis, we need to assume exchangeability of the effects ,12 i δ over the 1 vs 2 trials, and also exchangeability of the effects ,13 i δ over the 1 vs 3 trials. For network meta-analysis, we must assume the exchangeability of both treatment effects over both 1 vs 2 and 1 vs 3 trials. The theory extends readily to additional treatments k = 4,5…, S . In each case we must assume the exchangeability of the δ 's across the entire set of trials. Then the within-trial transitivity relation is  enough  to  imply  the  exchangeability  of  all  the  treatment  effects , i xy δ .  The consistency equations 21\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "are also therefore implied; they are assumptions required by indirect comparisons and MTC, but, given that we are assuming that all trials are relevant to the same research question, they are not additional assumptions. However, whilst in theory, consistency of the treatment effects must hold, there may be inconsistency in the evidence. Methods to assess evidence consistency are addressed in TSD4. 28 The consistency equations can also be seen as an example of the distinction between the ( s -1) basic parameters 62 d 12 , d 13 , d 14 , …, d 1 s on which prior distributions are placed, and the functional parameters which are functions of the basic parameters, and represent the remaining contrasts. It is precisely the reduction in the number of dimensions, from the number of functions on which there are data to the number of basic parameters, that allows all  data,  whether  directly  informing  basic  or  functional  parameters,  to  be  combined within a coherent (internally consistent) model.\n",
      "\n",
      "Now that several treatments are being compared, we clarify our notation a little, and have the trial-specific treatment effects of the treatment in arm k , relative to the control treatment (in arm 1), drawn from a common random effects distribution:\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where 1 , i ik t t d represents the mean effect of the treatment in arm k in trial i , t ik , compared to the treatment in arm 1 of trial i , t i 1 ,  and σ 2 represents the between-trial variability in treatment effects (heterogeneity). For trials that compare treatments 1 and 2 1 , 12 i ik t t d d = ,  for trials that compare treatments 2 and 3 1 , 23 i ik t t d d = and so on. The pooled treatment effect of treatment 3 compared to treatment 2, d 23 , is then obtained from equation (12).\n",
      "\n",
      "The WinBUGS code provided in the Appendix will extend to MTC. Examples 3 to 8 in the Appendix illustrate analyses with multiple treatments.\n",
      "\n",
      "## 5.1 I NCORPORATING MULTI -A RM TRIALS\n",
      "\n",
      "Suppose we have a number of multi-arm trials involving the treatments of interest, 1,2,3,4,… Among commonly suggested stratagems are combining all active arms into one, or splitting the control group between all relevant experimental groups, or ignoring all but two of the trial arms. 5 None of these are satisfactory. The question of how to conduct a meta-analysis of the multi-arms  trials  has  been  considered  in  a  Bayesian  framework  by  Lu  &amp;  Ades, 20 and  in  a frequentist framework by Lumley 22 and Chootrakool &amp; Shi. 63\n",
      "\n",
      "Based on the same exchangeability assumptions above, a single multi-arm trial will estimate a vector of random effects i δ . For example a three-arm trial will produce two random effects and  a  four-arm  trial  three.  Assuming,  as  before,  that  the  relative  effects  all  have  the  same between-trial variance we have\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where i δ is the vector of random effects, which follows a multivariate normal distribution, a i represents the number of arms in trial i ( a i =2,3,…) and 1 1 1, 1, i ik ik i t t t t d d d = -. Then the conditional\n",
      "\n",
      "univariate distributions for the random effect of arm k &gt;2, given all arms from 2 to k -1, is (see eg. Raiffa &amp; Schlaiffer 64 )\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "Either the multivariate distribution in equation (13) or the conditional distributions in equation (14) must be used to estimate the random effects for each multi-arm study so that the betweenarm  correlations  between  parameters  are  taken  into  account.  The  code  presented  in  the Appendix uses the formulation in equation (14) as it allows for a more generic code which works for trials with any number of arms.\n",
      "\n",
      "This formulation provides another interpretation of the exchangeability assumptions made in the previous section, and indeed another way of deducing the consistency relations. This is that we may consider a connected network of M trials involving S treatments to originate from M S -arm trials, but that some of the arms are missing at random (MAR). (Note that MAR does not mean that the choice of arms is random, but that the missingness of arms is unrelated to the efficacy of the treatment). It should be noted that the general formulation is no different from the model presented by Higgins &amp; Whitehead. 19\n",
      "\n",
      "The  WinBUGS  code  provided  in  the  Appendix  is  based  on  a  conditional  distribution formulation of the multivariate normal distribution. It therefore exactly instantiates the theory behind  network  meta-analysis  that  relates  it  to  pair-wise  meta-analysis.  The  code  in  the Appendix will analyse pair-wise meta-analysis, indirect comparisons, network meta-analysis (MTC) and multi-arm trials without distinction.\n",
      "\n",
      "## 5.1.1 Multi-arm trials with treatment differences (trial-based summaries)\n",
      "\n",
      "As mentioned in Section 3.5, when results from multi-arm trials are presented as (continuous) treatment differences relative to the control arm (arm 1), a correlation between the treatment differences is induced, since all differences are taken relative to the same control arm. Unlike the correlations between the relative effect parameters, this correlation is inherent in the data , and so requires an adjustment to the likelihood. A trial with a i arms produces a i -1 treatment differences which are correlated. The covariance between differences taken with respect to the same control arm is equal to the observed variance for the common control arm. So for example\n",
      "\n",
      "in a three arm trial comparing treatments A, B and C, letting y AB and y AC represent the treatment differences of treatments B and C relative to treatment A, we know that\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "and,\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "with, y A , y B and y C representing the original measurements on each arm of the trial, because, in a  randomised  controlled  trial  the  measurements  in  each  trial  arm  are  independent.  By successive replacement of the expressions in equation (16) into equation (15), we have:\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "So, the likelihood for a trial i with a i arms would be defined as multivariate normal\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where the diagonal elements in the variance-covariance matrix represent the variances of the treatment  differences  and  the  off-diagonal  elements  represent  the  observed  variance  in  the control  arm  in  trial i ,  denoted  by 2 1 i se (see  Section  3.4).  For  example,  when  the  treatment differences are given as log-odds ratios, 2 1 i se is the variance of the log-odds for arm 1 of trial i . Example 7 (Parkinson's  Difference)  in  the  Appendix  includes  a  three-arm  trial  in  a  metaanalysis of treatment differences where the variance of the common arm, 2 1 i se , is known. When 2 1 i se is not reported, an approximation should be made, perhaps based on the variances of the differences. 58 If  the value of the control variance is available only for some of the included trials, that information can be used to estimate the parameters of a distribution for the control variance (assumed to be common). This estimated distribution can then be used to predict the variance of the control arm, in the trials where it is missing. This method has been used, in a slightly different context, to predict missing variances. 65 Riley 66 provides a review of methods\n",
      "\n",
      "to impute unknown within-study correlations within the context of multivariate meta-analysis. These methods can also be applied to network meta-analysis with multi-arm trials.\n",
      "\n",
      "## 6 TECHNICAL ISSUES IN BAYESIAN MCMC\n",
      "\n",
      "The use of the WinBUGS Bayesian MCMC software has advantages (Section 7), but it also requires some care. Users are strongly advised to acquire a good understanding of Bayesian theory, 67 and to follow advice given in the WinBUGS manual. Particular care must be taken in checking convergence, and we suggest that at least three chains are run, starting from widely different (yet sensible) initial values. The diagnostics recommended in the literature should be used to check convergence. 68,69 Users should also ensure that, after convergence, each chain is sampling  from  the  same  posterior.  Posteriors  should  be  examined  visually  for  spikes  and unwanted  peculiarities,  and  both  the  initial  'burn-in'  and  the  posterior  samples  should  be conservatively large. The number of iterations for both must be reported in the analysis. An often cited guideline suggests that the Monte Carlo error, which reflects both the number of simulations and the degree of autocorrelation, should be no more than 5% of the posterior standard deviation of the parameters of interest.\n",
      "\n",
      "Beyond these  warnings,  which  apply  to  all  Bayesian  MCMC  analyses,  evidence  synthesis models have particular properties which may require careful examination: choice of reference treatment, choice of prior distributions and zero counts in binomial and Poisson data.\n",
      "\n",
      "## 6.1 C HOICE OF REFERENCE TREATMENT\n",
      "\n",
      "While the likelihood is not altered by a change in which treatment is taken to be 'Treatment 1', the choice of the reference treatment can affect the posterior estimates because priors cannot be totally non-informative. However, for the vague priors we suggest throughout for µ i and d 1 k (see below) we expect the effect to be negligible. Choice should therefore be based on ease of interpretation,  with  placebo  or  standard  treatment  usually  taken  as  Treatment  1.  In  larger networks, it is preferable to choose as Treatment 1 a treatment that is in the 'centre' of the network. In other words, choose the treatment that has been trialled against the highest number of other treatments. The purpose of this is to reduce strong correlations that may otherwise be induced between mean treatment effects for each pair of treatments k and h , d 1k and d 1h : these can slow convergence and make for inefficient sampling from the posterior.\n",
      "\n",
      "## 6.2 C HOICE OF PRIORS\n",
      "\n",
      "We recommend vague or flat priors, such as N(0, 100 2 ), throughout for µ i and d 1 k . Informative priors for relative effect measures would require special justification.\n",
      "\n",
      "It has become standard practice to also set vague priors for the between-trial variances. For binomial with logit links models, the usual practice is to place a Uniform prior on the standard deviation, for example σ ~ Uniform(0,2). The upper limit of 2 represents a huge range of trialspecific treatment effects. For example if the median treatment effect was an odds ratio of 1.5, then  we  would expect 95% of trials to have true odds ratios between 0.2 and 11. For rate models, whether with log or cloglog linking functions, uniform priors on σ may also be used, but investigators need to be aware of the scale: a prior that is vague for a rate per year may not be so vague for a rate per month. Similarly, for continuous outcomes close attention to the scale of measurement is essential. For trials with blood pressure as the outcome σ ~ Uniform(0,100) may be considered vague. The posterior distribution of σ should always be inspected to ensure that it is sufficiently different from the prior as this would otherwise indicate that the prior is dominating the data and no posterior updating has taken place.\n",
      "\n",
      "An alternative approach, which was once popular but has since fallen out of favour, is to set a vague Gamma prior on the precision, for example 1/ σ 2 ~ Gamma(.001,.001). This approach gives a low prior weight to unfeasibly large σ on the logit scale. The disadvantage is that this puts more weight on values of σ near zero. On the other hand, there are occasions where it may be an advantage that this prior rules out values of σ at zero,  because it is not uncommon, particularly when data is sparse, that MCMC sampling can 'get stuck' at σ = 0, leading to spikes in the posterior distribution of both σ and the treatment effect parameters d 1 k . In these cases a Gamma prior may improve numerical stability and speed convergence.\n",
      "\n",
      "However they are formulated, there are major disadvantages in routinely using vague priors, although this has become a widely accepted practice. In the absence of large numbers of large trials, the posterior distribution of σ will be poorly identified and likely to include values that, on reflection, are implausibly high or possibly implausibly low. Two further alternatives may be  found  useful  when  there  is  insufficient  data  to  adequately  estimate  the  between-trials variation. The first is the use of external data. 19 If there is insufficient data in the meta-analysis, it  may be reasonable to use an estimate for σ from a larger meta-analysis on the same trial outcome involving a similar treatment for the same condition. The posterior distribution, or a posterior  predictive  distribution,  from  such  an  analysis  could  be  used  to  approximate  an\n",
      "\n",
      "informative prior. The derivation of suitable priors from large numbers of meta-analyses is currently being actively researched.\n",
      "\n",
      "If there is no data on similar treatments and outcomes that can be used, an informative prior can be elicited from a clinician who knows the field. This can be done by posing the question in  this  way.  'Suppose  we  accept  that  different  trials,  even  if  infinitely  large,  can  produce different effect sizes. If the average effect was an odds ratio of 1.8 (choose a plausible average), what do you think an extremely high and an extremely low effect would be, in a very large trial?' Based on the answer to this it should be possible, by trial and error, to construct an informative Gamma prior for 1/ σ 2 ,  or  a  Normal  prior  for σ ,  subject  to σ &gt;  0.  For  further discussion of priors for variance parameters see Lambert et al . 70 and Spiegelhalter et al . 67\n",
      "\n",
      "## 6.3 Z ERO CELLS\n",
      "\n",
      "Because Binomial and Poisson likelihoods with zero cells are allowed, special precautions do not usually need to be taken in the case of the occasional trial with a zero cell count. This is a major strength of the Bayesian MCMC approach, because some popular frequentist approaches for log odds ratios or log relative risks have to add an arbitrary constant, usually 0.5, to cells in order to obtain non-infinite estimates of treatment effects and non-infinite variance, but in so doing they generate biased estimates of effect size. 71,72\n",
      "\n",
      "However, in extreme cases where several trials have zero cells and many of the trials are small, the models we have recommended can be numerically unstable, either failing to converge, or converging to a posterior with very high standard deviation on some of the treatment effects. This is unlikely to happen with fixed effect models, and it can often be remedied in random effects models by using a (more) informative prior on the variance parameter. A last resort, recognising the assumptions being made, is to put a random effect model on the treatment baselines µ i as well as the relative treatment effects d 1 k .\n",
      "\n",
      "A specific problem arises in sparse networks, in which for example there is only one trial making the comparison X vs Y, and treatment Y only appears in this one trial. If the trial contains a zero cell, it may not be possible to estimate a treatment effect. One solution is to revert to the practice of adding 1 to the denominator and 0.5 to the numerator, or the 0.5 can be replaced with a fraction that is closer to the expected treatment effect to reduce bias. 72 The problem can also be solved by placing a distribution on the baseline model. Trials with zero\n",
      "\n",
      "cells in both arms do not contribute evidence in the treatment effect and can be excluded, unless a model has been assumed for the baselines (see TSD5 29 ).\n",
      "\n",
      "Readers should be aware that, when evaluating model fit using the residual deviance, this will always  appear  large  (i.e.  &gt;1)  for  individual  data  points  where  there  are  zero  cells.  This  is because none of the models presented can actually predict a zero cell since probabilities at zero or one are ruled out. Also no leverage can be calculated for these points.\n",
      "\n",
      "## 7 NON-BAYESIAN APPROACHES AND COMPUTATIONAL ISSUES\n",
      "\n",
      "In this section we briefly review the advantages of the Bayesian MCMC approach to synthesis for probabilistic decision modelling. Bayesian methods are clearly convenient in this context, but  frequentist  analyses  can  be  used  to  approximate  Bayesian  posterior  sampling,  as  we describe below. We then provide some pointers to the literature that examines the statistical properties  of  alternative  Bayesian  and  frequentist  meta-analytic  estimators.  Finally,  we describe frequentist software that can be used for evidence synthesis. The statistical reliability of the different synthesis methods is, of course, an entirely separate issue from the accuracy of different computational approaches to implementing the synthesis method.\n",
      "\n",
      "## 7.1 B AYESIAN  VERSUS  FREQUENTIST  APPROACHES  IN  THE  CONTEXT  OF DECISION MAKING\n",
      "\n",
      "One of the advantages of the Bayesian MCMC approach is that sampling from the posterior distribution fulfils at the same time the need for posterior inference and the MC approach to probabilistic  modelling.  Although  inference  in  the  form  of  significance  tests  and  interval estimation tends to be set aside when a decision maker follows the rules of cost effectiveness analysis (CEA), 73 conclusions from CEA may be highly sensitive to the model that is assumed from  the  data.  Statistical  model  critique  and  model  choice  are,  therefore  critical  to  CEA, whether conducted in a Bayesian or frequentist framework.\n",
      "\n",
      "Posterior sampling in addition retains the correlation between parameters that is induced by their joint estimation from the same data. For this reason, when there are closed loops in the evidence structure, it is essential to either use the posterior samples from WinBUGS in the decision model or to take steps to propagate the correlations through the model (see below). Distributions based on the posterior marginal summaries are not adequate.\n",
      "\n",
      "Perfectly  valid  evidence  synthesis  is  also,  of  course,  produced  by  frequentist  software  (see below), and the question then arises of how the results from such analyses can be used in a probabilistic decision modelling context. For pair-wise meta-analysis and indirect comparisons, as long as they are restricted to two-arm trials, and do not involve covariates on baselines or treatment effects, it is simple to use the maximum likelihood (ML) estimates and their standard errors to create parameter distributions for forward MC sampling. Where multiarm trials or MTC evidence structures (in other words where there are loops in the evidence structure), or baseline models, or covariates are involved, two approaches are possible. One is the  bootstrap, 74 which  requires  re-sampling  from  the  data,  and  the  other  is  to  use  the  ML parameter estimates of all the parameters and their covariance matrix to form a multivariate normal distribution from which to carry out MC sampling. The latter is technically easier, and the  bootstrap  runs  into  difficulties  when  there  are  zero  cells.  This  multivariate  distribution obtained should be approximately the same as a Bayesian posterior distribution.\n",
      "\n",
      "## 7.2. C OMPARISON OF META -ANALYTIC METHODS\n",
      "\n",
      "While there is no technical reason why frequentist methods cannot be used, there are a wide variety of estimators to choose between for count data, which in specific circumstances can produce different results. There is a useful literature comparing meta-analytic estimators for binomial data, based on simulation studies. Bradburn et al 71 discuss the biases arising from the common  practice  of  adding  0.5,  or  other  amounts,  to  zero  cells,  and  it  is  an  undoubted advantage of methods using exact binomial and Poisson likelihoods, like Bayesian MCMC, that these problems are very largely avoided (though see Section 6.3). Simulation studies on fixed effect estimators 72 have shown that Bayesian MCMC has performed well, and ranks with Mantel Haenszel 75 and Exact method 76 estimators, and is superior to the Peto method 77 and inverse-variance weighting in a wide range of situations. There is a useful simulation study of tests of heterogeneity for binomial data. 78\n",
      "\n",
      "There has, however, been little work comparing Bayesian and non-Bayesian approaches in the context  of  random  effect  models,  nor  on  our  proposal  that  a  choice  can  be  made  between random and fixed effect models on the basis of the DIC statistics.\n",
      "\n",
      "It should be emphasised that except for the Exact method (which only applies to fixed effects models), none of the frequentist methods use the Binomial, Multinomial or Poisson likelihoods,\n",
      "\n",
      "but instead rely on normal approximations. This should not create problems as long as low cells counts are rare.\n",
      "\n",
      "Furthermore, in random effects models, the MCMC implementation automatically takes into account the uncertainty in the between-study heterogeneity parameter σ 2 . Whilst this is also possible using frequentist approaches, 79,80 it is rarely done in practice, possibly because such models are not currently implemented in user-friendly frequentist software.\n",
      "\n",
      "## 7.3. C OMPARISON OF EVIDENCE SYNTHESIS SOFTWARE\n",
      "\n",
      "In this section we provide a brief review of frequentist software for evidence synthesis, and where possible a comparison with the Bayesian MCMC WinBUGS software. We will refer to existing literature where possible. Alternative software for pair-wise meta-analysis has been developed over the past two decades, both as stand-alone applications and as 'macro' routines for  pre-existing  packages.  Probably  the  most  comprehensive  and  up-to-date  routines  for existing software are those developed and freely distributed for STATA 81 and R. 82 Stand alone packages include Comprehensive Meta-Analysis, 83 Meta-Analyst 84 and MIX 85 as well as the Cochrane Collaboration software RevMan. 86 If pair-wise meta-analysis is all that is required, and appropriate estimators are used, this software is perfectly adequate to produce estimates and corresponding standard errors to inform a distribution in a probabilistic decision model.\n",
      "\n",
      "These approaches can also be used to carry out two pairwise meta-analyses from which an 'indirect'  comparison  can  be  formed.  This  is  effectively  an  implementation  of  the  Bucher method for indirect comparisons 87 (and a simple example of an MTC network). Note that in a random effects context, this approach allows for separate and unrelated meta-analyses for AB and AC whereas all models considered in this guide (and software examples in the Appendix) have  considered  a  common  random  effect.  (Note  that  this  could  also  be  achieved  in  any simulation  package,  including  WinBUGS,  by  setting  up  distributions  for  the  AB  and  AC effects, and then subtracting one from the other to form a distribution for the BC effect).\n",
      "\n",
      "It would appear no stand-alone software to fit MTC models to arbitrarily complex networks exists. Perhaps the most general code for frequentist software is that developed by Lumley. 22 However, this fits a different model from the one described in this paper which does not assume consistency of direct and indirect evidence and will be discussed in TSD4. 28\n",
      "\n",
      "It is also important to note that most frequentist software for MTC is based on data on triallevel differences, and not data aggregated at arm-level. As we saw in Section 5.1, when multi-\n",
      "\n",
      "arm trials are involved, it is essential to take account of both the correlation in parameters in random effect models, but also the correlations in the likelihood, which affect both fixed and random effect models. To the best of our knowledge, there is only one frequentist software module  available  for  STATA, mvmeta ,  that  takes  account  of  the  correlations  at  the  data level. 81,88 Frequentist analysis can also be correctly carried out in SAS. 89 In our experience, failure to make the adjustment can give materially different results whenever multi-arm trials form a substantial proportion of the evidence for any treatment contrast.\n",
      "\n",
      "## 8. FURTHER READING\n",
      "\n",
      "This brief introduction raises many further questions. Some of these are taken up in detail in the other technical guides in this series. TSD3 35 for example covers issues of heterogeneity, looking at meta-regression and treatment effects in subgroups. Individual patient data has a particularly  important  role  in  meta-regression.  Regression  and  other  methods  for  bias adjustment, including publication bias and so-called 'small-study bias' will also be covered. Similarly,  the  introduction  of  network  meta-analysis  (Section  5)  raises  questions  about inconsistency between 'direct' and 'indirect' evidence, which will be addressed in TSD4. 28 Here we will restrict attention to further extensions involving multiple outcomes.\n",
      "\n",
      "There are a huge variety of multiple outcome structures, only a minority of which have been examined in the context of evidence synthesis. One particularly important area for multiple outcome synthesis is where a set of eligible trials have been identified, but some report one outcome, some another,  and perhaps others  report  both.  The  function  of  multiple  outcome synthesis in this case is to use all the available data, taking into account the correlation between outcomes at the within-trial (between-patient) level, and the between-trial level. Methods for doing this have been described by Riley and others. 90,91 Readers may also refer to earlier work also based on multivariate normal methods. 92,93\n",
      "\n",
      "A quite different form of multiple outcome synthesis occurs when different trials report a single outcome, but at different follow-up times. Further, some may report at several follow-up times. Lu et al 42 describe a series of piece-wise-constant hazard models that extend the cloglog models of Section 3.2, in that treatment effects are allowed to vary between time intervals.\n",
      "\n",
      "Multiple outcomes are often structurally related. For example, time-to-progression cannot postdate overall survival in cancer studies, and time to end of 'flu cannot post-date time to the end of symptoms in studies of influenza treatments. Where possible, these structural constraints\n",
      "\n",
      "should be built into the synthesis. Burch et al 94 and Welton et al 95,96 provide examples. A further form of structural relation can be seen in trials on treatments for myocardial infarction, where trial evidence on an early intermediary outcome, coronary patency, can be combined with trial evidence on mortality. 13,97\n",
      "\n",
      "Multiple reporting formats present further challenges for synthesis. Many of these are covered in the earlier section on shared parameter models (Section 4). A more complex example 94,95 involved a synthesis that combined trials reporting median time to an event, mean time to an event, and proportion experiencing the event before a certain time. Results may also be reported separately for different subgroups, or collapsed over subgroups. Here, too, methods exist that make it possible to combine all the available information. 98-101 Another example of multiple reporting formats would be trials reporting on binary, categorical or continuous scales. 57\n",
      "\n",
      "A  final  special  topic  is  synthesis  for  Markov  models.  It  seems  clear  that,  for  purposes  of synthesis, it may be preferable to express Markov models in terms of transition rates rather than transition probabilities. 102 This facilitates combining information from studies run over different follow-up periods, as explained in Section 3.2. It also gives the flexibility to model different treatment effects on different transitions (e.g. competing risks, Section 3.3), which is difficult to achieve with logit models. A further option is to combine data from studies where certain transitions are unobserved. 102 Finally, it is worth mentioning that it is often open to question whereabouts in a Markov model a treatment effect is operating. Readers are referred to  recent  work 103 showing  how  treatment  effects  can  be  parameterised,  synthesised  and estimated in Markov rate models.\n",
      "\n",
      "## 9. DISCUSSION\n",
      "\n",
      "Our  objective  in  this  document  has  been  to  present  a  single  unified  account  of  evidence synthesis of aggregate data from RCTs, specifically but not exclusively for use in probabilistic decision making. In order to cover the variety of outcomes that are reported, and the range of data  transformations  required  to  obtain  approximate  linearity,  we  have  set  this  within  the familiar framework of Generalised Linear Models. This leads to a modular approach: different likelihoods and link functions may be employed, but the 'synthesis' operation, which occurs at the level of the linear predictor, takes the exact same form in every case. The linear predictor, furthermore, is a regression model of a very specific type, with K -1 treatment effect parameters for  any K treatment  network,  offering  a  single  model  for  pair-wise  meta-analysis,  indirect\n",
      "\n",
      "comparisons, network meta-analysis (mixed treatment comparisons), and synthesis of multiarm trials in any combination. This has all been presented in a Bayesian MCMC context and supported  by  code  for  WinBUGS  1.4.3. 26 The  use  of  WinBUGS  dovetails  with  the  GLM approach, as it allows us to take full advantage of the modularity implied by GLMs.\n",
      "\n",
      "This document brings together a great deal of previous work on Bayesian meta-analysis and MTC methods, and on meta-analysis methods for particular outcomes, into a single accessible and unified treatment and with a modular approach to computation. One aspect that may be considered  novel  is  the  application  to  synthesis  of  multi-arm  trials.  Although  it  would  be relatively  simple  to  extend  all  the  commonly  used  estimators  for  use  in  meta-analysis  of multiple trials  on  the  same K comparators, this does not appear to have been done.  In our framework,  however,  the  transitivity  and  exchangeability  assumptions  required  for  MTC automatically deliver multiple-treatment meta-analysis, and vice versa.\n",
      "\n",
      "In the course of the document we have raised the question: what is the relation between the arm-based analyses assumed in our models and software, with the far more common trial-based summaries where the difference between treatments is taken as the data. With count data, there has always been a strong case for adopting an arm-based approach because it avoids normal approximations for the likelihood, and difficulties with zero cells. We have, however, brought to light a further problem with the arm-based approach, which is that with multi-arm trials a correction must be made to the likelihood to account for correlations in the data. This applies to continuous outcome data as well as count data, and to both fixed and random effect models. With the appropriate correction to the likelihood, the results from arm-based and treatment difference-based analyses are identical. Since all frequentist software for synthesis currently adopts the trial-level treatment difference approach, we can give a quite specific recommendation that this software should be avoided for multi-treatment syntheses with multiarm trials, unless the correlation between relative treatment effects from the same trail can be appropriately accounted for. For syntheses where all trials are two-arm, there is no reason why frequentist methods should not be used, as long as statistically sound estimators are used and appropriate steps are taken to propagate parameter uncertainty, including correlations, through the decision model.\n",
      "\n",
      "Bayesian analysis is by no means a panacea: one area that clearly deserves more work is how to specify a 'vague' prior distribution for the variance parameter. There can be little doubt that the vague priors that are generally recommended produce posteriors that are biased upwards. The extent of the bias is likely to be greater when the true variance is low, and when there is\n",
      "\n",
      "little data: either few trials or small trials, but this is also a problem when using frequentist estimators.  The  question  could  perhaps  be  resolved  through  a  comprehensive  simulation exercise. Although we can be reassured that the bias tends to be conservative, ultimately it may be preferable to use informative priors, perhaps tailored to particular outcomes and disease areas, based on studies of many hundreds of meta-analyses. This is currently an active research area.\n",
      "\n",
      "45,52,104,105\n",
      "\n",
      "## 10. REFERENCES\n",
      "\n",
      "1.   Zelen, M. The analysis of several 2 x 2 contingency tables. Biometrika 1971; 58(1):129137.\n",
      "2.   DerSimonian, R., Laird, N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7(3):177-188.\n",
      "3.   Cooper, H., Hedges, L. The handbook of research synthesis. Russell Sage Foundation, New York, 1994.\n",
      "4.   Egger, M., Davey Smith, G., Altman, D.G. Systematic reviews in health care: metaanalysis in context. Second ed. BMJ publishing group, London; 2001.\n",
      "5.   Higgins, J.P.T., Green, S.E. Cochrane handbook for systematic reviews of interventions version 5.0.0 [updated February 2008]. The Cochrane Collaboration 2008.\n",
      "6.   Smith, T.C., Spiegelhalter, D.J., Thomas, A. Bayesian approaches to random effects meta analysis: A comparative study. Statistics in Medicine 1995; 14(24):2685-2699.\n",
      "7.   Sutton, A.J., Abrams, K.R. Bayesian methods in meta-analysis and evidence synthesis. Statistical Methods in Medical Research 2001; 10(4):277-303.\n",
      "8.   Sutton, A.J., Higgins, J. Recent developments in meta analysis. Statistics in Medicine 2008; 27(5):625-650.\n",
      "9.   Whitehead, A. Meta-analysis of controlled clinical trials. Wiley, Chichester; 2002.\n",
      "10.   Whitehead, A., Whitehead, J. A general parametric approach to the meta analysis of randomized clinical trials. Statistics in Medicine 1991; 10(11):1665-1677.\n",
      "11.   National  Institute  for  health  and  Clinical  Excellence.  Guide  to  the  methods  of technology appraisal (updated June 2008). 2008.  NICE, London.\n",
      "12.   McCullagh, P., Nelder, J.A. Generalized linear models. Chapman &amp; Hall/CRC, 1989.\n",
      "13.   Ades, A.E. A chain of evidence with mixed comparisons: models for multi parameter synthesis and consistency of evidence. Statistics in Medicine 2003; 22(19):2995-3016.\n",
      "14.   Ades, A.E., Sculpher, M., Sutton, A.J., Abrams, K.R., Cooper, N., Welton, N.J. et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 24(1):1-19.\n",
      "15.   Caldwell,  D.M.,  Ades,  A.E.,  Higgins,  J.P.T.  Simultaneous  comparison  of  multiple treatments: combining direct and indirect evidence. Bmj 2005; 331(7521):897-900.\n",
      "16.   Gleser, L.J., Olkin, I. Stochastically dependent effect sizes. In: Cooper H., Hedges L., eds. The handbook of research synthesis . Russell Sage Foundation, New York; 1994; 339-355.\n",
      "\n",
      "17.   Gleser, L.J., Olkin, I. Meta-analysis for 2 x 2 Tables with Multiple Treatment Groups. In: Stangl D.K., Berry D.A., eds. Meta-analysis in medicine and health policy . Marcel Dekker, New York; 2000.\n",
      "18.   Hasselblad,  V.  Meta-analysis  of  multi-treatment  studies. Medical  Decision  Making 1998; 18:37-43.\n",
      "19.   Higgins,  J.P.T.,  Whitehead,  A.  Borrowing  strength  from  external  trials  in  a  meta analysis. Statistics in Medicine 1996; 15(24):2733-2749.\n",
      "20.   Lu,  G.,  Ades,  A.E.  Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004; 23(20):3105-3124.\n",
      "21.   Lu, G., Ades, A.E. Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association 2006; 101(474):447-459.\n",
      "22.   Lumley,  T.  Network  meta  analysis  for  indirect  treatment  comparisons. Statistics  in Medicine 2002; 21(16):2313-2324.\n",
      "23.   Salanti, G., Higgins, J.P.T., Ades, A.E., Ioannidis, J.P.A. Evaluation of networks of randomized trials. Statistical Methods in Medical Research 2008; 17(3):279-301.\n",
      "24.   Glenny, A.M., Altman, D.G., Song, F., Sakarovitch, C., Deeks, J.J., D'amico, R. et al. Indirect comparisons of competing interventions. Health Technology Assessment 2005; 9(26):1-149.\n",
      "25.   Parmigiani,  G.  Modeling  in  medical  decision  making:  a  Bayesian  approach.  Wiley, Chichester; 2002.\n",
      "26.   Spiegelhalter, D., Thomas, A., Best, N., Lunn, D. WinBUGS user manual version 1.4. 2003; available from http://www.mrc-bsu.cam.ac.uk/bugs/ (accessed 2007).\n",
      "27.   Spiegelhalter, D.J., Best, N.G., Carlin, B.P., Van der Linde, A. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society Series B (Statistical Methodology) 2002; 64(4):583-639.\n",
      "28.   Dias, S., Welton, N.J., Sutton, A.J., Caldwell, D.M., Lu, G., Ades, A.E. NICE DSU Technical  Support  Document  4:  Inconsistency  in  networks  of  evidence  based  on randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\n",
      "29.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  5:  Evidence  synthesis  in  the  baseline  natural  history  model.  2011;  last updated April 2012; available from http://www.nicedsu.org.uk\n",
      "30.   Bernado, J.M., Smith, A.F.M. Bayesian theory. Fourth ed. John Wiley and Sons, New York; 1994.\n",
      "31.   Carlin, J.B. Meta-analysis for 2 x 2 tables: a Bayesian approach. Statistics in Medicine 1992; 11(2):141-158.\n",
      "\n",
      "32.   Van Houwelingen, H.C., Zwinderman, K.H., Stijnen, T. A bivariate approach to meta analysis. Statistics in Medicine 1993; 12(24):2273-2284.\n",
      "33.   Van Houwelingen, H.C., Arends, L.R., Stijnen, T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Statistics in Medicine 2002; 21:589-624.\n",
      "34.   Dempster,  A.P.  The  direct  use  of  likelihood  for  significance  testing. Statistics  and Computing 1997; 7(4):247-252.\n",
      "35.   Dias,  S.,  Sutton,  A.J.,  Welton,  N.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  3:  Heterogeneity:  subgroups,  meta-regression,  bias  and  bias-adjustment. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\n",
      "36.   Deeks, J.J. Issues in the selection of a summary statistic for meta analysis of clinical trials with binary outcomes. Statistics in Medicine 2002; 21(11):1575-1600.\n",
      "37.   Cooper, N.J., Sutton, A.J., Lu, G., Khunti, K. Mixed comparison of stroke prevention treatments  in  individuals  with  nonrheumatic  atrial  fibrillation. Archives  of  Internal Medicine 2006; 166(12):1269-1275.\n",
      "38.   Dias,  S.,  Welton,  N.J.,  Marinho,  V.C.C.,  Salanti,  G.,  Higgins,  J.P.T.,  Ades,  A.E. Estimation and adjustment of bias in randomized evidence by using mixed treatment comparison meta-analysis. Journal of the Royal Statistical Society: Series A(Statistics in Society) 2010; 173(3):613-629.\n",
      "39.   Guevara, J.P., Berlin, J.A., Wolf, F.M. Meta-analytic methods for pooling rates when follow-up duration varies: a case study. BMC Medical Research Methodology 2004; 4(1):17.\n",
      "40.   Collett,  D.  Modelling survival data in medical research. Chapman &amp; Hall, London; 1994.\n",
      "41.   Prentice,  R.L.,  Gloeckler,  L.A.  Regression  analysis  of  grouped  survival  data  with application to breast cancer data. Biometrics 1978;57-67.\n",
      "42.   Lu,  G.,  Ades,  A.E.,  Sutton,  A.J.,  Cooper,  N.J., Briggs,  A.H.,  Caldwell,  D.M. Metaanalysis  of  mixed  treatment  comparisons  at  multiple  follow  up  times. Statistics  in Medicine 2007; 26(20):3681-3699.\n",
      "43.   Stettler, C., Wandel, S., Allemann, S., Kastrati, A., Morice, M.C., Schomig, A. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. The Lancet 2007; 370(9591):937-948.\n",
      "44.   NICE Collaborating Centre for Mental Health. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). 2010.  NICE, London.\n",
      "45.   Ades,  A.E.,  Mavranezouli,  I.,  Dias,  S.,  Welton,  N.J.,  Whittington,  C.,  Kendall,  T. Network  Meta  Analysis  with  Competing  Risk  Outcomes. Value  in  Health 2010; 13:976-983.\n",
      "\n",
      "46.   Frison,  L.,  Pocock,  S.J.  Repeated  measures  in  clinical  trials:  analysis  using  mean summary  statistics  and  its  implications  for  design. Statistics  in  Medicine 1992; 11(13):1685-1704.\n",
      "47.   Follmann, D., Elliott, P., Suh, I., Cutler, J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992; 45(7):769-773.\n",
      "48.   Abrams, K.R., Gillies, C.L., Lambert, P.C. Meta analysis of heterogeneously reported trials assessing change from baseline. Statistics in Medicine 2005; 24(24):3823-3844.\n",
      "49.   Cohen, J. Statistical power analysis for the behavioral sciences. Academic Press, New York, 1969.\n",
      "50.   Hedges,  L.V.,  Olkin,  I.  Statistical  methods  for  meta-analysis.  Academic  Press  New York: 1985.\n",
      "51.   Salanti,  G.,  Marinho,  V.,  Higgins,  J.P.T.  A  case  study  of  multiple-treatments  metaanalysis  demonstrates  that  covariates  should  be  considered. Journal  of  Clinical Epidemiology 2009; 62(8):857-864.\n",
      "52.   Woolacott, N., Hawkins, N., Mason, A., Kainth, A., Khadjesari, Z., Vergel, Y.B. et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technology Assessment 2006; 10(46):1-252.\n",
      "53.   Woolacott, N., Bravo Vergel, Y., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K. et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2006; 10(31):1-258.\n",
      "54.   Jobanputra,  P.,  Barton,  P.,  Bryan,  S.,  Burls,  A.  The  effectiveness  of  infliximab  and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2002; 6(21):1-110.\n",
      "55.   WACHOLDER,  S.  Binomial  regression  in  GLIM:  estimating  risk  ratios  and  risk differences. American Journal of Epidemiology 1986; 123(1):174-184.\n",
      "56.   Warn,  D.E.,  THOMPSON, S.G., Spiegelhalter,  D.J.  Bayesian  random  effects  metaanalysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Statistics in Medicine 2002; 21(11):1601-1623.\n",
      "57.   Dominici, F., Parmigiani, G., Wolpert, R.L., Hasselblad, V. Meta-Analysis of Migraine Headache Treatments: Combining Information from Heterogeneous Designs. Journal of the American Statistical Association 1999; 94(445):16-17.\n",
      "58.   Woods, B.S., Hawkins, N., Scott, D.A. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial. BMC Medical Research Methodology 2010; 10(1):54.\n",
      "59.   Chinn, S. A simple method for converting an odds ratio to effect size for use in metaanalysis. Statistics in Medicine 2000; 19(22):3127-3131.\n",
      "\n",
      "60.   Whitehead, A., Bailey, A.J., Elbourne, D. Combining summaries of binary outcomes with those of continuous outcomes in a meta-analysis. Journal of Biopharmaceutical Statistics 1999; 9(1):1-16.\n",
      "61.   Lu,  G.,  Ades,  A.  Modeling  between-trial  variance  structure  in  mixed  treatment comparisons. Biostatistics 2009; 10(4):792-805.\n",
      "62.   Eddy, D.M., Hasselblad, V., Shachter, R.D. Meta-analysis by the confidence profile method. Academic Press, London, 1992.\n",
      "63.   Chootrakool, H., Shi, J.Q. Meta-analysis of multi-arm trials using empirical logistic transform. The Open Medical Informatics Journal 2008; 2:112-116.\n",
      "64.   Raiffa,  H.,  Schlaiffer,  R.  Applied  statistical  decision  theory,  Wiley  Classics  Library edn.  Wiley Interscience, New York, 1967.\n",
      "65.   Dakin, H.A., Welton, N.J., Ades, A.E., Collins, S., Orme, M., Kelly, S. Mixed treatment comparison  of  repeated  measurements  of  a  continuous  endpoint:  an  example  using topical treatments for primary open-angle glaucoma and ocluar hypertension. Statistics in Medicine 2011; 30:2511-2535.\n",
      "66.   Riley,  R.  Multivariate  meta-analysis:  the  effect  of  ignoring  with-study  correlation. Journal of the Royal Statistical Society Series A (Statistics in Society) 2012; 172:789811.\n",
      "67.   Spiegelhalter, D.J., Abrams, K.R., Myles, J.P. Bayesian approaches to clinical trials and health-care evaluation. Wiley, New York; 2004.\n",
      "68.   Brooks, S.P., Gelman, A. Alternative methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 1998; 7(4):434-455.\n",
      "69.   Gelman,  A.  Inference  and  monitoring  convergence.  In:  Gilks  W.R.,  Richardson  S., Spiegelhalter  D.J.,  eds. Markov  chain  Monte  Carlo  in  practice .  Chapman  &amp;  Hall, London; 1996; 131-143.\n",
      "70.   Lambert, P.C., Sutton, A.J., Burton, P.R., Abrams, K.R., Jones, D.R. How vague is vague?  A  simulation  study  of  the  impact  of  the  use  of  vague  prior  distributions  in MCMC using WinBUGS. Statistics in Medicine 2005; 24(15):2401-2428.\n",
      "71.   Bradburn, M.J., Deeks, J.J., Berlin, J.A., Russell Localio, A. Much ado about nothing: a comparison of the performance of meta analytical methods with rare events. Statistics in Medicine 2007; 26(1):53-77.\n",
      "72.   Sweeting, M., Sutton, A.J., Lambert, P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004; 23(9):1351-1375.\n",
      "73.   Claxton, K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 1999; 18(3):341364.\n",
      "\n",
      "74.   Efron, B., Tibshirani, R. An introduction to the bootstrap. Chapman &amp; Hall/CRC, New York; 1993.\n",
      "75.   Mantel, N., Haenszel, W. Statistical aspects of the analysis of data from retrospective studies. Journal of the National Cancer Institute 1959; 22(4):719-748.\n",
      "76.   Fleiss, J.L. Measures of effect size for categorical data. In: Cooper H., Hedges L., eds. The handbook of research synthesis . Russell Sage Foundation, New York; 1994; 245260.\n",
      "77.   Yusuf, S., Petro, R., Lewis, J., Collins, R., Sleight, P. Beta blockade before and after myocrdial infarction: an overview of randomised trials. Progress in Cardiovascular Diseases 1985; 27:335-371.\n",
      "78.   Gavaghan, D.J., Moore, R.A., McQuay, H.J. An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain - Journal of the International Association for the Study of Pain 2000; 85(3):415-424.\n",
      "79.   Biggerstaff, B.J., Tweedie, R.L. Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis. Statistics in Medicine 1997; 16(7):753768.\n",
      "80.   Hardy, R., Thompson, S. A likelihood approach to meta analysis with random effects. Statistics in Medicine 1996; 15(6):619-629.\n",
      "81.   Sterne, J. Meta-analysis in Stata: An updated collection from the Stata Journal. Stata Press Copyright, 2009.\n",
      "82.   Viechtbauer, W. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software 2010.\n",
      "83.   Borenstein, M., Hedges, L., Higgins, J., Rothstein, H. Comprehensive meta-analysis version 2. Englewood, NJ: Biostat 2005.\n",
      "84.   Wallace,  B.C.,  Schmid,  C.H.,  Lau,  J.,  Trikalinos,  T.A.  Meta-Analyst:  software  for meta-analysis  of  binary,  continuous  and  diagnostic  data. BMC  Medical  Research Methodology 2009; 9:80.\n",
      "85.   Bax, L., Yu, L.M., Ikeda, N., Tsuruta, H., Moons, K.G.M. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Medical Research Methodology 2006; 6(1).\n",
      "86.   The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.0. The Cochrane Collaboration 2008.\n",
      "87.   Bucher,  H.C.,  Guyatt,  G.H.,  Griffith,  L.E.,  Walter,  S.D.  The  results  of  direct  and indirect  treatment  comparisons  in  meta-analysis  of  randomized  controlled  trials. Journal of Clinical Epidemiology 1997; 50(6):683-691.\n",
      "88.   White,  I.R.  Multivariate  random-effects  meta-analysis:  Updates  to  mvmeta. Stata Journal 2011; 11:255-270.\n",
      "\n",
      "89.   Jones,  B.,  Roger,  J.,  Lane,  P.W.,  Lawton,  A.,  Fletcher,  C.,  Cappellen,  J.C.  et  al. Statistical  approaches  for  conducting  network  meat-analysis  in  drug  development. Pharmaceutical Statistics 2011; 10:523-531.\n",
      "90.   Riley, R.D., Abrams, K.R., Lambert, P.C., Sutton, A.J., Thompson, J.R. An evaluation of  bivariate  random  effects  meta  analysis  for  the  joint  synthesis  of  two  correlated outcomes. Statistics in Medicine 2007; 26(1):78-97.\n",
      "91.   Riley, R.D., Thompson, J.R., Abrams, K.R. An alternative model for bivariate randomeffects  meta-analysis  when  the  within-study  correlations  are  unknown. Biostatistics 2008; 9(1):172-186.\n",
      "92.   Arends,  L.R.,  Hoes,  A.W.,  Lubsen,  J.,  Grobbee,  D.E.,  Stijnen,  T.  Baseline  risk  as predictor of treatment benefit: three clinical meta-re-analyses. Statistics in Medicine 2000; 19(24):3497-3518.\n",
      "93.   Nam,  I.S.,  Mengersen,  K.,  Garthwaite,  P.  Multivariate  meta  analysis. Statistics  in Medicine 2003; 22(14):2309-2333.\n",
      "94.   Burch, J., Paulden, M., Conti, S., Stock, C., Corbett, M., Welton, N.J. et al. Influenza zanamivir,  amantadine  and  oseltamivir  (review):  assessment  report.  2008.    NICE, London.\n",
      "95.   Welton,  N.J.,  Cooper,  N.J.,  Ades,  A.E.,  Lu,  G.,  Sutton,  A.J.  Mixed  treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals for treatment of influenza A and B. Statistics in Medicine 2008; 27(27):56205639.\n",
      "96.   Welton, N.J., Willis, S.R., Ades, A.E. Synthesis of survival and disease progression outcomes for health  technology  assessment  of  cancer  therapies. Research Synthesis Methods 2010; 1:239-257.\n",
      "97.   Eddy,  D.M.,  Hasselblad,  V.,  Shachter,  R.D.  Analysis  of  alcohol  and  breast  cancer. Meta-analysis by the confidence profile method . Academic Press, London; 1992; 271282.\n",
      "98.   Dominici, F. Combining contingency tables with missing dimensions. Biometrics 2000; 56(2):546-553.\n",
      "99.   Govan, L., Ades, A.E., Weir, C.J., Welton, N.J., Langhorne, P. Controlling ecological bias in evidence synthesis of trials reporting on collapsed and overlapping covariate categories. Statistics in Medicine 2010; 29(12):1340-1356.\n",
      "100.   Salanti,  G.,  Higgins,  J.,  White,  I.R.  Bayesian  synthesis  of  epidemiological  evidence with different combinations of exposure groups: application to a gene-geneenvironment interaction. Statistics in Medicine 2006; 25(24):4147-4163.\n",
      "101.   Welton, N.J., Johnstone, E.C., David, S.P., Munafo, M.R. A cost-effectiveness analysis of  genetic  testing  of  the  DRD2  Taq1A  polymorphism  to  aid  treatment  choice  for smoking cessation. Nicotine &amp; Tobacco Research 2008; 10(1):231-240.\n",
      "\n",
      "102.   Welton, N.J., Ades, A.E. Estimation of Markov chain transition probabilities and rates from fully and partially observed data: Uncertainty propagation, evidence synthesis, and model calibration. Medical Decision Making 2005; 25(6):633-645.\n",
      "103.   Price, M.J., Welton, N.J., Ades, A.E. Parameterization of treatment effects for meta analysis in multi state Markov models. Statistics in Medicine 2011; 30(2):140-151.\n",
      "104.   Hooper, L., Summerbell, C.D., Higgins, J.P., Thompson, R.L., Clements, G., Capps, N. et al. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database of Systematic Reviews 2001;(2):-CD002137.\n",
      "105.   Elliott, W.J., Meyer, P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. The Lancet 2007; 369(9557):201-207.\n",
      "\n",
      "## APPENDIX: ILLUSTRATIVE EXAMPLES AND WINBUGS CODE\n",
      "\n",
      "This appendix gives illustrative WinBUGS code for all the link functions and likelihoods, as well as example code for shared parameter models. All programming code is fully annotated. The  program  codes  are  printed  here,  but  are  also  available  as  WinBUGS  system  files  at www.nicedsu.org.uk. Users are advised to download the WinBUGS files from the website instead of copying and pasting from this document. We have provided the codes as complete programs. However, the majority of each RE program is identical to other RE programs, and similarly for the FE programs. We have therefore highlighted the linear predictor in blue, and the likelihood and deviance calculations in red to emphasise the modular nature of the code. Tables A1 gives an index of the programmes and their relation to the descriptions in the text. Note that for each example there are random and fixed effects versions of the code. All fixed effects code can be run using the same data structure described for the random effects.\n",
      "\n",
      "Table A1 Index of WinBUGS code with details of examples and sections where they are described.\n",
      "\n",
      "| Program number    | Fixed or Random Effects                   | Likelihood                | Link Function   | Example name   | Model specification   |\n",
      "|-------------------|-------------------------------------------|---------------------------|-----------------|----------------|-----------------------|\n",
      "| 1 (a) (b) (c) (d) | Random (2-arm) Fixed (2-arm) Random Fixed | Binomial                  | logit           | Blocker        | Section 2.1           |\n",
      "| 2 (a) (b)         | Random Fixed                              | Poisson                   | log             | Dietary fat    | Section 3.1           |\n",
      "| 3 (a) (b)         | Random Fixed                              | Binomial                  | cloglog         | Diabetes       | Section 3.2           |\n",
      "| 4 (a) (b)         | Random Fixed                              | Multinomial               | log             | Schizophren ia | Section 3.3           |\n",
      "| 5 (a) (b)         | Random Fixed                              | Normal                    | identity        | Parkinson's    | Section 3.4           |\n",
      "| 6 (a) (b)         | Random Fixed                              | Multinomial               | probit          | Psoriasis      | Section 3.6           |\n",
      "| 7 (a)             | Random Fixed                              | Normal (difference data)  | identity        | Parkinson's    | Section 3.5           |\n",
      "| (b) 8 (a) (b)     | Random Fixed                              | Normal (shared parameter) | identity        | Parkinson's    | Section 4             |\n",
      "\n",
      "## EXAMPLE 1. B LOCKER\n",
      "\n",
      "The  first  two  programmes  (Blocker  1(a)  and  1(b))  are  somewhat  apart  from  the  other programmes: these programmes are only capable of processing syntheses of two treatments and 2-arm trials. We include them for the benefit of readers who may wish to start with the simplest possible case and see how the more general code that allows incorporation of multiarm trials is related to the simpler code. The Blocker example is described in Section 2.1.\n",
      "\n",
      "## Program 1(a):  Binomial likelihood, logit link, Random Effects, two treatments (Blocker example). Two-arm trials Only\n",
      "\n",
      "```\n",
      "# Binomial likelihood, logit link, pairwise meta-analysis (2 treatments) # Random effects model model{ # *** PROGRAM STARTS for(i in 1:ns){ #   LOOP THROUGH STUDIES delta[i,1] <- 0 # treatment effect is zero for control arm mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:2) { #  LOOP THROUGH ARMS r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))   #Deviance contribution +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) } resdev[i] <- sum(dev[i,]) #  summed residual deviance contribution for this trial delta[i,2] ~ dnorm(d[2],tau) # trial-specific LOR distributions } totresdev <- sum(resdev[]) #Total Residual Deviance d[1]<- 0 # treatment effect is zero for reference treatment d[2] ~ dnorm(0,.0001) # vague prior for treatment effect sd ~ dunif(0,5) # vague prior for between-trial SD tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance) } # *** PROGRAM ENDS\n",
      "```\n",
      "\n",
      "The data structure has two components: a list specifying the number of studies ns and the main body of data which is in a column format: r[,1] and n[,1] are the numerators and denominators for the  first  treatment; r[,2] and n[,2] ,  the  numerators  and  denominators  for  the  second  listed treatment. Text can be included after the hash symbol ( # ) for ease of reference to the original data source.\n",
      "\n",
      "```\n",
      "# Data (Blocker example) list(ns=22) r[,1] n[,1] r[,2] n[,2] # Study ID 3 39 3 38 # 1 14 116 7 114 # 2 11 93 5 69 # 3 127 1520 102 1533 # 4 27 365 28 355 # 5 6 52 4 59 # 6 152 939 98 945 # 7 48 471 60 632 # 8 37 282 25 278 # 9 188 1921 138 1916 # 10 52 583 64 873 # 11\n",
      "```\n",
      "\n",
      "```\n",
      "47 266 45 263 # 12 16 293 9 291 # 13 45 883 57 858 # 14 31 147 25 154 # 15 38 213 33 207 # 16 12 122 28 251 # 17 6 154 8 151 # 18 3 134 6 174 # 19 40 218 32 209 # 20 43 364 27 391 # 21 39 674 22 680 # 22 END list(d=c( NA, -1), sd=4, mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3))\n",
      "```\n",
      "\n",
      "```\n",
      "# Initial values #chain 1 list(d=c( NA, 0), sd=1, mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) #chain 2 #chain 3 list(d=c( NA, 2), sd=2, mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0, -3, -3,0, 3, 5, -3, -3, -1, -3, -7, -3, -3))\n",
      "```\n",
      "\n",
      "## Program 1(b):  Binomial likelihood, logit link, Fixed Effects, two treatments (Blocker example), Two-arm trials only.\n",
      "\n",
      "```\n",
      "# Binomial likelihood, logit link, pairwise meta-analysis (2 treatments) # Fixed effect model model{ # *** PROGRAM STARTS for(i in 1:ns){ #   LOOP THROUGH STUDIES mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:2) { #  LOOP THROUGH ARMS r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood logit(p[i,k]) <- mu[i] + d[k] # model for linear predictor rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))   #Deviance contribution +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) } resdev[i] <- sum(dev[i,]) #  summed residual deviance contribution for this trial } totresdev <- sum(resdev[]) #Total Residual Deviance d[1]<- 0 # treatment effect is zero for reference treatment d[2] ~ dnorm(0,.0001) # vague prior for treatment effect } # *** PROGRAM ENDS # Initial values #chain 1 list(d=c( NA, 0),  mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) #chain 2 list(d=c( NA, -1), mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3)) #chain 3 list(d=c( NA, 2), mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0, -3, -3,0, 3, 5, -3, -3, -1, -3, -7, -3, -3))\n",
      "```\n",
      "\n",
      "All code presented below is completely general and will be suitable for fitting pairwise or network meta-analyses with any number of treatments and multi-arm trials. We also provide an indication of the relevant parameters to monitor for inference and model checking for the various programs.\n",
      "\n",
      "The nodes to monitor for the fixed effects models are the same as those for the random effects models, except that there is no heterogeneity parameter.\n",
      "\n",
      "This example and results are described in Section 2.1 of the paper (Table 1 and Table 2). The WinBUGS code for random effects is given in program 1(c) and the fixed effects code is given in program 1(d).\n",
      "\n",
      "## Program 1(c): Binomial likelihood, logit link, Random Effects (Blocker example)\n",
      "\n",
      "```\n",
      "# Binomial likelihood, logit link # Random effects model for multi-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns){ # LOOP THROUGH STUDIES w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm delta[i,1] <- 0 # treatment effect is zero for control arm mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:na[i])  { #  LOOP THROUGH ARMS r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) #Deviance contribution +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) } resdev[i] <- sum(dev[i,1:na[i]]) #  summed residual deviance contribution for this trial for (k in 2:na[i]) { # LOOP THROUGH ARMS delta[i,k] ~ dnorm(md[i,k],taud[i,k])  # trial-specific LOR distributions md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] # mean of LOR distributions (with multi-arm trial correction) taud[i,k] <- tau *2*(k-1)/k # precision of LOR distributions (with multi-arm trial correction) w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) # adjustment for multi-arm RCTs sw[i,k] <- sum(w[i,1:k-1])/(k-1) # cumulative adjustment for multi-arm trials } } totresdev <- sum(resdev[]) #Total Residual Deviance d[1] <- 0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects sd ~ dunif(0,5) # vague prior for between-trial SD. ALTERNATIVES BELOW tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance) } # *** PROGRAM ENDS\n",
      "```\n",
      "\n",
      "Alternative prior distributions can be used for the Random Effects Variance. For example, the last two lines above can be replaced by a vague Gamma prior on the precision parameter, which is sometimes also referred to as a vague inverse Gamma prior on the variance:\n",
      "\n",
      "```\n",
      "tau ~ dgamma(.001,.001)\n",
      "```\n",
      "\n",
      "```\n",
      "sd <- pow(tau,-0.5)\n",
      "```\n",
      "\n",
      "See Section 6.2 in the main document for further discussion of prior distributions.\n",
      "\n",
      "Additional code can be added before the closing brace to estimate all the pair-wise Log Odds Ratios and Odds Ratios, to generate ranking statistics and the probability that each treatment is the best treatment, and to produce estimates of absolute effects, given additional information on the absolute treatment effect on one of the treatments. In addition, given an assumption\n",
      "\n",
      "# vague gamma prior on the precision\n",
      "\n",
      "about the absolute effect of one treatment, it is possible to express the treatment effect on other scales  (risk  difference,  relative  risk),  or  number  needed  to  treat, and to  obtain  confidence intervals for all these quantities. This is illustrated below.\n",
      "\n",
      "```\n",
      "################################################################################ # Extra code for all odds ratios and log odds ratios, ranking, and absolute effects, and relative effects # on alternative scales: Numbers Needed to Treat, Risk Difference, Relative Risks ################################################################################ # pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2 for (c in 1:(nt-1)) { for (k in (c+1):nt)  { or[c,k] <- exp(d[k] - d[c]) lor[c,k] <- (d[k]-d[c]) } } # ranking on relative scale for (k in 1:nt) { rk[k] <- nt+1-rank(d[],k) # assumes events are 'good' #    rk[k] <- rank(d[],k) # assumes events are 'bad' best[k] <- equals(rk[k],1) #calculate probability that treat k is best for (h in 1:nt){  prob[h,k] <- equals(rk[k],h)  } # calculates probability that treat k is h-th best } # Provide estimates of treatment effects T[k] on the natural (probability) scale # Given a Mean Effect, meanA, for 'standard' treatment 1, with precision (1/variance) precA A ~ dnorm(meanA,precA) for (k in 1:nt) { logit(T[k]) <- A + d[k]  } # Provide estimates of number needed to treat NNT[k], Risk Difference RD[k], # and Relative Risk RR[k], for each treatment, relative to treatment 1 for (k in 2:nt) { NNT[k] <- 1/(T[k] - T[1]) # assumes events are 'good' #  NNT[k] <- 1/(T[1]- T[k]) # assumes events are 'bad' RD[k] <- T[k] - T[1] RR[k] <- T[k]/T[1] }\n",
      "```\n",
      "\n",
      "The  data  structure  has  two  components:  a  list  specifying  the  number  of  treatments nt and number of studies ns . Both data components need to be loaded into WinBUGS for the program to run. The main body of data is in a vector format, in the order r[,1] then n[,1] , the numerators and denominators for the first treatment,  then r[,2] then n[,2] , the numerators and denominators for the second listed treatment, then t[,1] and t[,2] , the treatment number identifiers for the first and second listed treatments, and finally the number of arms in each trial, na[] . The purpose for this structure becomes clearer in datasets with multi-arm trials. An important feature of the code  presented  is  the  assumption  that  the  treatments  are  always  presented  in  ascending (numerical) order and that treatment 1 is taken as the reference treatment. This rule is crucial when conducting network meta-analysis to ensure the correct relative effects are estimated.\n",
      "\n",
      "We strongly recommend the use of the column data format shown here in preference to the list format that WinBUGS also allows, and the use of comments to add trial names or references. This facilitates data checking.\n",
      "\n",
      "| # Data (Blocker example) list(nt=2, ns=22)   | # Data (Blocker example) list(nt=2, ns=22)   | # Data (Blocker example) list(nt=2, ns=22)   | # Data (Blocker example) list(nt=2, ns=22)   | # Data (Blocker example) list(nt=2, ns=22)   | # Data (Blocker example) list(nt=2, ns=22)   | # Data (Blocker example) list(nt=2, ns=22)   |\n",
      "|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|\n",
      "| r[,1]                                        | n[,1]                                        | r[,2]                                        | n[,2]                                        | t[,1]                                        | t[,2]                                        | na[]                                         |\n",
      "| 3                                            | 39                                           | 3                                            | 38                                           | 1                                            | 2                                            | 2                                            |\n",
      "| 14                                           | 116                                          | 7                                            | 114                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 11                                           | 93                                           | 5                                            | 69                                           | 1                                            | 2                                            | 2                                            |\n",
      "| 127                                          | 1520                                         | 102                                          | 1533                                         | 1                                            | 2                                            | 2                                            |\n",
      "| 27                                           | 365                                          | 28                                           | 355                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 6                                            | 52                                           | 4                                            | 59                                           | 1                                            | 2                                            | 2                                            |\n",
      "| 152                                          | 939                                          | 98                                           | 945                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 48                                           | 471                                          | 60                                           | 632                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 37                                           | 282                                          | 25                                           | 278                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 188                                          | 1921                                         | 138                                          | 1916                                         | 1                                            | 2                                            | 2                                            |\n",
      "| 52                                           | 583                                          | 64                                           | 873                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 47                                           | 266                                          | 45                                           | 263                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 16                                           | 293                                          | 9                                            | 291                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 45                                           | 883                                          | 57                                           | 858                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 31                                           | 147                                          | 25                                           | 154                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 38                                           | 213                                          | 33                                           | 207                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 12                                           | 122                                          | 28                                           | 251                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 6                                            | 154                                          | 8                                            | 151                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 3                                            | 134                                          | 6                                            | 174                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 40                                           | 218                                          | 32                                           | 209                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 43                                           | 364                                          | 27                                           | 391                                          | 1                                            | 2                                            | 2                                            |\n",
      "| 39                                           | 674                                          | 22                                           | 680                                          | 1                                            | 2                                            | 2                                            |\n",
      "\n",
      "```\n",
      "# Data (Blocker example) list(nt=2, ns=22) r[,1] n[,1] r[,2] n[,2] t[,1] t[,2] na[] 3 39 3 38 1 2 2 14 116 7 114 1 2 2 11 93 5 69 1 2 2 127 1520 102 1533 1 2 2 27 365 28 355 1 2 2 6 52 4 59 1 2 2 152 939 98 945 1 2 2 48 471 60 632 1 2 2 37 282 25 278 1 2 2 188 1921 138 1916 1 2 2 52 583 64 873 1 2 2 47 266 45 263 1 2 2 16 293 9 291 1 2 2 45 883 57 858 1 2 2 31 147 25 154 1 2 2 38 213 33 207 1 2 2 12 122 28 251 1 2 2 6 154 8 151 1 2 2 3 134 6 174 1 2 2 40 218 32 209 1 2 2 43 364 27 391 1 2 2 39 674 22 680 1 2 2 END # Initial values # Initial values for delta can be generated by WinBUGS. #chain 1 list(d=c( NA, 0), sd=1, mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) #chain 2 list(d=c( NA, -1), sd=4, mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3)) #chain 3 list(d=c( NA, 2), sd=2, mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0, -3, -3,0, 3, 5, -3, -3, -1, -3, -7, -3, -3))\n",
      "```\n",
      "\n",
      "To obtain the posterior summaries of the parameters of interest for inference, the nodes d and sd (in the random effects model only) need to be monitored. To obtain the posterior means of the parameters required to assess model fit and model comparison, dev , totresdev and the DIC (from the WinBUGS DIC tool), need to be monitored.  In addition, to calculate the leverage for each data point and to draw leverage plots, rhat needs to be monitored.\n",
      "\n",
      "Program 1(d):  Binomial likelihood, logit link, Fixed Effects (Blocker example)\n",
      "\n",
      "# Binomial likelihood, logit link\n",
      "\n",
      "# Fixed effects model model{\n",
      "\n",
      "for(i in 1:ns){\n",
      "\n",
      "mu[i] ~ dnorm(0,.0001)\n",
      "\n",
      "for (k in 1:na[i])  {\n",
      "\n",
      "# *** PROGRAM STARTS\n",
      "\n",
      "# LOOP THROUGH STUDIES\n",
      "\n",
      "# vague priors for all trial baselines\n",
      "\n",
      "#  LOOP THROUGH ARMS\n",
      "\n",
      "```\n",
      "r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood logit(p[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]] # model for linear predictor rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) #Deviance contribution +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) } resdev[i] <- sum(dev[i,1:na[i]]) # summed residual deviance contribution for this trial } totresdev <- sum(resdev[]) #Total Residual Deviance d[1]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects } # *** PROGRAM ENDS # Initial values #chain 1 list(d=c( NA, 0), mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) #chain 2 list(d=c( NA, -1), mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3, -3)) #chain 3 list(d=c( NA, 2),  mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0, -3, -3,0, 3, 5, -3, -3, -1, -3, -7, -3, -3))\n",
      "```\n",
      "\n",
      "## EXAMPLE 2. D IETARY FAT\n",
      "\n",
      "In a Cochrane Review of randomised controlled trials to assess the effect of change in dietary fats on total and cardiovascular mortality, 104 data extracted was in the form of rates and given as the number of events per person-years observed (Table A2).\n",
      "\n",
      "Table A2 Dietary fat example: Study names and treatment codes for the 10 included studies and personyears and total mortality observed in each study.\n",
      "\n",
      "|                           | Treatment     | Treatment   | Treatment    | Person-yrs obs   | Person-yrs obs   | Person-yrs obs   | Total mortality   | Total mortality   | Total mortality   | Number randomised   | Number randomised   | Number randomised   |\n",
      "|---------------------------|---------------|-------------|--------------|------------------|------------------|------------------|-------------------|-------------------|-------------------|---------------------|---------------------|---------------------|\n",
      "| Study name and ID         | control t[,1] | diet t[,2]  | diet 2 t[,3] | control E[,1]    | diet E[,2]       | diet 2 E[,3]     | control r[,1]     | diet r[,2]        | diet 2 r[,3]      | control n[,1]       | diet n[,2]          | diet 2 n[,3]        |\n",
      "| 1.DART                    | 1             | 2           |              | 1917             | 1925             |                  | 113               | 111               |                   | 1015                | 1018                |                     |\n",
      "| 2.London Corn /Olive      | 1             | 2           | 2            | 43.6             | 41.3             | 38               | 1                 | 5                 | 3                 | 26                  | 28                  | 26                  |\n",
      "| 3.London Low Fat          | 1             | 2           |              | 393.5            | 373.9            |                  | 24                | 20                |                   | 129                 | 123                 |                     |\n",
      "| 4.Minnesota Coronary      | 1             | 2           |              | 4715             | 4823             |                  | 248               | 269               |                   | 4516                | 4516                |                     |\n",
      "| 5.MRC Soya                | 1             | 2           |              | 715              | 751              |                  | 31                | 28                |                   | 194                 | 199                 |                     |\n",
      "| 6.Oslo Diet-Heart         | 1             | 2           |              | 885              | 895              |                  | 65                | 48                |                   | 206                 | 206                 |                     |\n",
      "| 7.STARS                   | 1             | 2           |              | 87.8             | 91               |                  | 3                 | 1                 |                   | 30                  | 30                  |                     |\n",
      "| 8.Sydney Diet-Heart       | 1             | 2           |              | 1011             | 939              |                  | 28                | 39                |                   | 237                 | 221                 |                     |\n",
      "| 9.Veterans Administration | 1             | 2           |              | 1544             | 1588             |                  | 177               | 174               |                   | 422                 | 424                 |                     |\n",
      "| 10.Veterans Diet& Skin CA | 1             | 2           |              | 125              | 123              |                  | 2                 | 1                 |                   | 67                  | 66                  |                     |\n",
      "\n",
      "Most of the trials compared only one reduced fat dietary intervention with a control diet (nonreduced fat). However, the 'London Corn/Olive' trial compared two types of reduced fat diets\n",
      "\n",
      "against control  (for more details see Hooper et al. 104 ).  For  the  purpose  of  this  example  we considered the two different types of diet as the same intervention (treatment 2), but kept the treatment  arms  separately,  so  that  in  a  random  effects  model,  this  trial  will  provide  two correlated estimates of the trial-specific treatment effect δ i,1 2 and in the fixed effects model, both arms will contribute to the estimate of the common treatment effect d 12 .\n",
      "\n",
      "The model for this type of data is outlined in Section 3.1. The WinBUGS code for random effects is given in program 2(a) and the fixed effects code is given in program 2(b).\n",
      "\n",
      "## Program 2(a):  Poisson likelihood, log link, Random Effects (Dietary fat example)\n",
      "\n",
      "```\n",
      "# Poisson likelihood, log link # Random effects model for multi-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns){ # LOOP THROUGH STUDIES w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm delta[i,1] <- 0 # treatment effect is zero for control arm mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:na[i]) { #  LOOP THROUGH ARMS r[i,k] ~ dpois(theta[i,k]) # Poisson likelihood theta[i,k] <- lambda[i,k]*E[i,k] # failure rate * exposure log(lambda[i,k]) <- mu[i] + delta[i,k] # model for linear predictor dev[i,k] <- 2*((theta[i,k]-r[i,k]) + r[i,k]*log(r[i,k]/theta[i,k]))  #Deviance contribution } resdev[i] <- sum(dev[i,1:na[i]]) #  summed residual deviance contribution for this trial for (k in 2:na[i]) { # LOOP THROUGH ARMS delta[i,k] ~ dnorm(md[i,k],taud[i,k]) # trial-specific LOR distributions md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] # mean of LOR distributions (with multi-arm trial correction) taud[i,k] <- tau *2*(k-1)/k # precision of LOR distributions (with multi-arm trial correction) w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) # adjustment for multi-arm RCTs sw[i,k] <- sum(w[i,1:k-1])/(k-1) # cumulative adjustment for multi-arm trials } } totresdev <- sum(resdev[]) #Total Residual Deviance d[1]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects sd ~ dunif(0,5) # vague prior for between-trial SD tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance) } # *** PROGRAM ENDS\n",
      "```\n",
      "\n",
      "As before, additional code can be added to monitor all the K ( K -1)/2 log hazard ratios and hazard ratios when there are more than 2 treatments:\n",
      "\n",
      "```\n",
      "# pairwise HRs and LHRs for all possible pair-wise comparisons, if nt>2 for (c in 1:(nt-1)) { for (k in (c+1):nt)  { lhr[c,k] <- (d[k]-d[c]) log(hr[c,k]) <- lhr[c,k] } }\n",
      "```\n",
      "\n",
      "or to rank treatments and monitor the probabilities that each is best, and to generate absolute rates for each treatment. For example if, on the basis of some external data we believe that the\n",
      "\n",
      "log-rate for Treatment 1 has mean -3, and precision 1.77, then we can generate absolute rates for other treatments as follows:\n",
      "\n",
      "```\n",
      "A ~ dnorm(-3,1.77) for (k in 1:nt) { log(T[k]) <- A + d[k]  }\n",
      "```\n",
      "\n",
      "A  further  variable  that  may  be  required  for  cost-effectiveness  modelling  might  be  the proportion of patients that would be expected to have an event, after a follow-up of, say, 3 months, under each treatment. In this example the rates are per year, so:\n",
      "\n",
      "```\n",
      "for (k in 1:nt) { p[k] <- 1-exp(-T[k]*0.25)  }\n",
      "```\n",
      "\n",
      "The data structure again has two components: a list specifying the number of treatments nt and number of studies ns . Both data components need to be loaded into WinBUGS for the program to run. The main body of data is in a vector format, and we need to allow for a 3-arm trial. Three places are therefore required to specify the treatments t[,] , the exposure times E[,] and the number of events r[,] in each arm; ' NA ' indicates that the data is missing for a particular cell. As before na[] is the number of arms in each study. Text can be included after a hash symbol for ease of reference to the original data source.\n",
      "\n",
      "# Data (Dietary fat example)\n",
      "\n",
      "list(ns=10, nt=2)\n",
      "\n",
      "| t[,1] t[,2]   | t[,3]   | E[,1]     | E[,2]   | E[,3]   |   r[,1] | r[,2]   | r[,3]   | na[]   | #ID                         |\n",
      "|---------------|---------|-----------|---------|---------|---------|---------|---------|--------|-----------------------------|\n",
      "| 1 2           | NA      | 1917 1925 | NA      | 113     |     111 | NA      | 2       |        | #2 DART                     |\n",
      "| 1 2           | 2 43.6  |           | 41.3    | 38      |       1 | 5       | 3       | 3      | #10 London Corn /Olive      |\n",
      "| 1 2           | NA      | 393.5     | 373.9   | NA      |      24 | 20      | NA      | 2      | #11 London Low Fat          |\n",
      "| 1 2           | NA      | 4715      | 4823    | NA      |     248 | 269     | NA      | 2      | #14 Minnesota Coronary      |\n",
      "| 1 2           | NA      | 715       | 751     | NA      |      31 | 28      | NA      | 2      | #15 MRC Soya                |\n",
      "| 1 2           | NA      | 885       | 895     | NA      |      65 | 48      | NA      | 2      | #18 Oslo Diet-Heart         |\n",
      "| 1 2           | NA      | 87.8      | 91      | NA      |       3 | 1       | NA      | 2      | #22 STARS                   |\n",
      "| 1 2           | NA      | 1011      | 939     | NA      |      28 | 39      | NA      | 2      | #23 Sydney Diet-Heart       |\n",
      "| 1 2           | NA      | 1544      | 1588    | NA      |     177 | 174     | NA      | 2      | #26 Veterans Administration |\n",
      "| 1 2           | NA      | 125       | 123     | NA      |       2 | 1       | NA      | 2      | #27 Veterans Diet & Skin CA |\n",
      "\n",
      "END\n",
      "\n",
      "```\n",
      "# Initial Values # Initial values for delta can be generated by WinBUGS. #chain 1 list(d=c( NA, 0), sd=1, mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) #chain 2 list(d=c( NA, -1), sd=4, mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3)) #chain 3 list(d=c( NA, 2), sd=2, mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0))\n",
      "```\n",
      "\n",
      "To get the posterior summaries of the parameters of interest for inference, the nodes d and sd (in the random effects model only) need to be monitored. To obtain the posterior means of the parameters required to assess model fit and model comparison, dev , totresdev and the DIC (from the WinBUGS the DIC tool), need to be monitored.  In addition, to calculate the leverage for each data point and to draw leverage plots, theta needs to be monitored.\n",
      "\n",
      "## Program 2(b):  Poisson likelihood, log link, Fixed Effects (Dietary fat)\n",
      "\n",
      "```\n",
      "# *** PROGRAM STARTS #   LOOP THROUGH STUDIES # vague priors for all trial baselines #  LOOP THROUGH ARMS # Poisson likelihood # event rate * exposure # model for linear predictor dev[i,k] <- 2*((theta[i,k]-r[i,k]) + r[i,k]*log(r[i,k]/theta[i,k])) #Deviance contribution #  summed residual deviance contribution for this trial #Total Residual Deviance # treatment effect is zero for reference treatment # vague priors for treatment effects # *** PROGRAM ENDS\n",
      "```\n",
      "\n",
      "```\n",
      "# Poisson likelihood, log link # Fixed effects model for multi-arm trials model{ for(i in 1:ns){ mu[i] ~ dnorm(0,.0001) for (k in 1:na[i]) { r[i,k] ~ dpois(theta[i,k]) theta[i,k] <- lambda[i,k]*E[i,k] log(lambda[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]] } resdev[i] <- sum(dev[i,1:na[i]]) } totresdev <- sum(resdev[]) d[1]<-0 for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } } # Initial Values #chain 1 list(d=c( NA, 0), mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0)) #chain 2 list(d=c( NA, -1), mu=c(-3, -3, -3, -3, -3, -3, -3, -3, -3, -3)) #chain 3 list(d=c( NA, 2), mu=c(-3, 5, -1, -3, 7, -3, -4, -3, -3, 0))\n",
      "```\n",
      "\n",
      "## R ESULTS\n",
      "\n",
      "The results from the two models (3 chains: 20,000 iterations after a burn-in of 20,000 for the FE model and 100,000 iterations after a burn-in of 100,000 for the RE model) are compared in Table A3. The random and fixed effects models are indistinguishable in terms of model fit, and both appear to fit the data well in that res D is  close  to  21,  the  number of data points.  The posterior median of the pooled log-rate of a reduced fat diet, compared to the control diet is 0.01 in the FE model with 95% Credible Interval (-0.11, 0.10) suggesting no difference in the number of cardiovascular mortalities in each group. The posterior medians of the absolute rates of mortality (and their 95% Credible intervals), having assumed that the log-rate of mortality on the control diet has mean -3 and precision 1.77, on the control and reduced fat diets are the same (Table A3).\n",
      "\n",
      "Table A3 Dietary fat example: posterior mean, standard deviation (sd), median and 95% Credible interval (CrI) for both the fixed and random effects models for the treatment effect d 12 , absolute effects of the control diet  ( T 1 )  and  the  reduced  fat  diet  ( T 2 )  for  a  log-rate  of  mortality  on  the  control  diet  with  mean  -3  and precision 1.77, heterogeneity parameter τ and model fit statistics.\n",
      "\n",
      "|         | FE model   | FE model   | FE model   | FE model     | RE model   | RE model   | RE model   | RE model     |\n",
      "|---------|------------|------------|------------|--------------|------------|------------|------------|--------------|\n",
      "|         | mean       | sd         | median     | CrI          | mean       | sd         | median     | CrI          |\n",
      "| d 12    | -0.01      | 0.054      | -0.01      | (-0.11,0.10) | -0.02      | 0.09       | -0.01      | (-0.19,0.16) |\n",
      "| T 1     | 0.06       | 0.04       | 0.05       | (0.01,0.18)  | 0.06       | 0.04       | 0.05       | (0.01,0.18)  |\n",
      "| T 2     | 0.06       | 0.04       | 0.05       | (0.01,0.18)  | 0.06       | 0.04       | 0.05       | (0.01,0.18)  |\n",
      "| τ       | -          | -          | -          | -            | 0.13       | 0.12       | 0.10       | (0.00,0.43)  |\n",
      "| res D * | 22.32      |            |            |              | 21.5       |            |            |              |\n",
      "| p D     | 10.9       |            |            |              | 13.3       |            |            |              |\n",
      "| DIC     | 33.2       |            |            |              | 34.8       |            |            |              |\n",
      "\n",
      "## EXAMPLE 3. D IABETES\n",
      "\n",
      "Here we show code for a linear model on the log rate scale based on binomial data gathered at different  follow-up  times.  We  use  as  an  illustration  a  network  meta-analysis  to  assess  the incidence of diabetes in randomised controlled trials of antihypertensive drugs. 105 The outcome was new cases of diabetes observed over the trial duration period (measured in years) for 6 different drugs: Diuretic (treatment 1), Placebo (treatment 2), β blocker (treatment 3), CCB (treatment 4), ACE inhibitor (treatment 5) and ARB (treatment 6). In this example of a network meta-analysis, the reference treatment chosen was diuretic, as recommended in this field - for more details  see  Elliott  &amp;  Meyer. 105 The  data  are  presented  in  Table  A4  and  the  network diagram in Figure A3.\n",
      "\n",
      "Table A4 Diabetes example: study names, follow-up time in years, treatments compared, total number of new cases of diabetes and number of patients in each trial arm, where Diuretic = treatment 1, Placebo = treatment  2,  β  blocker  =  treatment  3,  CCB  =  treatment  4,  ACE  inhibitor  =  treatment  5  and  ARB  = treatment 6. 105\n",
      "\n",
      "|                  | Study Follow-up (in years)   | Treatment   | Treatment   | Treatment   | New cases of diabetes arm 1 arm 2 arm 3   | New cases of diabetes arm 1 arm 2 arm 3   | New cases of diabetes arm 1 arm 2 arm 3   | Total number of patients   | Total number of patients   | Total number of patients   |\n",
      "|------------------|------------------------------|-------------|-------------|-------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|----------------------------|----------------------------|----------------------------|\n",
      "|                  | time[]                       | arm 1 t[,1] | arm 2 t[,2] | arm 3 t[,3] | r[,1]                                     | r[,2]                                     | r[,3]                                     | arm 1 n[,1]                | arm 2 n[,2]                | arm 3 n[,3]                |\n",
      "| Study ID 1.MRC-E | 5.8                          | 1           | 2           | 3           | 43                                        | 34                                        | 37                                        | 1081                       | 2213                       | 1102                       |\n",
      "| 2.EWPH           | 4.7                          | 1           | 2           |             | 29                                        | 20                                        |                                           | 416                        | 424                        |                            |\n",
      "| 3.SHEP           | 3                            | 1           | 2           |             | 140                                       | 118                                       |                                           | 1631                       | 1578                       |                            |\n",
      "| 4.HAPPHY         | 3.8                          | 1           | 3           |             | 75                                        | 86                                        |                                           | 3272                       | 3297                       |                            |\n",
      "| 5.ALLHAT         | 4                            | 1           | 4           | 5           | 302                                       | 154                                       | 119                                       | 6766                       | 3954                       | 4096                       |\n",
      "| 6.INSIGHT        | 3                            | 1           | 4           |             | 176                                       | 136                                       |                                           | 2511                       | 2508                       |                            |\n",
      "| 7.ANBP-2         | 4.1                          | 1           | 5           |             | 200                                       | 138                                       |                                           | 2826                       | 2800                       |                            |\n",
      "| 8.ALPINE         | 1                            | 1           | 6           |             | 8                                         | 1                                         |                                           | 196                        | 196                        |                            |\n",
      "| 9.FEVER          | 3.3                          | 2           | 4           |             | 154                                       | 177                                       |                                           | 4870                       | 4841                       |                            |\n",
      "| 10.DREAM         | 3                            | 2           | 5           |             | 489                                       | 449                                       |                                           | 2646                       | 2623                       |                            |\n",
      "| 11.HOPE          | 4.5                          | 2           | 5           |             | 155                                       | 102                                       |                                           | 2883                       | 2837                       |                            |\n",
      "| 12.PEACE         | 4.8                          | 2           | 5           |             | 399                                       | 335                                       |                                           | 3472                       | 3432                       |                            |\n",
      "| 13.CHARM         | 3.1                          | 2           | 6           |             | 202                                       | 163                                       |                                           | 2721                       | 2715                       |                            |\n",
      "| 14.SCOPE         | 3.7                          | 2           | 6           |             | 115                                       | 93                                        |                                           | 2175                       | 2167                       |                            |\n",
      "| 15.AASK          | 3.8                          | 3           | 4           | 5           | 70                                        | 32                                        | 45                                        | 405                        | 202                        | 410                        |\n",
      "| 16.STOP-2        | 4                            | 3           | 4           | 5           | 97                                        | 95                                        | 93                                        | 1960                       | 1965                       | 1970                       |\n",
      "| 17.ASCOT         | 5.5                          | 3           | 4           |             | 799                                       | 567                                       |                                           | 7040                       | 7072                       |                            |\n",
      "| 18.NORDIL        | 4.5                          | 3           | 4           |             | 251                                       | 216                                       |                                           | 5059                       | 5095                       |                            |\n",
      "| 19.INVEST        | 4                            | 3           | 4           |             | 665                                       | 569                                       |                                           | 8078                       | 8098                       |                            |\n",
      "| 20.CAPPP         | 6.1                          | 3           | 5           |             | 380                                       | 337                                       |                                           | 5230                       | 5183                       |                            |\n",
      "| 21.LIFE          | 4.8                          | 3           | 6           |             | 320                                       | 242                                       |                                           | 3979                       | 4020                       |                            |\n",
      "| 22.VALUE         | 4.2                          | 4           | 6           |             | 845                                       | 690                                       |                                           | 5074                       | 5087                       |                            |\n",
      "\n",
      "Figure A3 Diabetes network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison and the numbers by the treatment names are the treatment codes used in the modelling.\n",
      "\n",
      "<!-- image -->\n",
      "\n",
      "The model for this type of data is outlined in Section 3.2. The WinBUGS code for random effects is given in program 3(a) and the fixed effects code is given in program 3(b).\n",
      "\n",
      "## Program 3(a):  Binomial likelihood, cloglog link, Random Effects (Diabetes example)\n",
      "\n",
      "```\n",
      "# Binomial likelihood, cloglog link # Random effects model for multi-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns){ #   LOOP THROUGH STUDIES w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm delta[i,1] <- 0 # treatment effect is zero for control arm mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:na[i]) { #  LOOP THROUGH ARMS r[i,k] ~ dbin(p[i,k],n[i,k]) # Binomial likelihood cloglog(p[i,k]) <- log(time[i]) + mu[i] + delta[i,k] # model for linear predictor rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))  #Deviance contribution } resdev[i] <- sum(dev[i,1:na[i]]) #  summed residual deviance contribution for this trial for (k in 2:na[i]) { # LOOP THROUGH ARMS delta[i,k] ~ dnorm(md[i,k],taud[i,k]) # trial-specific LOR distributions md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] # mean of LOR distributions (with multi-arm correction) taud[i,k] <- tau *2*(k-1)/k # precision of LOR distributions (with multi-arm correction) w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) # adjustment for multi-arm RCTs sw[i,k] <- sum(w[i,1:k-1])/(k-1) # cumulative adjustment for multi-arm trials } } totresdev <- sum(resdev[]) #Total Residual Deviance d[1]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects\n",
      "```\n",
      "\n",
      "```\n",
      "sd ~ dunif(0,5) # vague prior for between-trial SD tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance) } # *** PROGRAM ENDS\n",
      "```\n",
      "\n",
      "Additional code to generate all the treatment contrasts, absolute effects, ranking can be added, as with the Poisson - log link models.  To generate absolute probabilities for each treatment, if, on the basis of some external data, we believe that the cloglog of the probability of an event for Treatment 1, after a time period of 3 years, has mean -4.2, and precision 1.11, then we can generate absolute probabilities for other treatments as follows:\n",
      "\n",
      "```\n",
      "A ~ dnorm(-4.2,1.11) for (k in 1:nt) { cloglog(T[k]) <- log(3) + A + d[k]  }\n",
      "```\n",
      "\n",
      "The main body of data is in the same format as the binomial likelihood with logit  link  in Example 1, with an additional vector for follow-up time, time[] . Note that treatments are ordered numerically so that the treatment in arm 2 has a higher code than the treatment in arm 1, and the treatment in arm 3 has a higher code than the treatment in arm 2. This is essential to ensure the correct relative effects are obtained.\n",
      "\n",
      "```\n",
      "# Data (Diabetes example) list(ns=22, nt=6) time[] t[,1] r[,1] n[,1] t[,2] r[,2] n[,2] t[,3] r[,3] n[,3] na[] #Study 5.8 1 43 1081 2 34 2213 3 37 1102 3 #MRC-E  38 4.7 1 29 416 2 20 424 NA NA NA 2 #EWPH 32 3 1 140 1631 2 118 1578 NA NA NA 2 #SHEP 42 3.8 1 75 3272 3 86 3297 NA NA NA 2 #HAPPHY33 4 1 302 6766 4 154 3954 5 119 4096 3 #ALLHAT 26 3 1 176 2511 4 136 2508 NA NA NA 2 #INSIGHT35 4.1 1 200 2826 5 138 2800 NA NA NA 2 #ANBP-2 18 1 1 8 196 6 1 196 NA NA NA 2 #ALPINE 27 3.3 2 154 4870 4 177 4841 NA NA NA 2 #FEVER  20 3 2 489 2646 5 449 2623 NA NA NA 2 #DREAM 31 4.5 2 155 2883 5 102 2837 NA NA NA 2 #HOPE 34 4.8 2 399 3472 5 335 3432 NA NA NA 2 #PEACE  40 3.1 2 202 2721 6 163 2715 NA NA NA 2 #CHARM 30 3.7 2 115 2175 6 93 2167 NA NA NA 2 #SCOPE 41 3.8 3 70 405 4 32 202 5 45 410 3 #AASK 25 4 3 97 1960 4 95 1965 5 93 1970 3 #STOP-2 43 5.5 3 799 7040 4 567 7072 NA NA NA 2 #ASCOT  28 4.5 3 251 5059 4 216 5095 NA NA NA 2 #NORDIL 39 4 3 665 8078 4 569 8098 NA NA NA 2 #INVEST 36 6.1 3 380 5230 5 337 5183 NA NA NA 2 #CAPPP  29 4.8 3 320 3979 6 242 4020 NA NA NA 2 #LIFE 37 4.2 4 845 5074 6 690 5087 NA NA NA 2 #VALUE  44 END\n",
      "```\n",
      "\n",
      "```\n",
      "# Initial Values # In this case it is advisable to initialise delta to avoid numerical errors #chain 1 list(d=c(NA,0,0,0,0,0),  sd=1,  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0),\n",
      "```\n",
      "\n",
      "```\n",
      "delta= structure(.Data= c(NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0,0, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA), .Dim=c(22, 3))) #chain 2 list(d=c(NA,-1,4,-1,2,3),  sd=3,  mu=c(1,1,0,1,0,    0,1,0,0,0,    1,1,0,0,0,   0,1,0,0,0,  1,1), delta= structure(.Data= c(NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0,0, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA), .Dim=c(22, 3))) #chain 3 list(d=c(NA,1,4,-3,-2,3),  sd=4.5,  mu=c(1,1,0,1,0,    0,1,0,0,0,    1,1,0,-2,0,   0,1,0,-2,0,  1,1), delta= structure(.Data= c(NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0,0, NA, 0, 0, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA, NA, 0, NA), .Dim=c(22, 3)))\n",
      "```\n",
      "\n",
      "## Program 3(b):  Binomial likelihood, cloglog link, Fixed Effects (Diabetes example)\n",
      "\n",
      "```\n",
      "# Binomial likelihood, cloglog link # Fixed effects model model{ # *** PROGRAM STARTS for(i in 1:ns){ # LOOP THROUGH STUDIES mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:na[i]) { # LOOP THROUGH ARMS r[i,k] ~ dbin(p[i,k],n[i,k]) # Binomial likelihood cloglog(p[i,k]) <- log(time[i]) + mu[i] + d[t[i,k]] - d[t[i,1]] # model for linear predictor rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) #Deviance contribution } resdev[i] <- sum(dev[i,1:na[i]]) #  summed residual deviance contribution for this trial } totresdev <- sum(resdev[]) #Total Residual Deviance d[1]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects } # *** PROGRAM ENDS # Initial Values #chain 1 list(d=c(NA,0,0,0,0,0),  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0) ) #chain 2 list(d=c(NA,1,1,1,1,1),  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0)  ) #chain 3 list(d=c(NA,1,1,1,1,2),  mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0)  )\n",
      "```\n",
      "\n",
      "## R ESULTS\n",
      "\n",
      "Both fixed and random effects models were fitted (3 chains: 100,000 iterations after a burn-in of 50,000). From the results presented in Table A5, we see that the fixed effects model has a very poor fit and the random effects model should be preferred for inference.\n",
      "\n",
      "Table A5 Diabetes example: posterior mean, standard deviation (sd), median and 95% Credible interval (CrI) for both the fixed and random effects models for the treatment effects of Placebo ( d 12 ), β blocker ( d 13 ), CCB ( d 14 ), ACE inhibitor ( d 15 ) and ARB ( d 16 ) relative to Diuretic; absolute effects of diuretic ( T 1 ) Placebo ( T 2 ), β blocker ( T 3 ), CCB ( T 4 ), ACE inhibitor ( T 5 ) and ARB ( T 6 ); heterogeneity parameter τ and model fit statistics.\n",
      "\n",
      "|         | FE model   | FE model   | FE model   | FE model      | RE model   | RE model   | RE model   | RE model      |\n",
      "|---------|------------|------------|------------|---------------|------------|------------|------------|---------------|\n",
      "|         | mean       | sd         | median     | CrI           | mean       | sd         | median     | CrI           |\n",
      "| d 12    | -0.25      | 0.06       | -0.25      | (-0.36,-0.14) | -0.29      | 0.09       | -0.29      | (-0.47,-0.12) |\n",
      "| d 13    | -0.06      | 0.06       | -0.06      | (-0.17,0.05)  | -0.07      | 0.09       | -0.07      | (-0.25,0.10)  |\n",
      "| d 14    | -0.25      | 0.05       | -0.25      | (-0.36,-0.15) | -0.24      | 0.08       | -0.24      | (-0.41,-0.08) |\n",
      "| d 15    | -0.36      | 0.05       | -0.36      | (-0.46,-0.25) | -0.40      | 0.09       | -0.40      | (-0.58,-0.24) |\n",
      "| d 16    | -0.45      | 0.06       | -0.45      | (-0.58,-0.33) | -0.47      | 0.11       | -0.47      | (-0.70,-0.27) |\n",
      "| T 1     | 0.065      | 0.067      | 0.044      | (0.01,0.25)   | 0.065      | 0.067      | 0.044      | (0.01,0.25)   |\n",
      "| T 2     | 0.052      | 0.055      | 0.034      | (0.01,0.20)   | 0.050      | 0.053      | 0.033      | (0.01,0.20)   |\n",
      "| T 3     | 0.062      | 0.064      | 0.042      | (0.01,0.24)   | 0.061      | 0.064      | 0.041      | (0.01,0.24)   |\n",
      "| T 4     | 0.051      | 0.055      | 0.034      | (0.01,0.20)   | 0.052      | 0.056      | 0.035      | (0.01,0.20)   |\n",
      "| T 5     | 0.047      | 0.050      | 0.031      | (0.00,0.18)   | 0.045      | 0.048      | 0.030      | (0.00,0.18)   |\n",
      "| T 6     | 0.043      | 0.046      | 0.028      | (0.00,0.17)   | 0.042      | 0.046      | 0.028      | (0.00,0.17)   |\n",
      "| τ       |            |            |            |               | 0.13       | 0.04       | 0.12       | (0.05,0.23)   |\n",
      "| res D * | 78.25      |            |            |               | 53.7       |            |            |               |\n",
      "| pD      | 27.0       |            |            |               | 38.0       |            |            |               |\n",
      "| DIC     | 105.2      |            |            |               | 91.7       |            |            |               |\n",
      "\n",
      "The posterior median of the pooled treatment effects, on the complementary log-log scale, of treatments 2 to 6 relative to the reference treatment show a beneficial effect of all the treatment with the exception of treatment 3 (Table A5).\n",
      "\n",
      "The posterior medians of the absolute probabilities of developing diabetes after a period of three years, assuming that the cloglog of the probability of developing diabetes on Placebo has mean -4.2 and precision 1.11, on each of the treatments are between 3 and 4% (Table A5).\n",
      "\n",
      "## EXAMPLE 4. S CHIZOPHRENIA\n",
      "\n",
      "In a network meta-analysis of trials of antipsychotic medication for the prevention of relapse in  people  with  schizophrenia,  17  trials  comparing  9  treatments  including  placebo  were included. 45 The  data  available  from  each  trial  are  the  number  of  patients  in  each  of  three outcome states at the end of follow-up.  The outcome states are: relapse ( j =1), discontinuation of treatment due to intolerable side effects ( j =2), and discontinuation for other reasons ( j =3), which might include inefficacy of treatment that did not fulfil all criteria for relapse, or loss to follow-up.  Patients  not  reaching  any  of  these  end-points  at  the  end  of  follow-up  were considered as censored observations, and still in remission ( j =4) (for more details see Ades et al. 45 ). The data are presented in Table A6 and the network diagram in Figure A4.\n",
      "\n",
      "Table  A6  Schizophrenia  example:  study  names,  follow-up  time  in  weeks,  treatments  compared,  total number of events for each of the four states and total number of patients in each trial arm, where Placebo =  treatment  1,  Olanzapine  =  2,  Amisulpride  =  3,  Zotepine  =  4,  Aripripazole  =  5,  Ziprasidone  =  6, Paliperidone = 7, Haloperidol = 8, Risperidone = 9. 45\n",
      "\n",
      "|       |                    |             |             | number of events   | number of events   | number of events                                | number of events                                | number of events                  | number of events                  | number of events           | number of events           |                      |                      |\n",
      "|-------|--------------------|-------------|-------------|--------------------|--------------------|-------------------------------------------------|-------------------------------------------------|-----------------------------------|-----------------------------------|----------------------------|----------------------------|----------------------|----------------------|\n",
      "|       | follow- up (weeks) | treatment   | treatment   | relapse            | relapse            | discontinuation due to intolerable side effects | discontinuation due to intolerable side effects | discontinuation for other reasons | discontinuation for other reasons | Patient still in remission | Patient still in remission | total no of patients | total no of patients |\n",
      "| Study | f[]                | arm 1 t[,1] | arm 2 t[,2] | arm 1 r[,1,1]      | arm 2 r[,2,1]      | arm 1 r[,1,2]                                   | arm 2 r[,2,2]                                   | arm 1 r[,1,3]                     | arm 2 r[,2,3]                     | arm 1 r[,1,4]              | arm 2 r[,2,4]              | arm 1 n[,1]          | arm 2 n[,2]          |\n",
      "| 1     | 42                 | 1           | 2           | 28                 | 9                  | 12                                              | 2                                               | 15                                | 19                                | 47                         | 194                        | 102                  | 224                  |\n",
      "| 2     | 46                 | 1           | 2           | 7                  | 10                 | 0                                               | 2                                               | 4                                 | 16                                | 2                          | 17                         | 13                   | 45                   |\n",
      "| 3     | 46                 | 1           | 2           | 5                  | 6                  | 2                                               | 10                                              | 5                                 | 15                                | 2                          | 17                         | 14                   | 48                   |\n",
      "| 4     | 26                 | 1           | 3           | 5                  | 4                  | 5                                               | 1                                               | 39                                | 26                                | 23                         | 38                         | 72                   | 69                   |\n",
      "| 5     | 26                 | 1           | 4           | 21                 | 4                  | 4                                               | 16                                              | 24                                | 21                                | 9                          | 20                         | 58                   | 61                   |\n",
      "| 6     | 26                 | 1           | 5           | 85                 | 50                 | 13                                              | 16                                              | 12                                | 18                                | 45                         | 71                         | 155                  | 155                  |\n",
      "| 7     | 52                 | 1           | 6           | 43                 | 71                 | 11                                              | 19                                              | 7                                 | 28                                | 10                         | 88                         | 71                   | 206                  |\n",
      "| 8     | 47                 | 1           | 7           | 52                 | 23                 | 1                                               | 3                                               | 7                                 | 17                                | 41                         | 61                         | 101                  | 104                  |\n",
      "| 9     | 28                 | 2           | 6           | 11                 | 8                  | 6                                               | 5                                               | 44                                | 33                                | 10                         | 9                          | 71                   | 55                   |\n",
      "| 10    | 52                 | 2           | 8           | 87                 | 34                 | 54                                              | 20                                              | 170                               | 50                                | 316                        | 76                         | 627                  | 180                  |\n",
      "| 11    | 52                 | 2           | 8           | 28                 | 29                 | 9                                               | 14                                              | 26                                | 25                                | 78                         | 66                         | 141                  | 134                  |\n",
      "| 12    | 28                 | 2           | 9           | 20                 | 53                 | 17                                              | 17                                              | 36                                | 18                                | 99                         | 79                         | 172                  | 167                  |\n",
      "| 13    | 52                 | 3           | 8           | 5                  | 9                  | 3                                               | 5                                               | 2                                 | 2                                 | 19                         | 15                         | 29                   | 31                   |\n",
      "| 14    | 52                 | 8           | 9           | 65                 | 41                 | 29                                              | 22                                              | 80                                | 60                                | 14                         | 54                         | 188                  | 177                  |\n",
      "| 15    | 104                | 8           | 9           | 8                  | 4                  | 0                                               | 3                                               | 4                                 | 4                                 | 18                         | 22                         | 30                   | 33                   |\n",
      "\n",
      "Figure A4 Schizophrenia network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison and the numbers by the treatment names are the treatment codes used in the modelling.\n",
      "\n",
      "<!-- image -->\n",
      "\n",
      "A random effects model with different between-trial variation for each outcome and a fixed effects model were fitted, as outlined in Section 3.3. The WinBUGS code for the random effects model is given in program 4(a), and the fixed effect code is given in program 4(b).\n",
      "\n",
      "## Program 4(a):  Multinomial likelihood (with competing risks), log link, Random Effects (Schizophrenia example)\n",
      "\n",
      "```\n",
      "# Multinomial likelihood, log link (competing risks) # Random effects model for multi-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns){ #   LOOP THROUGH STUDIES for (m in 1:3) { # LOOP OVER 3 ENDPOINTS w[i,1,m] <- 0 # adjustment for multi-arm trials is zero for control arm delta[i,1,m] <- 0 # treatment effect is zero for control arm mu[i,m] ~ dnorm(0,.0001) # vague priors for all trial baselines } for (k in 1:na[i]) { #  LOOP THROUGH ARMS r[i,k,1:4] ~ dmulti(p[i,k,1:4],n[i,k]) # multinomial likelihood p[i,k,4] <- 1 - sum(p[i,k,1:3]) slam[i,k] <- sum(lamda[i,k,]) # sum of the 3 hazard rates for (m in 1:4) { # LOOP OVER ALL ENDPOINTS rhat[i,k,m] <- p[i,k,m]*n[i,k] # predicted number events dv[i,k,m] <- 2*r[i,k,m]*log(r[i,k,m]/rhat[i,k,m]) #Deviance contribution } dev[i,k] <- sum(dv[i,k,]) # deviance contribution for arm for (m in 1:3) { # LOOP THROUGH 3 ENDPOINTS # cumulative pr(failed) at each end point (per year), data in weeks p[i,k,m] <- lamda[i,k,m] * (1-exp(-slam[i,k]*f[i]/52))/slam[i,k]\n",
      "```\n",
      "\n",
      "```\n",
      "log(lamda[i,k,m]) <- mu[i,m] + delta[i,k,m] # model for linear predictor for each outcome for (k in 2:na[i]) { # LOOP THROUGH ARMS delta[i,k,m] ~ dnorm(md[i,k,m],taud[i,k,m]) md[i,k,m] <- d[t[i,k],m] - d[t[i,1],m] + sw[i,k,m] # mean of LHR distributions (with multi-arm correction) taud[i,k,m] <- tau[m] *2*(k-1)/k # precision of LHR distributions with multi-arm correction w[i,k,m] <- (delta[i,k,m] - d[t[i,k],m] + d[t[i,1],m]) # adjustment for multi-arm RCTs sw[i,k,m] <- sum(w[i,1:k-1,m])/(k-1) # cumulative adjustment for multi-arm trials } } resdev[i] <- sum(dev[i,1:na[i]]) #  summed residual deviance contribution for this trial } totresdev <- sum(resdev[]) #Total Residual Deviance for (m in 1:3) { # LOOP THROUGH 3 END-POINTS d[1,m]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k,m] ~ dnorm(0,.0001) } # vague priors for treatment effects sd[m] ~ dunif(0,5) # vague prior for between-trial SD tau[m] <- pow(sd[m],-2) # between-trial precision = (1/between-trial variance) } } # *** PROGRAM ENDS\n",
      "```\n",
      "\n",
      "Additional code to monitor all treatment contrasts and rank treatments can be added as before. Given values for the mean for each outcome, meanA = c(-0.078,-1.723,-0.7185) , and precision, precA = c(1.6, 1.05, 0.61) , of the hazards for each endpoint on Treatment 1, from external sources, absolute effects, and absolute probabilities of the competing outcomes occurring within a given time period, timeA , say, a 1-month (1/12=0.083 years) interval, could be monitored as follows:\n",
      "\n",
      "```\n",
      "for (k in 1:nt) {pslam(k] <- sum(T[k,]) } #LOOP THROUGH TREATMENTS, summing the 3 rates for (m in 1:3) { # LOOP THROUGH 3 END-POINTS A[m] ~ dnorm(meanA[m],precA[m]) for (k in 1:nt) { # LOOP THROUGH TREATMENTS log(T[k,m]) <- A[m] + d[k,m] cumpr[k,m] <- T[k,m] * (1-exp(-pslam[k]*timeA))/pslam[k] # cumulative pr(failed) at each end point } }\n",
      "```\n",
      "\n",
      "The data structure again consists of a list specifying the number of treatments nt and number of studies ns , with the main body of data in a vector format; f[] represents the follow-up time in that trial. Only two columns are required for each arm variable since there are no multi-arm trials: t[,1] then t[,2] the treatment codes; then r[,k,j] the number of events for the k -th treatment, outcome j ; then n[,1] and n[,2] the total number of individuals in each trial arm; and finally the number  of  arms  in  the  study, na[] , and  the  study  identifiers  commented  out.  Both  data components need to be loaded into WinBUGS for the program to run.\n",
      "\n",
      "```\n",
      "# Data (Schizophrenia example) list(ns=15, nt=9) f[] t[,1] t[,2] r[,1,1] r[,2,1] r[,1,2] r[,2,2] r[,1,3] r[,2,3] r[,1,4] r[,2,4] n[,1] n[,2] na[] #study ID 42 1 2 28 9 12 2 15 19 47 194 102 224 2 #1\n",
      "```\n",
      "\n",
      "|   46 | 1 2   | 2 #2      |   7 |   10 |   0 |   2 |   4 |   16 |   2 |   17 |   13 |   45 |\n",
      "|------|-------|-----------|-----|------|-----|-----|-----|------|-----|------|------|------|\n",
      "|   46 | 1 2   | 2 #3      |   5 |    6 |   2 |  10 |   5 |   15 |   2 |   17 |   14 |   48 |\n",
      "|   26 | 1 2   | 3 #4      |   5 |    4 |   5 |   1 |  39 |   26 |  23 |   38 |   72 |   69 |\n",
      "|   26 | 1 2   | 4 #5      |  21 |    4 |   4 |  16 |  24 |   21 |   9 |   20 |   58 |   61 |\n",
      "|   26 | 1 2   | 5 #6      |  85 |   50 |  13 |  16 |  12 |   18 |  45 |   71 |  155 |  155 |\n",
      "|   52 | 1 2   | 6 #7      |  43 |   71 |  11 |  19 |   7 |   28 |  10 |   88 |   71 |  206 |\n",
      "|   47 | 1 2   | 7 #8      |  52 |   23 |   1 |   3 |   7 |   17 |  41 |   61 |  101 |  104 |\n",
      "|   28 | 2 2   | 6 #9      |  11 |    8 |   6 |   5 |  44 |   33 |  10 |    9 |   71 |   55 |\n",
      "|   52 | 2 2   | 8 #10     |  87 |   34 |  54 |  20 | 170 |   50 | 316 |   76 |  627 |  180 |\n",
      "|   52 | 2 2   | 8 #11     |  28 |   29 |   9 |  14 |  26 |   25 |  78 |   66 |  141 |  134 |\n",
      "|   28 | 2 2   | 9 #12     |  20 |   53 |  17 |  17 |  36 |   18 |  99 |   79 |  172 |  167 |\n",
      "|   52 | 3 2   | 8         |   5 |    9 |   3 |   5 |   2 |    2 |  19 |   15 |   29 |   31 |\n",
      "|   52 | 8 2   | #13 9 #14 |  65 |   41 |  29 |  22 |  80 |   60 |  14 |   54 |  188 |  177 |\n",
      "|  104 | 8 2   | 9 #15     |   8 |    4 |   0 |   3 |   4 |    4 |  18 |   22 |   30 |   33 |\n",
      "\n",
      "## # Initial Values\n",
      "\n",
      "# In this case it is advisable to initialise delta to avoid numerical errors\n",
      "\n",
      "## #chain 1\n",
      "\n",
      "list(d= structure(.Data= c(NA, NA, NA,   0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0), .Dim=c(9, 3)), sd=c(1, 1, 1), mu= structure(.Data= c(0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,   0,0,0,  0,0,0,  0,0,0,  0,0,0, 0,0,0), .Dim=c(15, 3)),\n",
      "\n",
      "delta= structure(.Data= c(NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,\n",
      "\n",
      "NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,\n",
      "\n",
      "NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0),  .Dim=c(15, 2, 3))   )\n",
      "\n",
      "## #chain 2\n",
      "\n",
      "list(d= structure(.Data= c(NA, NA, NA,   1,0,1,  0,0,1,  0,0,0,  0,0,1,  0,0,0,  0,0,0,  0,1,0,  0,0,1), .Dim=c(9, 3)), sd=c(1, 2, 1.5), mu= structure(.Data= c(0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,   0,0,0,  0,0,0,  0,0,0,  0,0,0, 0,0,0), .Dim=c(15, 3)),\n",
      "\n",
      "delta= structure(.Data= c(NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,\n",
      "\n",
      "NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,\n",
      "\n",
      "NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0),  .Dim=c(15, 2, 3))   )\n",
      "\n",
      "## #chain 3\n",
      "\n",
      "list(d= structure(.Data= c(NA, NA, NA,   -1,0,-1,  0,0,-1,  0,0,0,  0,0,-1,  0,0,0,  0,0,0,  0,-1,0,  0,0,-1), .Dim=c(9, 3)), sd=c(1, 2, 1.5), mu= structure(.Data= c(0,1,0,  0,1,0,  0,0,0,  0,0,1,  0,0,0,  0,0,1,  0,0,0,  0,0,1,  0,0,0,  0,1,0,   0,1,0,  0,0,0,  0,0,0,  1,0,1, 0,0,0), .Dim=c(15, 3)),\n",
      "\n",
      "delta= structure(.Data= c(NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,\n",
      "\n",
      "NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,\n",
      "\n",
      "NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0,  NA,NA,NA,  0,0,0),  .Dim=c(15, 2, 3))  )\n",
      "\n",
      "Readers experimenting with this example need to be aware of difficulties with starting values. We  have  found  one  set  of  starting  values  which  converges,  but  to  a  different  posterior.\n",
      "\n",
      "Examples like this remind us of the importance of careful attention to the technical aspects of fitting models by Bayesian MCMC, and the need to look at the results obtained with different starting  values.    This  is  also  an  example  where  inverse  gamma  priors  on  the  between  trial variance leads to faster convergence, and avoids spikes in the posterior distributions. 45\n",
      "\n",
      "## Program 4(b):  Multinomial likelihood (with competing risks), log link, Fixed Effects (Schizophrenia example)\n",
      "\n",
      "```\n",
      "# Multinomial likelihood, log link (competing risks) # Fixed effects model for multi-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns){ #   LOOP THROUGH STUDIES for (m in 1:3) { # LOOP OVER 3 ENDPOINTS w[i,1,m] <- 0 # adjustment for multi-arm trials is zero for control arm delta[i,1,m] <- 0 # treatment effect is zero for control arm mu[i,m] ~ dnorm(0,.0001) # vague priors for all trial baselines } for (k in 1:na[i]) { #  LOOP THROUGH ARMS r[i,k,1:4] ~ dmulti(p[i,k,1:4],n[i,k]) # multinomial likelihood p[i,k,4] <- 1 - sum(p[i,k,1:3]) slam[i,k] <- sum(lamda[i,k,]) # sum of the 3 hazard rates for (m in 1:4) { # LOOP OVER ALL ENDPOINTS rhat[i,k,m] <- p[i,k,m]*n[i,k] # predicted number events (adjusting zero fitted values) dv[i,k,m] <- 2*r[i,k,m]*log(r[i,k,m]/rhat[i,k,m]) #Deviance contribution } dev[i,k] <- sum(dev[i,k,]) # deviance contribution for arms for (m in 1:3) { # LOOP THORUGH ENDPOINTS p[i,k,m] <- lamda[i,k,m] * (1-exp(-slam[i,k]*f[i]/52))/slam[i,k]   # cumulative pr(failed) at each end point log(lamda[i,k,m]) <- mu[i,m] +  d[t[i,k],m] - d[t[i,1],m]    # model for linear predictor } } resdev[i] <- sum(dev[i,1:na[i]]) #  summed residual deviance contribution for this trial } totresdev <- sum(resdev[]) #Total Residual Deviance for (m in 1:3) { # LOOP THORUGH ENDPOINTS d[1,m]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k,m] ~ dnorm(0,.0001) } # vague priors for treatment effects } } # *** PROGRAM ENDS # Initial Values #chain 1 list(d= structure(.Data= c(NA, NA, NA,   0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0), .Dim=c(9, 3)), mu= structure(.Data= c(0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,   0,0,0,  0,0,0,  0,0,0,  0,0,0, 0,0,0), .Dim=c(15, 3))   ) #chain 2 list(d= structure(.Data= c(NA, NA, NA,   1,0,1,  0,0,1,  0,0,0,  0,0,1,  0,0,0,  0,0,0,  0,1,0,  0,0,1), .Dim=c(9, 3)), mu= structure(.Data= c(0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,  0,0,0,   0,0,0,  0,0,0,  0,0,0,  0,0,0, 0,0,0), .Dim=c(15, 3))   ) #chain 3 list(d= structure(.Data= c(NA, NA, NA,   -1,0,-1,  0,0,-1,  0,0,0,  0,0,-1,  0,0,0,  0,0,0,  0,-1,0,  0,0,-1), .Dim=c(9, 3)), mu= structure(.Data= c(0,5,0,  0,5,0,  0,0,0,  0,0,5,  0,0,0,  0,0,5,  0,0,0,  0,0,5,  0,0,0,  0,5,0,   0,5,0,  0,0,0,  0,0,0,  3,0,3, 0,0,0), .Dim=c(15, 3)))\n",
      "```\n",
      "\n",
      "## R ESULTS\n",
      "\n",
      "Results (based on 3 chains: 100,000 iterations after a burn-in of 50,000 for the FE model and 100,000 iterations after a burn-in of 10,000 for the RE model) are presented in Table A7. Note that the follow-up time data are entered in weeks, while the analysis delivers annual rates.  The model fit statistics suggest that the random effects model is a better fit to the data and the DIC shows that this model should be preferred. The log-hazard rates for each of the competing events and the absolute probabilities of the competing outcomes occurring within 1 month (assuming a baseline log-hazard as detailed above) are given in Table A7.  For a graphical representation  of  which  treatment  is  best  for  each  of  the  competing  outcomes  and  further comments see Ades et al. 45\n",
      "\n",
      "Table  A7  Schizophrenia  example:  posterior  mean,  standard  deviation  (sd),  median  and  95%  Credible interval (CrI) for both the fixed and random effects models for the treatment effects of Olanzapine ( d 12 ), Amisulpride ( d 13 ), Zotepine ( d 14 ), Aripripazole ( d 15 ), Ziprasidone ( d 16 ), Paliperidone ( d 17 ), Haloperidol ( d 18 ) and  Risperidone  ( d 19 )  relative  to  Placebo,  absolute  probabilities  of  reaching  each  of  the  outcomes  for Placebo ( Pr 1 ),  Olanzapine  ( Pr 2 ),  Amisulpride  ( Pr 3 ),  Zotepine  ( Pr 4 ),  Aripripazole  ( Pr 5 ),  Ziprasidone  ( Pr 6 ), Paliperidone ( Pr 7 ), Haloperidol ( Pr 8 ) and Risperidone ( Pr 9 ); heterogeneity parameter τ for each of the three outcomes, and model fit statistics for the fixed and random effects models.\n",
      "\n",
      "|         | FE model   | FE model   | FE model   | FE model      | RE      | RE      | RE           | RE            |\n",
      "|---------|------------|------------|------------|---------------|---------|---------|--------------|---------------|\n",
      "|         | mean       | sd         | median     | CrI           | mean    | sd      | model median | CrI           |\n",
      "| Relapse | Relapse    | Relapse    | Relapse    | Relapse       | Relapse | Relapse | Relapse      | Relapse       |\n",
      "| d 12    | -1.57      | 0.23       | -1.57      | (-2.01,-1.13) | -1.46   | 0.48    | -1.47        | (-2.39,-0.50) |\n",
      "| d 13    | -1.15      | 0.48       | -1.14      | (-2.10,-0.22) | -0.97   | 0.80    | -0.97        | (-2.53,0.63)  |\n",
      "| d 14    | -2.10      | 0.23       | -0.52      | (-0.96,-0.06) | -2.10   | 0.99    | -2.08        | (-4.11,-0.19) |\n",
      "| d 15    | -0.73      | 0.19       | -0.72      | (-1.10,-0.36) | -0.73   | 0.82    | -0.73        | (-2.37,0.92)  |\n",
      "| d 16    | -1.12      | 0.20       | -1.12      | (-1.50,-0.73) | -1.23   | 0.65    | -1.23        | (-2.56,0.05)  |\n",
      "| d 17    | -1.02      | 0.26       | -1.01      | (-1.53,-0.53) | -1.02   | 0.84    | -1.02        | (-2.70,0.66)  |\n",
      "| d 18    | -0.90      | 0.26       | -0.90      | (-1.41,-0.38) | -0.69   | 0.64    | -0.71        | (-1.93,0.63)  |\n",
      "| d 19    | -1.27      | 0.28       | -1.27      | (-1.82,-0.71) | -1.12   | 0.74    | -1.13        | (-2.59,0.37)  |\n",
      "| Pr 1    | 0.09       | 0.07       | 0.07       | (0.02,0.29)   | 0.09    | 0.07    | 0.07         | (0.02,0.29)   |\n",
      "| Pr 2    | 0.02       | 0.02       | 0.02       | (0.00,0.08)   | 0.03    | 0.03    | 0.02         | (0.00,0.10)   |\n",
      "| Pr 3    | 0.03       | 0.04       | 0.02       | (0.00,0.14)   | 0.05    | 0.07    | 0.03         | (0.00,0.23)   |\n",
      "| Pr 4    | 0.01       | 0.02       | 0.01       | (0.00,0.06)   | 0.02    | 0.04    | 0.01         | (0.00,0.10)   |\n",
      "| Pr 5    | 0.05       | 0.04       | 0.03       | (0.01,0.16)   | 0.06    | 0.08    | 0.03         | (0.00,0.27)   |\n",
      "| Pr 6    | 0.03       | 0.03       | 0.02       | (0.00,0.11)   | 0.03    | 0.05    | 0.02         | (0.00,0.15)   |\n",
      "| Pr 7    | 0.03       | 0.03       | 0.02       | (0.00,0.12)   | 0.04    | 0.06    | 0.02         | (0.00,0.20)   |\n",
      "| Pr 8    | 0.04       | 0.04       | 0.03       | (0.01,0.14)   | 0.06    | 0.07    | 0.04         | (0.00,0.24)   |\n",
      "| Pr 9    | 0.03       | 0.03       | 0.02       | (0.00,0.10)   | 0.04    | 0.06    | 0.02         | (0.00,0.19)   |\n",
      "| τ       |            |            |            |               | 0.73    | 0.32    | 0.66         | (0.30,1.53)   |\n",
      "\n",
      "| Discontinuation due to side effects                               | Discontinuation due to side effects                               | Discontinuation due to side effects                               | Discontinuation due to side effects                               | Discontinuation due to side effects                               | Discontinuation due to side effects                               | Discontinuation due to side effects                               | Discontinuation due to side effects                               | Discontinuation due to side effects                               |\n",
      "|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|\n",
      "| d 12                                                              | -1.33                                                             | 0.34                                                              | -1.33                                                             | (-2.01,-0.67)                                                     | -1.07                                                             | 0.89                                                              | -1.14                                                             | (-2.67,0.97)                                                      |\n",
      "| d 13                                                              | -1.67                                                             | 0.68                                                              | -1.64                                                             | (-3.09,-0.41)                                                     | -1.75                                                             | 1.39                                                              | -1.72                                                             | (-4.63,0.99)                                                      |\n",
      "| d 14                                                              | 1.15                                                              | 0.59                                                              | 1.12                                                              | (0.06,2.41)                                                       | 1.14                                                              | 1.56                                                              | 1.12                                                              | (-2.05,4.34)                                                      |\n",
      "| d 15                                                              | 0.02                                                              | 0.38                                                              | 0.02                                                              | (-0.72,0.78)                                                      | 0.02                                                              | 1.49                                                              | 0.02                                                              | (-3.10,3.12)                                                      |\n",
      "| d 16                                                              | -1.05                                                             | 0.34                                                              | -1.06                                                             | (-1.71,-0.35)                                                     | -0.98                                                             | 1.16                                                              | -1.02                                                             | (-3.28,1.52)                                                      |\n",
      "| d 17                                                              | 1.31                                                              | 1.43                                                              | 1.16                                                              | (-1.10,4.58)                                                      | 1.35                                                              | 2.05                                                              | 1.24                                                              | (-2.48,5.76)                                                      |\n",
      "| d 18                                                              | -0.90                                                             | 0.39                                                              | -0.90                                                             | (-1.67,-0.15)                                                     | -0.84                                                             | 1.14                                                              | -0.86                                                             | (-3.16,1.56)                                                      |\n",
      "| d 19                                                              | -1.34                                                             | 0.42                                                              | -1.33                                                             | (-2.17,-0.52)                                                     | -0.71                                                             | 1.40                                                              | -0.89                                                             | (-3.08,2.63)                                                      |\n",
      "| Pr 1                                                              | 0.02                                                              | 0.02                                                              | 0.01                                                              | (0.00,0.09)                                                       | 0.02                                                              | 0.03                                                              | 0.01                                                              | (0.00,0.09)                                                       |\n",
      "| Pr 2                                                              | 0.01                                                              | 0.01                                                              | 0.00                                                              | (0.00,0.03)                                                       | 0.01                                                              | 0.04                                                              | 0.00                                                              | (0.00,0.07)                                                       |\n",
      "| Pr 3                                                              | 0.01                                                              | 0.01                                                              | 0.00                                                              | (0.00,0.03)                                                       | 0.01                                                              | 0.05                                                              | 0.00                                                              | (0.00,0.06)                                                       |\n",
      "| Pr 4                                                              | 0.08                                                              | 0.10                                                              | 0.04                                                              | (0.00,0.35)                                                       | 0.12                                                              | 0.19                                                              | 0.04                                                              | (0.00,0.82)                                                       |\n",
      "| Pr 5                                                              | 0.02                                                              | 0.03                                                              | 0.01                                                              | (0.00,0.10)                                                       | 0.05                                                              | 0.12                                                              | 0.01                                                              | (0.00,0.38)                                                       |\n",
      "| Pr 6                                                              | 0.01                                                              | 0.01                                                              | 0.00                                                              | (0.00,0.04)                                                       | 0.02                                                              | 0.06                                                              | 0.01                                                              | (0.00,0.11)                                                       |\n",
      "| Pr 7                                                              | 0.13                                                              | 0.20                                                              | 0.04                                                              | (0.00,0.84)                                                       | 0.16                                                              | 0.26                                                              | 0.05                                                              | (0.00,0.97)                                                       |\n",
      "| Pr 8                                                              | 0.01                                                              | 0.01                                                              | 0.01                                                              | (0.00,0.04)                                                       | 0.02                                                              | 0.06                                                              | 0.01                                                              | (0.00,0.11)                                                       |\n",
      "| Pr 9                                                              | 0.01                                                              | 0.01                                                              | 0.00                                                              | (0.00,0.03)                                                       | 0.03                                                              | 0.10                                                              | 0.01                                                              | (0.00,0.26)                                                       |\n",
      "| τ 1.20 0.80 1.03 (0.14,3.31) Discontinuation due to other reasons | τ 1.20 0.80 1.03 (0.14,3.31) Discontinuation due to other reasons | τ 1.20 0.80 1.03 (0.14,3.31) Discontinuation due to other reasons | τ 1.20 0.80 1.03 (0.14,3.31) Discontinuation due to other reasons | τ 1.20 0.80 1.03 (0.14,3.31) Discontinuation due to other reasons | τ 1.20 0.80 1.03 (0.14,3.31) Discontinuation due to other reasons | τ 1.20 0.80 1.03 (0.14,3.31) Discontinuation due to other reasons | τ 1.20 0.80 1.03 (0.14,3.31) Discontinuation due to other reasons | τ 1.20 0.80 1.03 (0.14,3.31) Discontinuation due to other reasons |\n",
      "| d 12                                                              | -0.52                                                             | 0.23                                                              | -0.52                                                             | (-0.96,-0.06)                                                     | -0.51                                                             | 0.26                                                              | -0.52                                                             | (-0.99,0.03)                                                      |\n",
      "| d 13                                                              | -0.60                                                             | 0.25                                                              | -0.60                                                             | (-1.11,-0.11)                                                     | -0.59                                                             | 0.33                                                              | -0.60                                                             | (-1.23,0.07)                                                      |\n",
      "| d 14                                                              | -0.48                                                             | 0.32                                                              | -0.48                                                             | (-1.10,0.15)                                                      | -0.48                                                             | 0.40                                                              | -0.49                                                             | (-1.25,0.30)                                                      |\n",
      "| d 15                                                              | 0.24                                                              | 0.38                                                              | 0.23                                                              | (-0.50,1.00)                                                      | 0.23                                                              | 0.46                                                              | 0.24                                                              | (-0.64,1.11)                                                      |\n",
      "| d 16                                                              | -0.44                                                             | 0.27                                                              | -0.44                                                             | (-0.96,0.10)                                                      | -0.44                                                             | 0.33                                                              | -0.45                                                             | (-1.06,0.24)                                                      |\n",
      "| d 17                                                              | 0.74                                                              | 0.47                                                              | 0.73                                                              | (-0.13,1.70)                                                      | 0.75                                                              | 0.52                                                              | 0.76                                                              | (-0.26,1.79)                                                      |\n",
      "| d 18                                                              | -0.43                                                             | 0.26                                                              | -0.44                                                             | (-0.94,0.08)                                                      | -0.43                                                             | 0.32                                                              | -0.43                                                             | (-1.04,0.22)                                                      |\n",
      "| d 19                                                              | -1.07                                                             | 0.29                                                              | -1.07                                                             | (-1.64,-0.51)                                                     | -1.08                                                             | 0.36                                                              | -1.10                                                             | (-1.76,-0.33)                                                     |\n",
      "| Pr 1                                                              | 0.07                                                              | 0.10                                                              | 0.04                                                              | (0.00,0.37)                                                       | 0.07                                                              | 0.10                                                              | 0.04                                                              | (0.00,0.37)                                                       |\n",
      "| Pr 2                                                              | 0.05                                                              | 0.08                                                              | 0.02                                                              | (0.00,0.26)                                                       | 0.05                                                              | 0.08                                                              | 0.02                                                              | (0.00,0.27)                                                       |\n",
      "| Pr 3                                                              | 0.05                                                              | 0.07                                                              | 0.02                                                              | (0.00,0.24)                                                       | 0.05                                                              | 0.07                                                              | 0.02                                                              | (0.00,0.25)                                                       |\n",
      "| Pr 4                                                              | 0.05                                                              | 0.08                                                              | 0.02                                                              | (0.00,0.27)                                                       | 0.05                                                              | 0.08                                                              | 0.02                                                              | (0.00,0.27)                                                       |\n",
      "| Pr 5                                                              | 0.10                                                              | 0.13                                                              | 0.05                                                              | (0.00,0.49)                                                       | 0.09                                                              | 0.13                                                              | 0.05                                                              | (0.00,0.49)                                                       |\n",
      "| Pr 6                                                              | 0.05                                                              | 0.08                                                              | 0.03                                                              | (0.00,0.28)                                                       | 0.05                                                              | 0.08                                                              | 0.02                                                              | (0.00,0.29)                                                       |\n",
      "|                                                                   | 0.14                                                              | 0.17                                                              | 0.07                                                              |                                                                   | 0.13                                                              |                                                                   |                                                                   | (0.00,0.66)                                                       |\n",
      "| Pr 7                                                              |                                                                   | 0.08                                                              | 0.03                                                              | (0.00,0.66)                                                       |                                                                   | 0.17                                                              | 0.07                                                              |                                                                   |\n",
      "| Pr 8 Pr 9                                                         | 0.05                                                              | 0.05                                                              | 0.01                                                              | (0.00,0.28) (0.00,0.16)                                           | 0.05 0.03                                                         | 0.08 0.05                                                         | 0.02 0.01                                                         | (0.00,0.29) (0.00,0.16)                                           |\n",
      "| τ                                                                 | 0.03                                                              |                                                                   |                                                                   |                                                                   | 0.17                                                              | 0.16                                                              | 0.13                                                              | (0.00,0.59)                                                       |\n",
      "| res D * pD                                                        | 120.0 68.5                                                        |                                                                   |                                                                   |                                                                   | 89.1 80.2                                                         |                                                                   |                                                                   |                                                                   |\n",
      "| DIC                                                               | 188.5                                                             |                                                                   |                                                                   |                                                                   | 169.3                                                             |                                                                   |                                                                   |                                                                   |\n",
      "\n",
      "## EXAMPLE 5. P ARKINSON ' S\n",
      "\n",
      "The data presented in Table A8 are the mean off-time reduction in patients given dopamine Agonists as adjunct therapy in Parkinson's disease.  The data available are the mean, standard\n",
      "\n",
      "deviation and number of patients in each trial arm, for 7 studies of five different drugs: placebo, coded 1, and five active drugs coded 2 to 5.  The network diagram is presented in Figure A5. The authors are grateful to Jeroen Jansen of Mapi Values for giving us access to this data.\n",
      "\n",
      "Table  A8    Parkinson's  example:  study  names,  treatments  compared,  mean  off-time  reduction  with  its standard deviation, total number of patients in each trial arm; treatment differences and standard error of the differences; where treatment 1 is a placebo and treatments 2-5 are active drugs.\n",
      "\n",
      "| Study   |   Treatment |     y |   sd |   n | diff   | se(diff)   |\n",
      "|---------|-------------|-------|------|-----|--------|------------|\n",
      "| 1       |           1 | -1.22 | 3.7  |  54 |        |            |\n",
      "|         |           3 | -1.53 | 4.28 |  95 | -0.31  | 0.668      |\n",
      "| 2       |           1 | -0.7  | 3.7  | 172 |        |            |\n",
      "|         |           2 | -2.4  | 3.4  | 173 | -1.7   | 0.383      |\n",
      "| 3       |           1 | -0.3  | 4.4  |  76 |        |            |\n",
      "|         |           2 | -2.6  | 4.3  |  71 | -2.3   | 0.718      |\n",
      "|         |           4 | -1.2  | 4.3  |  81 | -0.9   | 0.695      |\n",
      "| 4       |           3 | -0.24 | 3    | 128 |        |            |\n",
      "|         |           4 | -0.59 | 3    |  72 | -0.35  | 0.442      |\n",
      "| 5       |           3 | -0.73 | 3    |  80 |        |            |\n",
      "|         |           4 | -0.18 | 3    |  46 | 0.55   | 0.555      |\n",
      "| 6       |           4 | -2.2  | 2.31 | 137 |        |            |\n",
      "|         |           5 | -2.5  | 2.18 | 131 | -0.3   | 0.274      |\n",
      "| 7       |           4 | -1.8  | 2.48 | 154 |        |            |\n",
      "|         |           5 | -2.1  | 2.99 | 143 | -0.3   | 0.320      |\n",
      "\n",
      "Figure  A5  Parkinson  network:  each  edge  represents  a  treatment,  connecting  lines  indicate  pairs  of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison and the numbers by the treatment names are the treatment codes used in the modelling.\n",
      "\n",
      "<!-- image -->\n",
      "\n",
      "The model for this type of data is outlined in Section 3.4. The WinBUGS code for random effects is given in program 5(a) and the fixed effects code is given in program 5(b).\n",
      "\n",
      "## Program 5(a):  Normal likelihood, identity link, Random Effects (Parkinson's example)\n",
      "\n",
      "```\n",
      "# Normal likelihood, identity link # Random effects model for multi-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns){ #   LOOP THROUGH STUDIES w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm delta[i,1] <- 0 # treatment effect is zero for control arm mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:na[i]) { #  LOOP THROUGH ARMS var[i,k] <- pow(se[i,k],2) # calculate variances prec[i,k] <- 1/var[i,k] # set precisions y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # normal likelihood theta[i,k] <- mu[i] + delta[i,k] # model for linear predictor dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k]    #Deviance contribution } resdev[i] <- sum(dev[i,1:na[i]]) #  summed residual deviance contribution for this trial for (k in 2:na[i]) { # LOOP THROUGH ARMS delta[i,k] ~ dnorm(md[i,k],taud[i,k]) # trial-specific LOR distributions md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] # mean of treat effects distributions (with multi-arm trial correction) taud[i,k] <- tau *2*(k-1)/k # precision of treat effects distributions (with multi-arm trial correction) w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) # adjustment for multi-arm RCTs sw[i,k] <- sum(w[i,1:k-1])/(k-1) # cumulative adjustment for multi-arm trials } } totresdev <- sum(resdev[]) #Total Residual Deviance d[1]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects sd ~ dunif(0,5) # vague prior for between-trial SD. tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance) } # *** PROGRAM ENDS\n",
      "```\n",
      "\n",
      "Additional code to monitor all treatment contrasts and rank treatments can be added as before. Given values for the mean, -0.73, and precision, 21, of the outcome on Treatment 1, from external sources, absolute effects, and the absolute treatment effect, could be monitored by adding the following code:\n",
      "\n",
      "```\n",
      "A ~ dnorm(-.73,21) for (k in 1:nt) { T[k] <- A + d[k]  }\n",
      "```\n",
      "\n",
      "The maximum number of arms is 3, so 3 vectors are needed for the treatment indicators, t[,1] t[,2] , t[,3] ; the continuous outcomes y[,] ; and their standard errors se[,] ; and finally the number of arms, na[] .\n",
      "\n",
      "```\n",
      "# Data (Parkinson's example) list(ns=7, nt=5) t[,1] t[,2] t[,3] y[,1] y[,2] y[,3] se[,1] se[,2] se[,3] na[] 1 3 NA -1.22 -1.53 NA 0.504 0.439 NA 2 1 2 NA -0.7 -2.4 NA 0.282 0.258 NA 2 1 2 4 -0.3 -2.6 -1.2 0.505 0.510 0.478 3 3 4 NA -0.24 -0.59 NA 0.265 0.354 NA 2 3 4 NA -0.73 -0.18 NA 0.335 0.442 NA 2 4 5 NA -2.2 -2.5 NA 0.197 0.190 NA 2 4 5 NA -1.8 -2.1 NA 0.200 0.250 NA 2 END\n",
      "```\n",
      "\n",
      "```\n",
      "# Initial Values # Initial values for delta can be generated by WinBUGS. #chain 1 list(d=c( NA, 0,0,0,0), sd=1, mu=c(0, 0, 0, 0, 0,    0, 0)) #chain 2 #chain 3 list(d=c( NA, 2,2,2,2), sd=2, mu=c(-3, 5, -1, -3, 7,    -3, -4))\n",
      "```\n",
      "\n",
      "```\n",
      "list(d=c( NA, -1,-3,-1,1), sd=4, mu=c(-3, -3, -3, -3, -3,    -3, -3)) Program 5(b):  Normal likelihood, identity link, Fixed Effects (Parkinson's example)\n",
      "```\n",
      "\n",
      "```\n",
      "# Normal likelihood, identity link # Fixed effects model for multi-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns){ #   LOOP THROUGH STUDIES mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:na[i]) { #  LOOP THROUGH ARMS var[i,k] <- pow(se[i,k],2) # calculate variances prec[i,k] <- 1/var[i,k] # set precisions y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # normal likelihood theta[i,k] <- mu[i] + d[t[i,k]] - d[t[i,1]] # model for linear predictor dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k] #Deviance contribution } resdev[i] <- sum(dev[i,1:na[i]]) #  summed residual deviance contribution for this trial } totresdev <- sum(resdev[]) #Total Residual Deviance d[1]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects } # *** PROGRAM ENDS # Initial Values #chain 1 list(d=c( NA, 0,0,0,0), mu=c(0, 0, 0, 0, 0,    0, 0)) #chain 2 list(d=c( NA, -1,-3,-1,1), mu=c(-3, -3, -3, -3, -3,    -3, -3)) #chain 3 list(d=c( NA, 2,2,2,2), mu=c(-3, 5, -1, -3, 7,    -3, -4))\n",
      "```\n",
      "\n",
      "## R ESULTS\n",
      "\n",
      "Results (based on 3 chains: 100,000 iterations after a burn-in of 50,000) are presented in Table A9. The random and fixed effects model both fit the data well, and since the random effects model has a higher DIC (due to having a higher effective number of parameters) the FE model should be preferred. The difference in mean of symptoms for each of the treatments compared to placebo and the absolute mean reduction in symptoms (assuming a baseline treatment effect as detailed above) are given in Table A9.\n",
      "\n",
      "Table A9 Parkinson example: posterior mean, standard deviation (sd), median and 95% Credible interval (CrI) for both the fixed and random effects models for the treatment effects of Treatments 2 to 5 ( d 12 to d 15 ) relative to Placebo, absolute effects of Placebo ( T 1 ) and treatments 2 to 5 ( T 2 to T 5 ), heterogeneity parameter τ and model fit statistics for different data types.\n",
      "\n",
      "|                                 | mean                                                         | sd                                                           | FE model median                                              | CrI                                                          | mean                                                         | sd                                                           | RE model median                                              | CrI                                                          |\n",
      "|---------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|\n",
      "|                                 | Arm-level data: Example 5                                    | Arm-level data: Example 5                                    | Arm-level data: Example 5                                    | Arm-level data: Example 5                                    | Arm-level data: Example 5                                    | Arm-level data: Example 5                                    | Arm-level data: Example 5                                    | Arm-level data: Example 5                                    |\n",
      "| d 12                            | -1.81                                                        | 0.33                                                         | -1.81                                                        | (-2.46,-1.16)                                                | -1.85                                                        | 0.54                                                         | -1.84                                                        | (-2.91,-0.85)                                                |\n",
      "| d 13                            | -0.47                                                        | 0.49                                                         | -0.47                                                        | (-1.43,0.49)                                                 | -0.50                                                        | 0.66                                                         | -0.50                                                        | (-1.78,0.75)                                                 |\n",
      "| d 14                            | -0.52                                                        | 0.48                                                         | -0.52                                                        | (-1.46,0.43)                                                 | -0.53                                                        | 0.65                                                         | -0.53                                                        | (-1.77,0.71)                                                 |\n",
      "| d 15                            | -0.82                                                        | 0.52                                                         | -0.82                                                        | (-1.84,0.22)                                                 | -0.83                                                        | 0.80                                                         | -0.83                                                        | (-2.35,0.69)                                                 |\n",
      "| T 1                             | -0.73                                                        | 0.22                                                         | -0.73                                                        | (-1.16,-0.30)                                                | -0.73                                                        | 0.22                                                         | -0.73                                                        | (-1.16,-0.30)                                                |\n",
      "| T 2                             | -2.54                                                        | 0.40                                                         | -2.54                                                        | (-3.32,-1.76)                                                | -2.58                                                        | 0.58                                                         | -2.57                                                        | (-3.72,-1.50)                                                |\n",
      "| T 3                             | -1.21                                                        | 0.53                                                         | -1.20                                                        | (-2.25,-0.15)                                                | -1.23                                                        | 0.70                                                         | -1.23                                                        | (-2.57,0.10)                                                 |\n",
      "| T 4                             | -1.25                                                        | 0.53                                                         | -1.25                                                        | (-2.28,-0.21)                                                | -1.26                                                        | 0.69                                                         | -1.26                                                        | (-2.57,0.05)                                                 |\n",
      "| T 5                             | -1.55                                                        | 0.57                                                         | -1.55                                                        | (-2.66,-0.43)                                                | -1.57                                                        | 0.83                                                         | -1.56                                                        | (-3.14,0.02)                                                 |\n",
      "| τ                               | -                                                            | -                                                            | -                                                            | -                                                            | 0.40                                                         | 0.43                                                         | 0.28                                                         | (0.01,1.55)                                                  |\n",
      "| res D *                         | 13.3                                                         |                                                              |                                                              |                                                              | 13.6                                                         |                                                              |                                                              |                                                              |\n",
      "| pD                              | 11.0                                                         |                                                              |                                                              |                                                              | 12.4                                                         |                                                              |                                                              |                                                              |\n",
      "| DIC                             | 24.3                                                         |                                                              |                                                              |                                                              | 26.0                                                         |                                                              |                                                              |                                                              |\n",
      "| Trial-level data (differences): | Example 7                                                    | Example 7                                                    | Example 7                                                    | Example 7                                                    | Example 7                                                    | Example 7                                                    | Example 7                                                    | Example 7                                                    |\n",
      "| d 12                            | -1.81                                                        | 0.33                                                         | -1.81                                                        | (-2.47,-1.16)                                                | -1.85                                                        | 0.54                                                         | -1.84                                                        | (-2.92,-0.84)                                                |\n",
      "| d 13                            | -0.48                                                        | 0.49                                                         | -0.48                                                        | (-1.43,0.47)                                                 | -0.50                                                        | 0.66                                                         | -0.49                                                        | (-1.79,0.75)                                                 |\n",
      "| d 14                            | -0.52                                                        | 0.48                                                         | -0.52                                                        | (-1.46,0.42)                                                 | -0.53                                                        | 0.65                                                         | -0.53                                                        | (-1.79,0.72)                                                 |\n",
      "| d 15                            | -0.82                                                        | 0.52                                                         | -0.82                                                        | (-1.84,0.20)                                                 | -0.83                                                        | 0.81                                                         | -0.83                                                        | (-2.38,0.69)                                                 |\n",
      "| T 1                             | -0.73                                                        | 0.22                                                         | -0.73                                                        | (-1.16,-0.30)                                                | -0.73                                                        | 0.22                                                         | -0.73                                                        | (-1.16,-0.30)                                                |\n",
      "| T 2                             | -2.54                                                        | 0.40                                                         | -2.54                                                        | (-3.33,-1.76)                                                | -2.58                                                        | 0.58                                                         | -2.57                                                        | (-3.72,-1.49)                                                |\n",
      "| T 3                             | -1.21                                                        | 0.53                                                         | -1.21                                                        | (-2.25,-0.17)                                                | -1.23                                                        | 0.70                                                         | -1.22                                                        | (-2.59,0.10)                                                 |\n",
      "| T 4                             | -1.25                                                        | 0.53                                                         | -1.25                                                        | (-2.28,-0.22)                                                | -1.26                                                        | 0.69                                                         | -1.26                                                        | (-2.59,0.06)                                                 |\n",
      "| T 5                             | -1.55                                                        | 0.56                                                         | -1.55                                                        | (-2.66,-0.44)                                                | -1.56                                                        | 0.83                                                         | -1.56                                                        | (-3.17,0.01)                                                 |\n",
      "| τ                               |                                                              |                                                              |                                                              |                                                              | 0.41                                                         | 0.44                                                         | 0.28                                                         | (0.01,1.56)                                                  |\n",
      "| res D †                         | 6.3                                                          |                                                              |                                                              |                                                              | 6.6                                                          |                                                              |                                                              |                                                              |\n",
      "| pD                              | 4.0                                                          |                                                              |                                                              |                                                              | 5.5                                                          |                                                              |                                                              |                                                              |\n",
      "| DIC                             | 10.3                                                         |                                                              |                                                              |                                                              | 12.1                                                         |                                                              |                                                              |                                                              |\n",
      "|                                 | Arm and Trial-level data (shared parameter model): Example 8 | Arm and Trial-level data (shared parameter model): Example 8 | Arm and Trial-level data (shared parameter model): Example 8 | Arm and Trial-level data (shared parameter model): Example 8 | Arm and Trial-level data (shared parameter model): Example 8 | Arm and Trial-level data (shared parameter model): Example 8 | Arm and Trial-level data (shared parameter model): Example 8 | Arm and Trial-level data (shared parameter model): Example 8 |\n",
      "| d 12                            | -1.81                                                        | 0.33                                                         | -1.81                                                        | (-2.46,-1.16)                                                | -1.85                                                        | 0.54                                                         | -1.83                                                        | (-2.91,-0.86)                                                |\n",
      "| d 13                            | -0.48                                                        | 0.49                                                         | -0.48                                                        | (-1.43,0.48)                                                 | -0.51                                                        | 0.66                                                         | -0.50                                                        | (-1.79,0.75)                                                 |\n",
      "| d 14                            | -0.52                                                        | 0.48                                                         | -0.52                                                        | (-1.47,0.41)                                                 | -0.54                                                        | 0.65                                                         | -0.54                                                        | (-1.78,0.70)                                                 |\n",
      "| d 15                            | -0.82                                                        | 0.52                                                         | -0.82                                                        | (-1.85,0.20)                                                 | -0.84                                                        | 0.80                                                         | -0.84                                                        | (-2.35,0.69)                                                 |\n",
      "| T 1                             | -0.73                                                        | 0.22                                                         | -0.73                                                        | (-1.16,-0.30)                                                | -0.73                                                        | 0.22                                                         | -0.73                                                        | (-1.16,-0.30)                                                |\n",
      "| T 2                             | -2.54                                                        | 0.40                                                         | -2.54                                                        | (-3.32,-1.77)                                                | -2.57                                                        | 0.58                                                         | -2.57                                                        | (-3.71,-1.49)                                                |\n",
      "| T 3                             | -1.21                                                        | 0.53                                                         | -1.21                                                        | (-2.25,-0.17)                                                | -1.23                                                        | 0.70                                                         | -1.23                                                        | (-2.58,0.09)                                                 |\n",
      "| T 4                             | -1.26                                                        | 0.53                                                         | -1.25                                                        | (-2.29,-0.23)                                                | -1.27                                                        | 0.68                                                         | -1.27                                                        | (-2.58,0.05)                                                 |\n",
      "| T 5                             | -1.56                                                        | 0.57                                                         | -1.56                                                        | (-2.67,-0.45)                                                | -1.57                                                        | 0.83                                                         | -1.57                                                        | (-3.14,0.02)                                                 |\n",
      "| τ                               |                                                              |                                                              |                                                              |                                                              | 0.40                                                         | 0.43                                                         | 0.28                                                         | (0.01,1.53)                                                  |\n",
      "| res D ‡                         | 9.3                                                          |                                                              |                                                              |                                                              | 9.6                                                          |                                                              |                                                              |                                                              |\n",
      "| pD DIC                          | 7.0 16.3                                                     |                                                              |                                                              |                                                              | 8.5 18.1                                                     |                                                              |                                                              |                                                              |\n",
      "\n",
      "## EXAMPLE 6. P SORIASIS\n",
      "\n",
      "In an HTA report to evaluate the effectiveness of treatments for moderate to severe chronic plaque psoriasis, 52 16 trials, comparing 8 treatments were identified: Supportive care (coded 1); Etanercept 25 mg (2); Etanercept 50 mg (3); Efalizumab (4); Ciclosporin (5); Fumaderm (6); Infliximab (7) and Methotrexate (8). The network diagram is presented in Figure A6. Each trial  reported  the  number  of  patients  in  mutually  exclusive  categories  representing  the percentage improvement in symptoms as measured by the PASI score. Different trials reported on different categories defining 3 cut-points, 50, 75 and 90% improvement, in addition to the scale's lower and upper bounds (0 and 100% improvement, respectively). In the code below, we define: C=1 representing 0% improvement (the scale's lower bound); C=2 representing 50%  improvement;  C=3  representing  75%  improvement;  and  C=4  representing  90% improvement. The data is presented in Table A10.\n",
      "\n",
      "Figure  A6  Psoriasis  network:  each  edge  represents  a  treatment,  connecting  lines  indicate  pairs  of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison and the numbers by the treatment names are the treatment codes  used  in  the  modelling.  One  trial  compared  two  arms  of  Ciclosporin  with  Placebo  and  another compared two arms of Infliximab with placebo - these comparisons are not represented in the network.\n",
      "\n",
      "<!-- image -->\n",
      "\n",
      "The model for this type of data is outlined in Section 3.6. The likelihood contribution of each trial is multinomial and this can be used to model the data directly in WinBUGS. However, since the reported categories are different in different studies and overlap, it is helpful to rewrite the multinomial likelihood as a series of conditional Binomials.\n",
      "\n",
      "So, for a trial i reporting the number of patients r ikj in category j =1,…, J i -1, we can write\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where\n",
      "\n",
      "( ) 1 Pr PASI score in category 1 of trial ik q i =\n",
      "\n",
      "( ) 2 Pr PASI score in category 2 of trial    |  not in category 1 ik q i =\n",
      "\n",
      "…\n",
      "\n",
      "( ) Pr PASI score in category   of trial    |  not in categories 1, 2, , 1 ikj q j i j = … - and 1 1 j ikj ik iku u N n r -= = -∑ .\n",
      "\n",
      "Noting that the lower and upper bounds of each mutually exclusive category are defined by the cut-points above and the scale's lower and upper bounds, for arm k of trial i we can define q ikj as the probability of belonging to category j , in arm k of trial i ,\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where L j and U j define the lower and upper bounds of the interval defining category j . So, for example, for arm 1 of study 1 in Table A10 category 1 is 0-50% improvement so q 111 = Pr(having less than 50% improvement in PASI score) = Pr(0&lt; PASI score &lt; 50).\n",
      "\n",
      "Letting p ikc denote the probability of achieving a PASI score of at least c , in arm k of trial i , for c =50, 75, 90 we model\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "where θ ik is the linear predictor and Φ is the standard normal cumulative distribution function. Cut- points z 50 , z 75 and z 90 have been coded z 1 , z 2 and z 3 , respectively, in the code below. We set z 1 =0 and give independent, non-informative priors to z 2 and z 3 .\n",
      "\n",
      "The 'fixed effect' model above assumes that the distance on the standard normal scale between category boundaries are the same in every trial and for every treatment. An alternative might be that they differ between trials, but that within a trial the distances between categories are the same. This leads us to a 'random effects' model in which for each trial i , z ic varies around a mean\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "The mean and variance are then given vague priors in the usual way. One interpretation of this model, which can be used with a Fixed or Random treatment effects, is that there may be\n",
      "\n",
      "differences between trials in the way that the underlying symptoms are scored, in this case on the PASI scale.\n",
      "\n",
      "It can be shown that, for j =1,…, J i -1\n",
      "\n",
      "<!-- formula-not-decoded -->\n",
      "\n",
      "Using these relationships simplifies the code and makes it general for any number of categories and cut-off points.\n",
      "\n",
      "Table A10 Psoriasis example: study names, treatments compared, total number of patients with different percentage improvement and total number of patients in each trial arm, where Supportive Care = treatment 1, Etanercept 25mg = 2, Etanercept 50 mg = 3, Efalizumab = 4, Ciclosporin = 5, Fumaderm = 6, Infliximab = 7, Methotreaxate = 8. 52\n",
      "\n",
      "|                                               |                                               |                                               |                                               | Outcomes presented arm 1 for each category    | Outcomes presented arm 1 for each category    | Outcomes presented arm 1 for each category    | in total of patients arm 1                    | number in for                                 | Outcomes presented in arm each category       | Outcomes presented in arm each category       | Outcomes presented in arm each category       | Outcomes presented in arm each category       | 2 total number of patients in arm 2           | Outcomes presented in arm 3 for each category   | Outcomes presented in arm 3 for each category   | Outcomes presented in arm 3 for each category   | total number of patients in arm 3             |\n",
      "|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-----------------------------------------------|\n",
      "|                                               | Trials                                        |                                               |                                               | presenting                                    |                                               |                                               | outcomes in 4                                 | categories                                    |                                               |                                               |                                               |                                               |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "|                                               | arm 1arm 2arm                                 | arm 1arm 2arm                                 | arm 1arm 2arm                                 |                                               |                                               |                                               |                                               |                                               |                                               |                                               |                                               |                                               |                                               |                                                 |                                                 | 90-                                             |                                               |\n",
      "| Trial                                         | t[,1]                                         | t[,2]                                         | t[,3]                                         | 0-50                                          | 50-75                                         | 75-90                                         | 90-100                                        | n[,1]                                         | 0-50                                          | 50-75                                         | 75-90                                         | 90-100                                        | n[,2]                                         | 0-50 50-75                                      | 75-90                                           | 100                                             | n[,3]                                         |\n",
      "| 1.Elewski 2004                                | 1                                             | 2                                             | 3                                             | 175                                           | 12                                            | 5                                             | 1                                             | 193                                           | 70                                            | 59                                            | 46                                            | 21 196                                        | 44                                            | 54                                              | 56                                              | 40                                              | 194                                           |\n",
      "| 2.Gottlieb 2003                               | 1                                             | 2                                             |                                               | 49                                            | 5                                             | 1                                             | 0                                             | 55                                            | 17                                            | 23                                            | 11                                            | 6 57                                          |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "| 3.Lebwohl 2003                                | 1                                             | 4                                             |                                               | 103                                           | 13                                            | 5                                             | 1                                             | 122                                           | 112                                           | 68                                            | 42                                            | 10 232                                        |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "| 4.Leonardi 2003                               | 1                                             | 2                                             | 3                                             | 142                                           | 18                                            | 5                                             | 1                                             | 166                                           | 68                                            | 39                                            | 36 19                                         | 162                                           | 43                                            | 40                                              | 45                                              | 36                                              | 164                                           |\n",
      "| presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories           | presenting outcomes in 3 categories             | presenting outcomes in 3 categories             | presenting outcomes in 3 categories             | presenting outcomes in 3 categories           |\n",
      "|                                               | t[,1]                                         | t[,2]                                         | t[,3]                                         | Trials 0-50 50-75                             |                                               | 75-100                                        |                                               |                                               | 0-50                                          | 50-75                                         | 75-100                                        |                                               | 0-50                                          | 50-75                                           | 75-100                                          |                                                 |                                               |\n",
      "| 5.Gordon 2003                                 | 1                                             | 4                                             |                                               | 161                                           | 18                                            | 8                                             |                                               | 187                                           | 153                                           | 118                                           | 98                                            | 369                                           |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "| presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50) | presenting outcomes in 2 categories (PASI 50)   | presenting outcomes in 2 categories (PASI 50)   | presenting outcomes in 2 categories (PASI 50)   | presenting outcomes in 2 categories (PASI 50) |\n",
      "| Trial                                         | t[,1]                                         | t[,2]                                         | t[,3]                                         | 0-50                                          | 50-100                                        |                                               |                                               | 0-50                                          | 50-100                                        |                                               |                                               |                                               | 0-50                                          | 50-100                                          |                                                 |                                                 |                                               |\n",
      "| 6.ACD2058g                                    | 1                                             | 4                                             |                                               | 145                                           | 25                                            |                                               | 170                                           |                                               | 63 99                                         |                                               |                                               | 162                                           |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "| 7.ACD2600g                                    | 1                                             | 4                                             |                                               | 230                                           | 33                                            |                                               | 263                                           |                                               | 216                                           | 234                                           |                                               | 450                                           |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "| 8.Guenther 1991                               | 1                                             | 5                                             |                                               | 10                                            | 1                                             |                                               |                                               | 11                                            | 0                                             | 12                                            |                                               | 12                                            |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "| 9.IMP24011                                    | 1                                             | 4                                             |                                               | 226                                           | 38                                            |                                               | 264                                           |                                               | 245                                           | 284                                           |                                               | 529                                           |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "| presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75) | presenting outcomes in 2 categories (PASI 75)   | presenting outcomes in 2 categories (PASI 75)   | presenting outcomes in 2 categories (PASI 75)   | presenting outcomes in 2 categories (PASI 75) |\n",
      "| Trial                                         | t[,1]                                         | t[,2]                                         | t[,3]                                         | Trials 0-75 75-100                            |                                               |                                               |                                               | 0-75                                          | 75-100                                        |                                               |                                               |                                               | 0-75                                          | 75-100                                          |                                                 |                                                 |                                               |\n",
      "| 10.Altmeyer 1994                              | 1                                             | 6                                             |                                               | 50                                            | 1                                             |                                               |                                               | 51                                            | 37                                            | 12                                            |                                               | 49                                            |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "| 11.Chaudari 2001                              | 1                                             | 7                                             |                                               | 9                                             | 2                                             |                                               |                                               | 11                                            | 2                                             | 9                                             |                                               | 11                                            |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "| 12.Ellis 1991                                 | 1                                             | 5                                             | 5                                             | 25                                            | 0                                             |                                               | 25                                            |                                               | 16                                            | 9                                             |                                               | 25                                            | 7                                             | 13                                              |                                                 |                                                 | 20                                            |\n",
      "| 13.Gottlieb 2004                              | 1                                             | 7                                             | 7                                             | 48                                            | 3                                             |                                               |                                               | 51                                            | 28                                            | 71                                            |                                               | 99                                            | 12                                            | 87                                              |                                                 |                                                 | 99                                            |\n",
      "| 14.Heydendael 2003                            | 5                                             | 8                                             |                                               | 12                                            | 30                                            |                                               | 42                                            |                                               | 17                                            | 26                                            |                                               | 43                                            |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "| 15.Meffert 1997                               | 1                                             | 5                                             |                                               | 41                                            | 2                                             |                                               | 43                                            |                                               | 37                                            | 4                                             |                                               | 41                                            |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "| 16.Van Joost 1988                             | 1                                             | 5                                             |                                               | 10                                            | 0                                             |                                               |                                               | 10                                            | 3                                             | 7                                             |                                               | 10                                            |                                               |                                                 |                                                 |                                                 |                                               |\n",
      "\n",
      "The WinBUGS code for random effects is given in program 6(a) and the fixed effects code is given in program 6(b).\n",
      "\n",
      "## Program 6(a): Conditional Binomial likelihood, probit link, Random Effects (Psoriasis example)\n",
      "\n",
      "```\n",
      "# Binomial likelihood, probit link (different categories) # Random effects model for multi-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns){ #   LOOP THROUGH STUDIES w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm delta[i,1] <- 0 # treatment effect is zero for control arm mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:na[i]) { # LOOP THROUGH ARMS p[i,k,1] <- 1 # Pr(PASI >0) for (j in 1:nc[i]-1) { # LOOP THROUGH CATEGORIES r[i,k,j] ~ dbin(q[i,k,j],n[i,k,j]) # binomial likelihood q[i,k,j] <- 1-(p[i,k,C[i,j+1]]/p[i,k,C[i,j]]) # conditional probabilities theta[i,k,j] <- mu[i] + delta[i,k] + z[C[i,j+1]-1]  # linear predictor rhat[i,k,j] <-  q[i,k,j] * n[i,k,j] # predicted number events dv[i,k,j] <- 2 * (r[i,k,j]*(log(r[i,k,j])-log(rhat[i,k,j]))  #Deviance contribution of each category +(n[i,k,j]-r[i,k,j])*(log(n[i,k,j]-r[i,k,j]) - log(n[i,k,j]-rhat[i,k,j]))) } dev[i,k] <- sum(dv[i,k,1:nc[i]-1]) # deviance contribution of each arm for (j in 2:nc[i])  { # LOOP THROUGH CATEGORIES p[i,k,C[i,j]] <- 1 - phi.adj[i,k,j] # link function # adjust link function phi(x) for extreme values that can give numerical errors # when x< -5, phi(x)=0, when x> 5, phi(x)=1: use only if needed phi.adj[i,k,j] <- step(5+theta[i,k,j-1]) * (step(theta[i,k,j-1]-5) + step(5-theta[i,k,j-1])*phi(theta[i,k,j-1]) ) } } for (k in 2:na[i]) { # LOOP THROUGH ARMS delta[i,k] ~ dnorm(md[i,k],taud[i,k]) md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] # mean of LHR distributions, with multi-arm trial correction taud[i,k] <- tau *2*(k-1)/k # precision of LHR distributions (with multi-arm trial correction) w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) # adjustment, multi-arm RCTs sw[i,k] <- sum(w[i,1:k-1])/(k-1) # cumulative adjustment for multi-arm trials } resdev[i] <- sum(dev[i,1:na[i]]) #  summed residual deviance contribution for this trial } z[1] <- 0 # set z50=0 for (j in 2:Cmax-1) { # Set priors for z, for any number of categories z.aux[j] ~ dunif(0,5) # priors z[j] <- z[j-1] + z.aux[j] # ensures z[j]~Uniform(z[j-1], z[j-1]+5) } totresdev <- sum(resdev[]) #Total Residual Deviance d[1] <- 0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects sd ~ dunif(0,5) # vague prior for between-trial SD tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance) } # *** PROGRAM ENDS\n",
      "```\n",
      "\n",
      "Additional code to monitor all treatment contrasts and rank treatments can be added as before. Given values for the mean, 1.097, and precision, 123, of the effects on Treatment 1 on the probit scale, from external sources, absolute effects, and absolute probabilities T [ j , k ] of having\n",
      "\n",
      "over 50, 75 or 90% improvement ( j =1,2,3 respectively) on treatment k , could be monitored as follows:\n",
      "\n",
      "```\n",
      "A ~ dnorm(1.097,123) # calculate prob of achieving PASI50,75,90 on treat k for (k in 1:nt) { for (j in 1: Cmax-1) {  T[j,k] <- 1 - phi(A + d[k] + z[j]) } }\n",
      "```\n",
      "\n",
      "The data structure again consists of a list specifying the number of treatments nt , number of studies ns and total number of categories Cmax , with the main body of data in a vector format. Both data components need to be loaded into WinBUGS for the program to run. Three columns are required for each arm variable since there are four three-arm trials: t[,1], t[,2] and t[,3] are the treatment codes; na[] represents the number of arms and nc[] the number of cut-offs in that trial; C[,1] , C[,2] , C[,3] , C[,4] represent the cut-offs used to define the categories reported in each trial four columns are needed as the maximum number of cut-offs given in a trial is four - these cutoffs are coded 1 to 4 as described above; then r[,k,j] the number of events for the k -th treatment, in category j given the number of events in categories 1 to j -1; then n[,k,1] represents the total number of individuals in trial arm k , n[,k,2] represents the total number of individuals in trial arm k , which were not in category 1 of that trial and n[,k,3] represents the total number of individuals in trial arm k , which were not in categories 1 or 2 of that trial. So, for example, for the first trial in Table A10, Elewski 2004, 193 patients were included in arm 1 of the trial. These patients were split between the four categories as follows: 175 out of 193 patients had between 0 and 50% improvement, leaving 18 patients who could belong to any of the other categories, thus r 111 =173, n 111 =193; 12 out of 18 patients had between 50 and 75% improvement, leaving 6 patients who could belong to any of the other categories, thus r 112 =12, n 112 =193-175=18; 5 out of 6 patients had between 75 and 90% improvement, leaving 1 patient (who necessarily had over 90% improvement), thus r 113 =5, n 112 =18-12=6. All other n ikj were similarly calculated for the other trials.\n",
      "\n",
      "Note  that  for  trials  reporting j categories, r and n only  need  to  be  defined  for  the  first  j-1 categories  with  the  remaining  columns  coded NA ,  and  some  of  the  data  given  below  is redundant.\n",
      "\n",
      "```\n",
      "# Data (Psoriasis example) list(ns=16, nt=8, Cmax=4) t[,1] t[,2] t[,3] na[] nc[] C[,1] C[,2] C[,3] C[,4] r[,1,1] r[,1,2] r[,1,3] n[,1,1] n[,1,2] n[,1,3] r[,2,1] r[,2,2] r[,2,3] n[,2,1] n[,2,2] n[,2,3] r[,3,1] r[,3,2] r[,3,3] n[,3,1] n[,3,2] n[,3,3] # Trial Year\n",
      "```\n",
      "\n",
      "| 1   | 2   | 3   | 3   | 4          | 1         | 2    | 3   | 4   | 175   | 12   | 5   | 193   |\n",
      "|-----|-----|-----|-----|------------|-----------|------|-----|-----|-------|------|-----|-------|\n",
      "|     | 18  | 6   | 70  | 59         | 46        | 196  | 126 | 67  | 44    | 54   | 56  | 194   |\n",
      "|     | 150 | 96  | #   | Elewski    | 2004      |      |     |     |       |      |     |       |\n",
      "| 1   | 2   | NA  | 2   | 4          | 1         | 2    | 3   | 4   | 49    | 5    | 1   | 55    |\n",
      "|     | 6   | 1   | 17  | 23         | 11        | 57   | 40  | 17  | NA    | NA   | NA  | NA    |\n",
      "|     | NA  | NA  | #   | Gottlieb   | 2003      |      |     |     |       |      |     |       |\n",
      "| 1   | 4   | NA  | 2   | 4          | 1         | 2    | 3   | 4   | 103   | 13   | 5   | 122   |\n",
      "|     | 19  | 6   | 112 | 68         | 42        | 232  | 120 | 52  | NA    | NA   | NA  | NA    |\n",
      "|     | NA  | NA  | #   | Lebwohl    | 2003      |      |     |     |       |      |     |       |\n",
      "| 1   | 2   | 3   | 3   | 4          | 1         | 2    | 3   | 4   | 142   | 18   | 5   | 166   |\n",
      "|     | 24  | 6   | 68  | 39         | 36        | 162  | 94  | 55  | 43    | 40   | 45  | 164   |\n",
      "|     | 121 | 81  | #   | Leonardi   | 2003      |      |     |     |       |      |     |       |\n",
      "| 1   | 4   | NA  | 2   | 3          | 1         | 2    | 3   | NA  | 161   | 18   | 8   | 187   |\n",
      "|     | 26  | 8   | 153 | 118        | 98        | 369  | 216 | 98  | NA    | NA   | NA  | NA    |\n",
      "|     | NA  | NA  | #   | Gordon     | 2003      |      |     |     |       |      |     |       |\n",
      "| 1   | 4   | NA  | 2   | 2          | 1         | 2    | NA  | NA  | 145   | 25   | NA  | 170   |\n",
      "|     | 25  | NA  | 63  | 99         | NA        | 162  | 99  | NA  | NA    | NA   | NA  | NA    |\n",
      "|     | NA  | NA  | #   | ACD2058g   |           | 2004 |     |     |       |      |     |       |\n",
      "| 1   | 4   | NA  | 2   | 2          | 1         | 2    | NA  | NA  | 230   | 33   | NA  | 263   |\n",
      "|     | 33  | NA  | 216 | 234        | NA        | 450  | 234 | NA  | NA    | NA   | NA  | NA    |\n",
      "|     | NA  | NA  | #   | ACD2600g   |           | 2004 |     |     |       |      |     |       |\n",
      "| 1   | 5   | NA  | 2   | 2          | 1         | 2    | NA  | NA  | 10    | 1    | NA  | 11    |\n",
      "|     | 1   | NA  | 0   | 12         | NA        | 12   | 12  | NA  | NA    | NA   | NA  | NA    |\n",
      "|     | NA  | NA  | #   | Guenther   | 1991      |      |     |     |       |      |     |       |\n",
      "| 1   | 4   | NA  | 2   | 2          | 1         | 2    | NA  | NA  | 226   | 38   | NA  | 264   |\n",
      "|     | 38  | NA  | 245 | 284        | NA        | 529  | 284 | NA  | NA    | NA   | NA  | NA    |\n",
      "|     | NA  | NA  | #   | IMP24011   |           | 2004 |     |     |       |      |     |       |\n",
      "| 1   | 6   | NA  | 2   | 2          | 1         | 3    | NA  | NA  | 50    | 1    | NA  | 51    |\n",
      "|     | 1   | NA  | 37  | 12         | NA        | 49   | 12  | NA  | NA    | NA   | NA  | NA    |\n",
      "|     | NA  | NA  | #   | Altmeyer   | 1994      |      |     |     |       |      |     |       |\n",
      "| 1   | 7   | NA  | 2   | 2          | 1         | 3    | NA  | NA  | 9     | 2    | NA  | 11    |\n",
      "|     | 2   | NA  | 2   | 9          | NA        | 11   | 9   | NA  | NA    | NA   | NA  | NA    |\n",
      "|     | NA  | NA  | #   | Chaudari   | 2001      |      |     |     |       |      |     |       |\n",
      "| 1   | 5   | 5   | 3   | 2          | 1         | 3    | NA  | NA  | 25    | 0    | NA  | 25    |\n",
      "|     | 0   | NA  | 16  | 9          | NA        | 25   | 9   | NA  | 7     | 13   | NA  | 20    |\n",
      "|     | 13  | 0   | #   | Ellis      | 1991      |      |     |     |       |      |     |       |\n",
      "| 1   | 7   | 7   | 3   | 2          | 1         | 3    | NA  | NA  | 48    | 3    | NA  | 51    |\n",
      "|     | 3   | NA  | 28  | 71         | NA        | 99   | 71  | NA  | 12    | 87   | NA  | 99    |\n",
      "|     | 87  | 0   | #   | Gottlieb   | 2004      |      |     |     |       |      |     |       |\n",
      "| 5   | 8   | NA  | 2   | 2          | 1         | 3    | NA  | NA  | 12    | 30   | NA  | 42    |\n",
      "|     | 30  | NA  | 17  | 26         | NA        | 43   | 26  | NA  | NA    | NA   | NA  | NA    |\n",
      "|     | NA  | NA  | #   | Heydendael |           | 2003 |     |     |       |      |     |       |\n",
      "| 1   | 5   | NA  | 2   | 2          | 1         | 3    | NA  | NA  | 41    | 2    | NA  | 43    |\n",
      "|     | 2   | NA  | 37  | 4          | NA        | 41   | 4   | NA  | NA    | NA   | NA  | NA    |\n",
      "|     | NA  | NA  | #   | Meffert    | 1997      |      |     |     |       |      |     |       |\n",
      "| 1   | 5   | NA  | 2   | 2          | 1         | 3    | NA  | NA  | 10    | 0    | NA  | 10    |\n",
      "|     | 0   | NA  | 3   | 7          | NA        | 10   | 7   | NA  | NA    | NA   | NA  | NA    |\n",
      "| END | NA  | NA  | #   | Van        | Joost1988 |      |     |     |       |      |     |       |\n",
      "\n",
      "```\n",
      "# Initial Values # Initial values for delta can be generated by WinBUGS. #chain 1 list(d = c(NA,0,0,0,0,0,0,0), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0),  sd = 1, z.aux=c(NA, 0.66,1.3)) #chain 2 list(d = c(NA,0,0,1,0,0,2,0), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0),  sd = 1.5, z.aux=c(NA, 0.5,1)) #chain 3 list(d = c(NA,1,1,1,1,1,1,1), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0),  sd = 3, z.aux=c(NA, 0.1,2))\n",
      "```\n",
      "\n",
      "The parameters to monitor are the same as in Example 1. We may in addition want to monitor node z to obtain the posterior summaries for the different cut-off points.\n",
      "\n",
      "## Program  6(b):  Conditional  Binomial  likelihood,  probit  link,  Fixed  Effects  (Psoriasis example)\n",
      "\n",
      "```\n",
      "# Binomial likelihood, probit link (different categories) # Fixed effects model for multi-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns){ #   LOOP THROUGH STUDIES mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:na[i]) { # LOOP THROUGH ARMS p[i,k,1] <- 1 # Pr(PASI >0) for (j in 1:nc[i]-1) { # LOOP THROUGH CATEGORIES r[i,k,j] ~ dbin(q[i,k,j],n[i,k,j]) # binomial likelihood q[i,k,j] <- 1-(p[i,k,C[i,j+1]]/p[i,k,C[i,j]]) # conditional probabilities theta[i,k,j] <- mu[i] + d[t[i,k]] - d[t[i,1]] + z[C[i,j+1]-1]  # linear predictor rhat[i,k,j] <-  q[i,k,j] * n[i,k,j] # predicted number events dv[i,k,j] <- 2 * (r[i,k,j]*(log(r[i,k,j])-log(rhat[i,k,j]))  #Deviance contribution of each category +(n[i,k,j]-r[i,k,j])*(log(n[i,k,j]-r[i,k,j]) - log(n[i,k,j]-rhat[i,k,j]))) } dev[i,k] <- sum(dv[i,k,1:nc[i]-1]) # deviance contribution of each arm for (j in 2:nc[i])  { # LOOP THROUGH CATEGORIES p[i,k,C[i,j]] <- 1 - phi.adj[i,k,j] # link function # adjust phi(x) for extreme values that can give numerical errors # when x< -5, phi(x)=0, when x> 5, phi(x)=1: use only if needed phi.adj[i,k,j] <- step(5+theta[i,k,j-1]) * (step(theta[i,k,j-1]-5) + step(5-theta[i,k,j-1])*phi(theta[i,k,j-1]) ) } } resdev[i] <- sum(dev[i,1:na[i]]) #  summed residual deviance contribution for this trial } z[1] <- 0 # set z50=0 for (j in 2:Cmax-1) { # Set priors for z, for any number of categories z.aux[j] ~ dunif(0,5) # priors z[j] <- z[j-1] + z.aux[j] # ensures z[j]~Uniform(z[j-1], z[j-1]+5) } totresdev <- sum(resdev[]) #Total Residual Deviance d[1] <- 0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects } # *** PROGRAM ENDS # Initial Values #chain 1 list(d = c(NA,0,0,0,0,0,0,0), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0), z.aux=c(NA, 0.66,1.3) #chain 2 list(d = c(NA,0,0,1,0,0,2,0), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0), z.aux=c(NA, 0.5,1) )\n",
      "```\n",
      "\n",
      "list(d = c(NA,1,1,1,1,1,1,1), mu = c(0,0,0,0,0,     0,0,0,0,0,     0,0,0,0,0,     0), z.aux=c(NA, 0.1,2))\n",
      "\n",
      "## R ESULTS\n",
      "\n",
      "Results for the fixed and random effects models are presented in Table A11 (results based on 3 chains: 100,000 iterations after a burn-in of 40,000 and 50,000 for the FE and RE models, respectively). From the residual deviance and DIC we conclude that the random effects model should be preferred as it is a better fit to the data and has a smaller DIC. The treatment effects relative to Supportive care (treatment 1) are all below zero which suggests that all treatments are better than Supportive care at increasing the probability of a reduction in symptoms on the probit scale. The absolute probabilities of achieving a reduction on at least 50, 75 or 90% in symptoms show that, for example, there is on average 0% probability of achieving at least a 90% reduction in symptoms with Supportive care, but this probability is on average 37% with Infliximab.  A  model  which  assumes  the  cut-points  differ  between  trials  and  come  from  a common distribution was also fitted and gave very similar results.\n",
      "\n",
      "Table A11 Psoriasis example: posterior mean, standard deviation (sd), median and 95% Credible interval (CrI) for the fixed and random effects models for the treatment effects, on the probit scale, of Etanercept 25 mg ( d 12 ), Etanercept 50 mg ( d 13 ), Efalizumab ( d 14 ), Ciclosporin ( d 15 ) , Fumaderm ( d 16 ) , Infliximab ( d 17 ), and Methotrexate ( d 18 ) relative to Supportive Care; absolute probabilities of achieving at least 50, 70 or 90% relief in symptoms for each treatment; heterogeneity parameter τ and model fit statistics.\n",
      "\n",
      "|      | FE model   | FE model   | FE model   | FE model      | RE model   | RE model   | RE model   | RE model      |\n",
      "|------|------------|------------|------------|---------------|------------|------------|------------|---------------|\n",
      "|      | mean       | sd         | median     | CrI           | mean       | sd         | median     | CrI           |\n",
      "| d 12 | -1.51      | 0.10       | -1.51      | (-1.70,-1.32) | -1.53      | 0.24       | -1.52      | (-2.05,-1.03) |\n",
      "| d 13 | -1.92      | 0.10       | -1.92      | (-2.12,-1.72) | -1.93      | 0.28       | -1.92      | (-2.51,-1.35) |\n",
      "| d 14 | -1.19      | 0.06       | -1.19      | (-1.30,-1.08) | -1.19      | 0.18       | -1.19      | (-1.56,-0.81) |\n",
      "| d 15 | -1.92      | 0.34       | -1.90      | (-2.62,-1.30) | -2.04      | 0.43       | -2.00      | (-3.02,-1.30) |\n",
      "| d 16 | -1.49      | 0.49       | -1.46      | (-2.55,-0.63) | -1.49      | 0.62       | -1.46      | (-2.81,-0.33) |\n",
      "| d 17 | -2.33      | 0.26       | -2.33      | (-2.87,-1.84) | -2.32      | 0.38       | -2.32      | (-3.06,-1.55) |\n",
      "| d 18 | -1.61      | 0.44       | -1.60      | (-2.50,-0.77) | -1.74      | 0.64       | -1.70      | (-3.14,-0.59) |\n",
      "| τ    | -          | -          | -          | -             | 0.31       | 0.23       | 0.26       | (0.01,0.88)   |\n",
      "\n",
      "| Probability of achieving at least 50% relief in symptoms (PASI50)   | Probability of achieving at least 50% relief in symptoms (PASI50)   | Probability of achieving at least 50% relief in symptoms (PASI50)   | Probability of achieving at least 50% relief in symptoms (PASI50)   | Probability of achieving at least 50% relief in symptoms (PASI50)   | Probability of achieving at least 50% relief in symptoms (PASI50)   | Probability of achieving at least 50% relief in symptoms (PASI50)   | Probability of achieving at least 50% relief in symptoms (PASI50)   | Probability of achieving at least 50% relief in symptoms (PASI50)   |\n",
      "|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|\n",
      "| Supportive Care                                                     | 0.14                                                                | 0.02                                                                | 0.14                                                                | (0.10,0.18)                                                         | 0.14                                                                | 0.02                                                                | 0.14                                                                | (0.10,0.18)                                                         |\n",
      "| Etanercept 25 mg                                                    | 0.66                                                                | 0.05                                                                | 0.66                                                                | (0.56,0.75)                                                         | 0.66                                                                | 0.09                                                                | 0.66                                                                | (0.46,0.83)                                                         |\n",
      "| Etanercept 50 mg                                                    | 0.79                                                                | 0.04                                                                | 0.79                                                                | (0.71,0.86)                                                         | 0.79                                                                | 0.08                                                                | 0.80                                                                | (0.59,0.92)                                                         |\n",
      "| Efalizumab                                                          | 0.54                                                                | 0.04                                                                | 0.54                                                                | (0.45,0.62)                                                         | 0.54                                                                | 0.08                                                                | 0.54                                                                | (0.38,0.69)                                                         |\n",
      "| Ciclosporin                                                         | 0.78                                                                | 0.10                                                                | 0.79                                                                | (0.57,0.94)                                                         | 0.81                                                                | 0.10                                                                | 0.82                                                                | (0.57,0.97)                                                         |\n",
      "| Fumaderm                                                            | 0.64                                                                | 0.16                                                                | 0.64                                                                | (0.31,0.93)                                                         | 0.63                                                                | 0.20                                                                | 0.64                                                                | (0.22,0.96)                                                         |\n",
      "| Infliximab                                                          | 0.88                                                                | 0.05                                                                | 0.89                                                                | (0.76,0.96)                                                         | 0.87                                                                | 0.08                                                                | 0.89                                                                | (0.67,0.98)                                                         |\n",
      "| Methotrexate                                                        | 0.68                                                                | 0.15                                                                | 0.69                                                                | (0.37,0.92)                                                         | 0.70                                                                | 0.18                                                                | 0.73                                                                | (0.30,0.98)                                                         |\n",
      "| Probability of achieving at least 75% relief in symptoms (PASI75)   | Probability of achieving at least 75% relief in symptoms (PASI75)   | Probability of achieving at least 75% relief in symptoms (PASI75)   | Probability of achieving at least 75% relief in symptoms (PASI75)   | Probability of achieving at least 75% relief in symptoms (PASI75)   | Probability of achieving at least 75% relief in symptoms (PASI75)   | Probability of achieving at least 75% relief in symptoms (PASI75)   | Probability of achieving at least 75% relief in symptoms (PASI75)   | Probability of achieving at least 75% relief in symptoms (PASI75)   |\n",
      "| Supportive Care                                                     | 0.03                                                                | 0.01                                                                | 0.03                                                                | (0.02,0.05)                                                         | 0.03                                                                | 0.01                                                                | 0.03                                                                | (0.02,0.05)                                                         |\n",
      "| Etanercept 25 mg                                                    | 0.37                                                                | 0.05                                                                | 0.37                                                                | (0.28,0.47)                                                         | 0.38                                                                | 0.09                                                                | 0.37                                                                | (0.20,0.58)                                                         |\n",
      "| Etanercept 50 mg                                                    | 0.53                                                                | 0.05                                                                | 0.53                                                                | (0.42,0.63)                                                         | 0.53                                                                | 0.11                                                                | 0.53                                                                | (0.30,0.75)                                                         |\n",
      "| Efalizumab                                                          | 0.25                                                                | 0.03                                                                | 0.25                                                                | (0.19,0.33)                                                         | 0.26                                                                | 0.06                                                                | 0.25                                                                | (0.14,0.40)                                                         |\n",
      "| Ciclosporin                                                         | 0.52                                                                | 0.13                                                                | 0.52                                                                | (0.28,0.79)                                                         | 0.56                                                                | 0.15                                                                | 0.56                                                                | (0.28,0.88)                                                         |\n",
      "| Fumaderm                                                            | 0.37                                                                | 0.17                                                                | 0.35                                                                | (0.11,0.76)                                                         | 0.38                                                                | 0.20                                                                | 0.35                                                                | (0.06,0.83)                                                         |\n",
      "| Infliximab                                                          | 0.68                                                                | 0.10                                                                | 0.68                                                                | (0.48,0.85)                                                         | 0.67                                                                | 0.13                                                                | 0.68                                                                | (0.37,0.89)                                                         |\n",
      "| Methotrexate                                                        | 0.41                                                                | 0.16                                                                | 0.40                                                                | (0.14,0.75)                                                         | 0.46                                                                | 0.21                                                                | 0.44                                                                | (0.10,0.90)                                                         |\n",
      "| Probability of achieving at least 90% relief in symptoms (PASI90)   | Probability of achieving at least 90% relief in symptoms (PASI90)   | Probability of achieving at least 90% relief in symptoms (PASI90)   | Probability of achieving at least 90% relief in symptoms (PASI90)   | Probability of achieving at least 90% relief in symptoms (PASI90)   | Probability of achieving at least 90% relief in symptoms (PASI90)   | Probability of achieving at least 90% relief in symptoms (PASI90)   | Probability of achieving at least 90% relief in symptoms (PASI90)   | Probability of achieving at least 90% relief in symptoms (PASI90)   |\n",
      "| Supportive Care                                                     | 0.00                                                                | 0.00                                                                | 0.00                                                                | (0.00,0.01)                                                         | 0.00                                                                | 0.00                                                                | 0.00                                                                | (0.00,0.01)                                                         |\n",
      "| Etanercept 25 mg                                                    | 0.13                                                                | 0.03                                                                | 0.13                                                                | (0.08,0.19)                                                         | 0.14                                                                | 0.06                                                                | 0.13                                                                | (0.05,0.28)                                                         |\n",
      "| Etanercept 50 mg                                                    | 0.23                                                                | 0.04                                                                | 0.23                                                                | (0.16,0.32)                                                         | 0.24                                                                | 0.09                                                                | 0.23                                                                | (0.09,0.45)                                                         |\n",
      "| Efalizumab                                                          | 0.07                                                                | 0.02                                                                | 0.07                                                                | (0.04,0.11)                                                         | 0.07                                                                | 0.03                                                                | 0.07                                                                | (0.03,0.15)                                                         |\n",
      "| Ciclosporin                                                         | 0.24                                                                | 0.11                                                                | 0.22                                                                | (0.08,0.49)                                                         | 0.28                                                                | 0.14                                                                | 0.26                                                                | (0.08,0.65)                                                         |\n",
      "| Fumaderm                                                            | 0.15                                                                | 0.12                                                                | 0.11                                                                | (0.02,0.46)                                                         | 0.16                                                                | 0.15                                                                | 0.12                                                                | (0.01,0.57)                                                         |\n",
      "| Infliximab                                                          | 0.38                                                                | 0.10                                                                | 0.37                                                                | (0.19,0.60)                                                         | 0.37                                                                | 0.14                                                                | 0.37                                                                | (0.13,0.67)                                                         |\n",
      "| Methotrexate                                                        | 0.17                                                                | 0.11                                                                | 0.14                                                                | (0.03,0.44)                                                         | 0.21                                                                | 0.17                                                                | 0.17                                                                | (0.02,0.69)                                                         |\n",
      "| res D *                                                             | 74.9                                                                |                                                                     |                                                                     |                                                                     | 63.0                                                                |                                                                     |                                                                     |                                                                     |\n",
      "| pD                                                                  | 25.0                                                                |                                                                     |                                                                     |                                                                     | 33.3                                                                |                                                                     |                                                                     |                                                                     |\n",
      "| DIC                                                                 | 99.9                                                                |                                                                     |                                                                     |                                                                     | 96.2                                                                |                                                                     |                                                                     |                                                                     |\n",
      "\n",
      "## EXAMPLE 7. P ARKINSON ' S D IFFERENCE ( TREATMENT  DIFFERENCES  AS DATA )\n",
      "\n",
      "We now assume that the data available for the Parkinson's example were not the mean off-time reduction for patients in each arm of the trial, but rather the differences in off-time reduction, and their standard errors, between the intervention and control arms for each trial, as presented in the last two columns of Table A8. The data available are therefore the differences, their standard errors and the treatments compared in each trial, coded as before.\n",
      "\n",
      "Random and fixed effects models were fitted, as outlined in Section 3.4. The code is given below. As explained in Section 5.1 the coding for the likelihood has been modified to allow for the 3-arm trial. This requires users to set up the data file with all two-arm trials first, then 3-arm trials, then - if any were present - 4-arm trials, and so on.\n",
      "\n",
      "## Program 7(a):  Normal likelihood, identity link, treatment differences, Random Effects (Parkinson's Differences)\n",
      "\n",
      "```\n",
      "# Normal likelihood, identity link, trial-level data given as treatment differences # Random effects model for multi-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns2) { # LOOP THROUGH 2-ARM STUDIES y[i,2] ~ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]  #Deviance contribution for trial i } for(i in (ns2+1):(ns2+ns3)) { # LOOP THROUGH 3-ARM STUDIES for (k in 1:(na[i]-1)) { # set variance-covariance matrix for (j in 1:(na[i]-1)) {  Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)   } } Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i,,])  #Precision matrix # multivariate normal likelihood for 3-arm trials y[i,2:na[i]] ~ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)]) #Deviance contribution for trial i for (k in 1:(na[i]-1)){ # multiply vector & matrix ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)] z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)]) } resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)]) } for(i in 1:(ns2+ns3)){ # LOOP THROUGH ALL STUDIES w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm delta[i,1] <- 0 # treatment effect is zero for control arm for (k in 2:na[i]) { #  LOOP THROUGH ARMS var[i,k] <- pow(se[i,k],2) # calculate variances prec[i,k] <- 1/var[i,k] # set precisions } for (k in 2:na[i]) { # LOOP THROUGH ARMS delta[i,k] ~ dnorm(md[i,k],taud[i,k]) # trial-specific treat effects distributions md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] # mean of treat effects distributions (with multi-arm trial correction) taud[i,k] <- tau *2*(k-1)/k # precision of treat effects distributions (with multi-arm trial correction) w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) # adjustment for multi-arm RCTs sw[i,k] <- sum(w[i,1:k-1])/(k-1) # cumulative adjustment for multi-arm trials } } totresdev <- sum(resdev[]) #Total Residual Deviance d[1]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects sd ~ dunif(0,5) # vague prior for between-trial SD tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance) } # *** PROGRAM ENDS\n",
      "```\n",
      "\n",
      "Additional code to monitor all treatment contrasts and rank treatments can be added as before. Given values for the mean, meanA=-0.73, and precision, precA=21, of the effects on Treatment 1, from external sources, absolute effects, could be monitored as follows:\n",
      "\n",
      "```\n",
      "A ~ dnorm(meanA,precA) for (k in 1:nt) { T[k] <- A + d[k]  }\n",
      "```\n",
      "\n",
      "If  trials  with  four  or  more  arms  were  included,  a  further  multivariate  normal  likelihood statement would need to be added and the corresponding variance-covariance and precision matrices built ( Sigma2 and Omega2 , say). So, for example if ns4 4-arm trials were available, we\n",
      "\n",
      "would add the following lines of code to the above, taking care to change all the relevant loops to go through all trials:\n",
      "\n",
      "```\n",
      "for(i in (ns2+ns3+1):(ns2+ns3+ns4)) { # LOOP THROUGH 4-ARM STUDIES for (k in 1:(na[i]-1)) { # set variance-covariance matrix for (j in 1:(na[i]-1)) {  Sigma2[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)   } } Omega2[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma2[i,,])  #Precision matrix # multivariate normal likelihood for 4-arm trials y[i,2:na[i]] ~ dmnorm(delta[i,2:na[i]],Omega2[i,1:(na[i]-1),1:(na[i]-1)]) } If no multi-arm trials are included, the code simplifies to: # Normal likelihood, identity link, trial-level data given as treatment differences # Random effects model for two-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns2) { # LOOP THROUGH 2-ARM STUDIES y[i,2] ~ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials var[i,2] <- pow(se[i,2],2) # calculate variances prec[i,2] <- 1/var[i,2] # set precisions dev[i,2] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]  #Deviance contribution delta[i,2] ~ dnorm(md[i,2],tau) # trial-specific treat effects distributions md[i,2] <-  d[t[i,2]] - d[t[i,1]] # mean of treat effects distributions } totresdev <- sum(dev[,2]) #Total Residual Deviance d[1]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects sd ~ dunif(0,5) # vague prior for between-trial SD tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance) } # *** PROGRAM ENDS\n",
      "```\n",
      "\n",
      "The data structure is similar to that of Example 5 but we now have to specify the number of two-arm trials ns2 and the number of three-arm trials ns3 .  The maximum number of arms is 3, so 3 vectors are needed for the treatment indicators, t[,1] t[,2] , t[,3] ; for a trial with 3 treatment arms, two treatment differences will be available, so 2 vectors of differences (the continuous outcomes) y[,] and their standard errors se[,] are needed; and finally the number of arms, na[] and V[] the variance of the baseline treatment in that trial (needed to adjust for the correlation in multi-arm trials - note that this variable only need to have values assigned when there are multiarm trials),  with NA denoting  a  missing  observation.  Note  that  any  three-arm  trials  need  to appear at the end of the column format data.\n",
      "\n",
      "```\n",
      "# Data (Parkinson's example - trial-level data: treatment differences) list(ns2=6, ns3=1, nt=5) t[,1] t[,2] t[,3] y[,2] y[,3] se[,2] se[,3] na[] V[] 1 3 NA -0.31 NA 0.668089651 NA 2 NA 1 2 NA -1.7 NA 0.382640605 NA 2 NA 3 4 NA -0.35 NA 0.441941738 NA 2 NA 3 4 NA 0.55 NA 0.555114559 NA 2 NA 4 5 NA -0.3 NA 0.274276316 NA 2 NA 4 5 NA -0.3 NA 0.320087245 NA 2 NA 1 2 4 -2.3 -0.9 0.71774604 0.694988091 3 0.254736842 END\n",
      "```\n",
      "\n",
      "```\n",
      "# Initial Values # Initial values for delta can be generated by WinBUGS. #chain 1 list(d=c( NA, 0,0,0,0), sd=1) #chain 2 list(d=c( NA, -1,-3,-1,1), sd=4) #chain 3 list(d=c( NA, 2,2,2,2), sd=2)\n",
      "```\n",
      "\n",
      "The parameters to monitor are the same as in Example 5.\n",
      "\n",
      "## Program  7(b):    Normal  likelihood,  identity  link,  treatment  differences,  Fixed  Effects (Parkinson's Differences)\n",
      "\n",
      "```\n",
      "# Normal likelihood, identity link, trial-level data given as treatment differences # Fixed effects model model{ # *** PROGRAM STARTS for(i in 1:ns2) { # LOOP THROUGH 2-ARM STUDIES y[i,2] ~ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]  #Deviance contribution for trial i } for(i in (ns2+1):(ns2+ns3)) { # LOOP THROUGH MULTI-ARM STUDIES for (k in 1:(na[i]-1)) { # set variance-covariance matrix for (j in 1:(na[i]-1)) {  Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)  } } Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i,,])  #Precision matrix # multivariate normal likelihood for 3-arm trials y[i,2:na[i]] ~ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)]) #Deviance contribution for trial i for (k in 1:(na[i]-1)){ # multiply vector & matrix ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)] z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)]) } resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)]) } for(i in 1:(ns2+ns3)){ # LOOP THROUGH ALL STUDIES for (k in 2:na[i]) { #  LOOP THROUGH ARMS var[i,k] <- pow(se[i,k],2) # calculate variances prec[i,k] <- 1/var[i,k] # set precisions delta[i,k] <-  d[t[i,k]] - d[t[i,1]] } } totresdev <- sum(resdev[]) #Total Residual Deviance d[1]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects } # *** PROGRAM ENDS # Initial Values #chain 1 list(d=c( NA, 0,0,0,0)) #chain 2 list(d=c( NA, -1,-3,-1,1)) #chain 3 list(d=c( NA, 2,2,2,2))\n",
      "```\n",
      "\n",
      "## R ESULTS\n",
      "\n",
      "Results (based on 3 chains: 100,000 iterations after a burn-in of 50,000) are presented in Table A9 and are the same as the results obtained using the model in Example 5.\n",
      "\n",
      "## EXAMPLE 8. P ARKINSON ' S  SHARED  PARAMETERS ( MIXED  TREATMENT DIFFERENCE AND ARM -LEVEL DATA )\n",
      "\n",
      "To illustrate a meta-analysis with a shared parameter model (Section 4) we will assume that the data available for the Parkinson's example were the mean off-time reduction for patients in each arm of the trial for the first three trials, but only the differences between the intervention and control arms (and their standard errors) were available for the remaining trials (Table A8). Random and fixed effects models were fitted. The code below consists of a combination of the code used in Example 5, for the arm-level data, and the code used in Example 7, for the trial level data.\n",
      "\n",
      "## Program 8(a): Normal likelihood, identity link, shared parameter model, Random Effects (Parkinson's shared parameters)\n",
      "\n",
      "```\n",
      "# Normal likelihood, identity link, Arm and Trial-level data (treatment differences) # Random effects model for multi-arm trials model{ # *** PROGRAM STARTS for(i in 1:ns.a){ # LOOP THROUGH STUDIES WITH ARM DATA w.a[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm delta[i,1] <- 0 # treatment effect is zero for control arm mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:na.a[i]) { #  LOOP THROUGH ARMS var.a[i,k] <- pow(se.a[i,k],2) # calculate variances prec.a[i,k] <- 1/var.a[i,k] # set precisions y.a[i,k] ~ dnorm(theta[i,k],prec.a[i,k]) # normal likelihood theta[i,k] <- mu[i] + delta[i,k] # model for linear predictor dev[i,k] <- (y.a[i,k]-theta[i,k])*(y.a[i,k]-theta[i,k])*prec.a[i,k]    #Deviance contribution } resdev[i] <- sum(dev[i,1:na.a[i]]) #  summed residual deviance contribution for this trial for (k in 2:na.a[i]) { # LOOP THROUGH ARMS delta[i,k] ~ dnorm(md[i,k],taud.a[i,k]) # trial-specific LOR distributions # mean of LOR distributions, with multi-arm trial correction md[i,k] <-  d[t.a[i,k]] - d[t.a[i,1]] + sw.a[i,k] taud.a[i,k] <- tau *2*(k-1)/k # precision of LOR distributions (with multi-arm trial correction) w.a[i,k] <- (delta[i,k] - d[t.a[i,k]] + d[t.a[i,1]]) # adjustment, multi-arm RCTs sw.a[i,k] <- sum(w.a[i,1:k-1])/(k-1) # cumulative adjustment for multi-arm trials } } for(i in 1:ns.t){ # LOOP THROUGH STUDIES WITH TRIAL DATA w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm delta[i+ns.a,1] <- 0 # treatment effect is zero for control arm for (k in 2:na[i]) { #  LOOP THROUGH ARMS var[i,k] <- pow(se[i,k],2) # calculate variances prec[i,k] <- 1/var[i,k] # set precisions y[i,k] ~ dnorm(delta[i+ns.a,k],prec[i,k]) # normal likelihood dev[i+ns.a,k] <- (y[i,k]-delta[i+ns.a,k])* #Deviance contribution (y[i,k]-delta[i+ns.a,k])* prec[i,k] } resdev[i+ns.a] <- sum(dev[i+ns.a,2:na[i]]) #  summed residual deviance contribution for this trial for (k in 2:na[i]) { # LOOP THROUGH ARMS delta[i+ns.a,k] ~ dnorm(md[i+ns.a,k],taud[i,k]) # trial-specific LOR distributions md[i+ns.a,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] # mean of LOR distributions, with multi-arm trial correction taud[i,k] <- tau *2*(k-1)/k # precision of LOR distributions (with multi-arm trial correction) w[i,k] <- (delta[i+ns.a,k] - d[t[i,k]] + d[t[i,1]]) # adjustment, multi-arm RCTs sw[i,k] <- sum(w[i,1:k-1])/(k-1) # cumulative adjustment for multi-arm trials\n",
      "```\n",
      "\n",
      "```\n",
      "} } totresdev <- sum(resdev[]) d[1]<-0 sd ~ dunif(0,5) tau <- pow(sd,-2) }\n",
      "```\n",
      "\n",
      "```\n",
      "#Total Residual Deviance # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects # vague prior for between-trial SD # between-trial precision = (1/between-trial variance) # *** PROGRAM ENDS\n",
      "```\n",
      "\n",
      "Additional  code  to  monitor  all  treatment  contrasts,  rank  treatments  and  obtain  absolute treatment effects can be added as before.\n",
      "\n",
      "The data structure for this code consists of three parts. First, a list giving the number of studies with arm-level information, ns.a , the number of studies with trial-level information, ns.t , and the number of treatments, nt .  Two sections of column format data follow: one with the arm-level data, with the structure described for program 5(a), and another with the trial-level data and the same structure described for program 7(a).  All three data components need to be loaded into WinBUGS for the program to run. Note that, because two separate sets of data are being read into WinBUGS, the variable names referring to the arm-level data have the added suffix .a , to distinguish them from the trial-level data.\n",
      "\n",
      "```\n",
      "# Data (Parkinson's example: Arm and Trial-level data) list(ns.a=3, ns.t=4, nt=5) # Arm-level data t.a[,1] t.a[,2] t.a[,3] y.a[,1] y.a[,2] y.a[,3] se.a[,1] se.a[,2] se.a[,3] na.a[] # study 1 3 NA -1.22 -1.53 NA 0.504 0.439 NA 2 # 1 1 2 NA -0.7 -2.4 NA 0.282 0.258 NA 2 # 2 1 2 4 -0.3 -2.6 -1.2 0.505 0.510 0.478 3 # 3 END # Trial-level data t[,1] t[,2] y[,2] se[,2] na[] # study 3 4 -0.35 0.441941738 2 # 4 3 4 0.55 0.555114559 2 # 5 4 5 -0.3 0.274276316 2 # 6 4 5 -0.3 0.320087245 2 # 7 END # Initial Values # Initial values for delta can be generated by WinBUGS. #chain 1 list(d=c( NA, 0,0,0,0), sd=1, mu=c(0, 0, 0)) #chain 2 list(d=c( NA, -1,-3,-1,1), sd=4, mu=c(-3, -3, -3)) #chain 3 list(d=c( NA, 2,2,2,2), sd=2, mu=c(-3, 5, -1))\n",
      "```\n",
      "\n",
      "The parameters to monitor are the same as in Example 5.\n",
      "\n",
      "## Program 8(b):  Normal likelihood, identity link, shared parameter model, Fixed Effects (Parkinson's shared parameters)\n",
      "\n",
      "```\n",
      "# Normal likelihood, identity link, Arm and Trial-level data (treatment differences) # Fixed effects model model{ # *** PROGRAM STARTS for(i in 1:ns.a){ # LOOP THROUGH STUDIES WITH ARM DATA mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines for (k in 1:na.a[i]) { #  LOOP THROUGH ARMS var.a[i,k] <- pow(se.a[i,k],2) # calculate variances prec.a[i,k] <- 1/var.a[i,k] # set precisions y.a[i,k] ~ dnorm(theta[i,k],prec.a[i,k]) # normal likelihood theta[i,k] <- mu[i] + d[t.a[i,k]] - d[t.a[i,1]] # model for linear predictor dev[i,k] <- (y.a[i,k]-theta[i,k])*(y.a[i,k]-theta[i,k])*prec.a[i,k]    #Deviance contribution } resdev[i] <- sum(dev[i,1:na.a[i]]) #  summed residual deviance contribution for this trial } for(i in 1:ns.t){ # LOOP THROUGH STUDIES WITH TRIAL DATA for (k in 2:na[i]) { #  LOOP THROUGH ARMS var[i,k] <- pow(se[i,k],2) # calculate variances prec[i,k] <- 1/var[i,k] # set precisions y[i,k] ~ dnorm(theta[i+ns.a,k],prec[i,k]) # normal likelihood theta[i+ns.a,k] <- d[t[i,k]] - d[t[i,1]] # model for linear predictor dev[i+ns.a,k] <- (y[i,k]-theta[i+ns.a,k])* #Deviance contribution (y[i,k]-theta[i+ns.a,k])* prec[i,k] } resdev[i+ns.a] <- sum(dev[i+ns.a,2:na[i]]) #  summed residual deviance contribution for this trial } totresdev <- sum(resdev[]) #Total Residual Deviance d[1]<-0 # treatment effect is zero for reference treatment for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } # vague priors for treatment effects } # *** PROGRAM ENDS # Initial Values #chain 1 list(d=c( NA, 0,0,0,0), mu=c(0, 0, 0)) #chain 2 list(d=c( NA, -1,-3,-1,1), mu=c(-3, -3, -3)) #chain 3 list(d=c( NA, 2,2,2,2), mu=c(-3, 5, -1))\n",
      "```\n",
      "\n",
      "## R ESULTS\n",
      "\n",
      "Results (based on 3 chains: 100,000 iterations after a burn-in of 20,000 and 50,000 for the FE and Re models, respectively) are presented in Table A9 and are the same as the results obtained using the model in Example 5.\n"
     ]
    }
   ],
   "source": [
    "print(doc.document.export_to_markdown())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "d1060be1",
   "metadata": {},
   "outputs": [],
   "source": [
    "from docling.datamodel.pipeline_options import PdfPipelineOptions\n",
    "from docling.document_converter import PdfFormatOption\n",
    "\n",
    "pipeline_options = PdfPipelineOptions()\n",
    "\n",
    "pipeline_options.do_formula_enrichment = True\n",
    "\n",
    "converter = DocumentConverter(\n",
    "    format_options={\n",
    "        InputFormat.PDF: PdfFormatOption(pipeline_options=pipeline_options)\n",
    "    }\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "22d708f6",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[32m[INFO] 2026-01-28 20:03:56,773 [RapidOCR] base.py:22: Using engine_name: torch\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 20:03:56,774 [RapidOCR] device_config.py:50: Using CPU device\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 20:03:56,844 [RapidOCR] download_file.py:60: File exists and is valid: C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_det_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 20:03:56,844 [RapidOCR] main.py:50: Using C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_det_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 20:03:57,009 [RapidOCR] base.py:22: Using engine_name: torch\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 20:03:57,010 [RapidOCR] device_config.py:50: Using CPU device\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 20:03:57,034 [RapidOCR] download_file.py:60: File exists and is valid: C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_ptocr_mobile_v2.0_cls_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 20:03:57,035 [RapidOCR] main.py:50: Using C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_ptocr_mobile_v2.0_cls_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 20:03:57,092 [RapidOCR] base.py:22: Using engine_name: torch\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 20:03:57,093 [RapidOCR] device_config.py:50: Using CPU device\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 20:03:57,167 [RapidOCR] download_file.py:60: File exists and is valid: C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_rec_infer.pth\u001b[0m\n",
      "\u001b[32m[INFO] 2026-01-28 20:03:57,168 [RapidOCR] main.py:50: Using C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_rec_infer.pth\u001b[0m\n",
      "Xet Storage is enabled for this repo, but the 'hf_xet' package is not installed. Falling back to regular HTTP download. For better performance, install the package with: `pip install huggingface_hub[hf_xet]` or `pip install hf_xet`\n",
      "c:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\huggingface_hub\\file_download.py:143: UserWarning: `huggingface_hub` cache-system uses symlinks by default to efficiently store duplicated files but your machine does not support them in C:\\Users\\DevanshUpadhyay\\.cache\\huggingface\\hub\\models--docling-project--CodeFormulaV2. Caching files will still work but in a degraded version that might require more space on your disk. This warning can be disabled by setting the `HF_HUB_DISABLE_SYMLINKS_WARNING` environment variable. For more details, see https://huggingface.co/docs/huggingface_hub/how-to-cache#limitations.\n",
      "To support symlinks on Windows, you either need to activate Developer Mode or to run Python as an administrator. In order to activate developer mode, see this article: https://docs.microsoft.com/en-us/windows/apps/get-started/enable-your-device-for-development\n",
      "  warnings.warn(message)\n"
     ]
    },
    {
     "ename": "OSError",
     "evalue": "[WinError 1314] A required privilege is not held by the client: '..\\\\..\\\\blobs\\\\a6344aac8c09253b3b630fb776ae94478aa0275b' -> 'C:\\\\Users\\\\DevanshUpadhyay\\\\.cache\\\\huggingface\\\\hub\\\\models--docling-project--CodeFormulaV2\\\\snapshots\\\\ecedbe111d15c2dc60bfd4a823cbe80127b58af4\\\\.gitattributes'",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mOSError\u001b[39m                                   Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[34]\u001b[39m\u001b[32m, line 1\u001b[39m\n\u001b[32m----> \u001b[39m\u001b[32m1\u001b[39m doc = \u001b[43mconverter\u001b[49m\u001b[43m.\u001b[49m\u001b[43mconvert\u001b[49m\u001b[43m(\u001b[49m\u001b[43mfile\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\pydantic\\_internal\\_validate_call.py:39\u001b[39m, in \u001b[36mupdate_wrapper_attributes.<locals>.wrapper_function\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m     37\u001b[39m \u001b[38;5;129m@functools\u001b[39m.wraps(wrapped)\n\u001b[32m     38\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mwrapper_function\u001b[39m(*args, **kwargs):\n\u001b[32m---> \u001b[39m\u001b[32m39\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mwrapper\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\pydantic\\_internal\\_validate_call.py:136\u001b[39m, in \u001b[36mValidateCallWrapper.__call__\u001b[39m\u001b[34m(self, *args, **kwargs)\u001b[39m\n\u001b[32m    133\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28mself\u001b[39m.__pydantic_complete__:\n\u001b[32m    134\u001b[39m     \u001b[38;5;28mself\u001b[39m._create_validators()\n\u001b[32m--> \u001b[39m\u001b[32m136\u001b[39m res = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m__pydantic_validator__\u001b[49m\u001b[43m.\u001b[49m\u001b[43mvalidate_python\u001b[49m\u001b[43m(\u001b[49m\u001b[43mpydantic_core\u001b[49m\u001b[43m.\u001b[49m\u001b[43mArgsKwargs\u001b[49m\u001b[43m(\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    137\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m.__return_pydantic_validator__:\n\u001b[32m    138\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m.__return_pydantic_validator__(res)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\docling\\document_converter.py:325\u001b[39m, in \u001b[36mDocumentConverter.convert\u001b[39m\u001b[34m(self, source, headers, raises_on_error, max_num_pages, max_file_size, page_range)\u001b[39m\n\u001b[32m    293\u001b[39m \u001b[38;5;250m\u001b[39m\u001b[33;03m\"\"\"Convert one document fetched from a file path, URL, or DocumentStream.\u001b[39;00m\n\u001b[32m    294\u001b[39m \n\u001b[32m    295\u001b[39m \u001b[33;03mNote: If the document content is given as a string (Markdown or HTML\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m    315\u001b[39m \u001b[33;03m    ConversionError: An error occurred during conversion.\u001b[39;00m\n\u001b[32m    316\u001b[39m \u001b[33;03m\"\"\"\u001b[39;00m\n\u001b[32m    317\u001b[39m all_res = \u001b[38;5;28mself\u001b[39m.convert_all(\n\u001b[32m    318\u001b[39m     source=[source],\n\u001b[32m    319\u001b[39m     raises_on_error=raises_on_error,\n\u001b[32m   (...)\u001b[39m\u001b[32m    323\u001b[39m     page_range=page_range,\n\u001b[32m    324\u001b[39m )\n\u001b[32m--> \u001b[39m\u001b[32m325\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mnext\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mall_res\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\docling\\document_converter.py:368\u001b[39m, in \u001b[36mDocumentConverter.convert_all\u001b[39m\u001b[34m(self, source, headers, raises_on_error, max_num_pages, max_file_size, page_range)\u001b[39m\n\u001b[32m    365\u001b[39m conv_res_iter = \u001b[38;5;28mself\u001b[39m._convert(conv_input, raises_on_error=raises_on_error)\n\u001b[32m    367\u001b[39m had_result = \u001b[38;5;28;01mFalse\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m368\u001b[39m \u001b[43m\u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mconv_res\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mconv_res_iter\u001b[49m\u001b[43m:\u001b[49m\n\u001b[32m    369\u001b[39m \u001b[43m    \u001b[49m\u001b[43mhad_result\u001b[49m\u001b[43m \u001b[49m\u001b[43m=\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mTrue\u001b[39;49;00m\n\u001b[32m    370\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mraises_on_error\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mand\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mconv_res\u001b[49m\u001b[43m.\u001b[49m\u001b[43mstatus\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mnot\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[32m    371\u001b[39m \u001b[43m        \u001b[49m\u001b[43mConversionStatus\u001b[49m\u001b[43m.\u001b[49m\u001b[43mSUCCESS\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    372\u001b[39m \u001b[43m        \u001b[49m\u001b[43mConversionStatus\u001b[49m\u001b[43m.\u001b[49m\u001b[43mPARTIAL_SUCCESS\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    373\u001b[39m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m:\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\docling\\document_converter.py:467\u001b[39m, in \u001b[36mDocumentConverter._convert\u001b[39m\u001b[34m(self, conv_input, raises_on_error)\u001b[39m\n\u001b[32m    465\u001b[39m             \u001b[38;5;28;01myield\u001b[39;00m item\n\u001b[32m    466\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m467\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mitem\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mmap\u001b[39;49m\u001b[43m(\u001b[49m\n\u001b[32m    468\u001b[39m \u001b[43m        \u001b[49m\u001b[43mprocess_func\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    469\u001b[39m \u001b[43m        \u001b[49m\u001b[43minput_batch\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    470\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\u001b[43m:\u001b[49m\n\u001b[32m    471\u001b[39m \u001b[43m        \u001b[49m\u001b[43melapsed\u001b[49m\u001b[43m \u001b[49m\u001b[43m=\u001b[49m\u001b[43m \u001b[49m\u001b[43mtime\u001b[49m\u001b[43m.\u001b[49m\u001b[43mmonotonic\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m \u001b[49m\u001b[43m-\u001b[49m\u001b[43m \u001b[49m\u001b[43mstart_time\u001b[49m\n\u001b[32m    472\u001b[39m \u001b[43m        \u001b[49m\u001b[43mstart_time\u001b[49m\u001b[43m \u001b[49m\u001b[43m=\u001b[49m\u001b[43m \u001b[49m\u001b[43mtime\u001b[49m\u001b[43m.\u001b[49m\u001b[43mmonotonic\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\docling\\document_converter.py:514\u001b[39m, in \u001b[36mDocumentConverter._process_document\u001b[39m\u001b[34m(self, in_doc, raises_on_error)\u001b[39m\n\u001b[32m    510\u001b[39m valid = (\n\u001b[32m    511\u001b[39m     \u001b[38;5;28mself\u001b[39m.allowed_formats \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;129;01mand\u001b[39;00m in_doc.format \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m.allowed_formats\n\u001b[32m    512\u001b[39m )\n\u001b[32m    513\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m valid:\n\u001b[32m--> \u001b[39m\u001b[32m514\u001b[39m     conv_res = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_execute_pipeline\u001b[49m\u001b[43m(\u001b[49m\u001b[43min_doc\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mraises_on_error\u001b[49m\u001b[43m=\u001b[49m\u001b[43mraises_on_error\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    515\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m    516\u001b[39m     error_message = \u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33mFile format not allowed: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00min_doc.file\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m\"\u001b[39m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\docling\\document_converter.py:535\u001b[39m, in \u001b[36mDocumentConverter._execute_pipeline\u001b[39m\u001b[34m(self, in_doc, raises_on_error)\u001b[39m\n\u001b[32m    531\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m_execute_pipeline\u001b[39m(\n\u001b[32m    532\u001b[39m     \u001b[38;5;28mself\u001b[39m, in_doc: InputDocument, raises_on_error: \u001b[38;5;28mbool\u001b[39m\n\u001b[32m    533\u001b[39m ) -> ConversionResult:\n\u001b[32m    534\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m in_doc.valid:\n\u001b[32m--> \u001b[39m\u001b[32m535\u001b[39m         pipeline = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_get_pipeline\u001b[49m\u001b[43m(\u001b[49m\u001b[43min_doc\u001b[49m\u001b[43m.\u001b[49m\u001b[43mformat\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    536\u001b[39m         \u001b[38;5;28;01mif\u001b[39;00m pipeline \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[32m    537\u001b[39m             conv_res = pipeline.execute(in_doc, raises_on_error=raises_on_error)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\docling\\document_converter.py:497\u001b[39m, in \u001b[36mDocumentConverter._get_pipeline\u001b[39m\u001b[34m(self, doc_format)\u001b[39m\n\u001b[32m    493\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m cache_key \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m.initialized_pipelines:\n\u001b[32m    494\u001b[39m     _log.info(\n\u001b[32m    495\u001b[39m         \u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33mInitializing pipeline for \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mpipeline_class.\u001b[34m__name__\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m with options hash \u001b[39m\u001b[38;5;132;01m{\u001b[39;00moptions_hash\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m\"\u001b[39m\n\u001b[32m    496\u001b[39m     )\n\u001b[32m--> \u001b[39m\u001b[32m497\u001b[39m     \u001b[38;5;28mself\u001b[39m.initialized_pipelines[cache_key] = \u001b[43mpipeline_class\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    498\u001b[39m \u001b[43m        \u001b[49m\u001b[43mpipeline_options\u001b[49m\u001b[43m=\u001b[49m\u001b[43mpipeline_options\u001b[49m\n\u001b[32m    499\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    500\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m    501\u001b[39m     _log.debug(\n\u001b[32m    502\u001b[39m         \u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33mReusing cached pipeline for \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mpipeline_class.\u001b[34m__name__\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m with options hash \u001b[39m\u001b[38;5;132;01m{\u001b[39;00moptions_hash\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m\"\u001b[39m\n\u001b[32m    503\u001b[39m     )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\docling\\pipeline\\standard_pdf_pipeline.py:438\u001b[39m, in \u001b[36mStandardPdfPipeline.__init__\u001b[39m\u001b[34m(self, pipeline_options)\u001b[39m\n\u001b[32m    435\u001b[39m \u001b[38;5;28mself\u001b[39m._run_seq = itertools.count(\u001b[32m1\u001b[39m)  \u001b[38;5;66;03m# deterministic, monotonic run ids\u001b[39;00m\n\u001b[32m    437\u001b[39m \u001b[38;5;66;03m# initialise heavy models once\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m438\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_init_models\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\docling\\pipeline\\standard_pdf_pipeline.py:480\u001b[39m, in \u001b[36mStandardPdfPipeline._init_models\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m    475\u001b[39m \u001b[38;5;28mself\u001b[39m.reading_order_model = ReadingOrderModel(options=ReadingOrderOptions())\n\u001b[32m    477\u001b[39m \u001b[38;5;66;03m# --- optional enrichment ------------------------------------------------\u001b[39;00m\n\u001b[32m    478\u001b[39m \u001b[38;5;28mself\u001b[39m.enrichment_pipe = [\n\u001b[32m    479\u001b[39m     \u001b[38;5;66;03m# Code Formula Enrichment Model\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m480\u001b[39m     \u001b[43mCodeFormulaModel\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    481\u001b[39m \u001b[43m        \u001b[49m\u001b[43menabled\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mpipeline_options\u001b[49m\u001b[43m.\u001b[49m\u001b[43mdo_code_enrichment\u001b[49m\n\u001b[32m    482\u001b[39m \u001b[43m        \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mpipeline_options\u001b[49m\u001b[43m.\u001b[49m\u001b[43mdo_formula_enrichment\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    483\u001b[39m \u001b[43m        \u001b[49m\u001b[43martifacts_path\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43martifacts_path\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    484\u001b[39m \u001b[43m        \u001b[49m\u001b[43moptions\u001b[49m\u001b[43m=\u001b[49m\u001b[43mCodeFormulaModelOptions\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    485\u001b[39m \u001b[43m            \u001b[49m\u001b[43mdo_code_enrichment\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mpipeline_options\u001b[49m\u001b[43m.\u001b[49m\u001b[43mdo_code_enrichment\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    486\u001b[39m \u001b[43m            \u001b[49m\u001b[43mdo_formula_enrichment\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mpipeline_options\u001b[49m\u001b[43m.\u001b[49m\u001b[43mdo_formula_enrichment\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    487\u001b[39m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    488\u001b[39m \u001b[43m        \u001b[49m\u001b[43maccelerator_options\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mpipeline_options\u001b[49m\u001b[43m.\u001b[49m\u001b[43maccelerator_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    489\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m,\n\u001b[32m    490\u001b[39m     *\u001b[38;5;28mself\u001b[39m.enrichment_pipe,\n\u001b[32m    491\u001b[39m ]\n\u001b[32m    493\u001b[39m \u001b[38;5;28mself\u001b[39m.keep_backend = \u001b[38;5;28many\u001b[39m(\n\u001b[32m    494\u001b[39m     (\n\u001b[32m    495\u001b[39m         \u001b[38;5;28mself\u001b[39m.pipeline_options.do_formula_enrichment,\n\u001b[32m   (...)\u001b[39m\u001b[32m    499\u001b[39m     )\n\u001b[32m    500\u001b[39m )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\docling\\models\\stages\\code_formula\\code_formula_model.py:107\u001b[39m, in \u001b[36mCodeFormulaModel.__init__\u001b[39m\u001b[34m(self, enabled, artifacts_path, options, accelerator_options)\u001b[39m\n\u001b[32m     97\u001b[39m \u001b[38;5;28mself\u001b[39m.device = decide_device(\n\u001b[32m     98\u001b[39m     accelerator_options.device,\n\u001b[32m     99\u001b[39m     supported_devices=[\n\u001b[32m   (...)\u001b[39m\u001b[32m    103\u001b[39m     ],\n\u001b[32m    104\u001b[39m )\n\u001b[32m    106\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m artifacts_path \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m107\u001b[39m     artifacts_path = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mdownload_models\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    108\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m    109\u001b[39m     artifacts_path = artifacts_path / \u001b[38;5;28mself\u001b[39m._model_repo_folder\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\docling\\models\\stages\\code_formula\\code_formula_model.py:128\u001b[39m, in \u001b[36mCodeFormulaModel.download_models\u001b[39m\u001b[34m(local_dir, force, progress)\u001b[39m\n\u001b[32m    122\u001b[39m \u001b[38;5;129m@staticmethod\u001b[39m\n\u001b[32m    123\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mdownload_models\u001b[39m(\n\u001b[32m    124\u001b[39m     local_dir: Optional[Path] = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m    125\u001b[39m     force: \u001b[38;5;28mbool\u001b[39m = \u001b[38;5;28;01mFalse\u001b[39;00m,\n\u001b[32m    126\u001b[39m     progress: \u001b[38;5;28mbool\u001b[39m = \u001b[38;5;28;01mFalse\u001b[39;00m,\n\u001b[32m    127\u001b[39m ) -> Path:\n\u001b[32m--> \u001b[39m\u001b[32m128\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mdownload_hf_model\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    129\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrepo_id\u001b[49m\u001b[43m=\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mdocling-project/CodeFormulaV2\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m    130\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrevision\u001b[49m\u001b[43m=\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmain\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m    131\u001b[39m \u001b[43m        \u001b[49m\u001b[43mlocal_dir\u001b[49m\u001b[43m=\u001b[49m\u001b[43mlocal_dir\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    132\u001b[39m \u001b[43m        \u001b[49m\u001b[43mforce\u001b[49m\u001b[43m=\u001b[49m\u001b[43mforce\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    133\u001b[39m \u001b[43m        \u001b[49m\u001b[43mprogress\u001b[49m\u001b[43m=\u001b[49m\u001b[43mprogress\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    134\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\docling\\models\\utils\\hf_model_download.py:20\u001b[39m, in \u001b[36mdownload_hf_model\u001b[39m\u001b[34m(repo_id, local_dir, force, progress, revision)\u001b[39m\n\u001b[32m     18\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m progress:\n\u001b[32m     19\u001b[39m     disable_progress_bars()\n\u001b[32m---> \u001b[39m\u001b[32m20\u001b[39m download_path = \u001b[43msnapshot_download\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m     21\u001b[39m \u001b[43m    \u001b[49m\u001b[43mrepo_id\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrepo_id\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m     22\u001b[39m \u001b[43m    \u001b[49m\u001b[43mforce_download\u001b[49m\u001b[43m=\u001b[49m\u001b[43mforce\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m     23\u001b[39m \u001b[43m    \u001b[49m\u001b[43mlocal_dir\u001b[49m\u001b[43m=\u001b[49m\u001b[43mlocal_dir\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m     24\u001b[39m \u001b[43m    \u001b[49m\u001b[43mrevision\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrevision\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m     25\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     27\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m Path(download_path)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\huggingface_hub\\utils\\_validators.py:114\u001b[39m, in \u001b[36mvalidate_hf_hub_args.<locals>._inner_fn\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    111\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m check_use_auth_token:\n\u001b[32m    112\u001b[39m     kwargs = smoothly_deprecate_use_auth_token(fn_name=fn.\u001b[34m__name__\u001b[39m, has_token=has_token, kwargs=kwargs)\n\u001b[32m--> \u001b[39m\u001b[32m114\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfn\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\huggingface_hub\\_snapshot_download.py:332\u001b[39m, in \u001b[36msnapshot_download\u001b[39m\u001b[34m(repo_id, repo_type, revision, cache_dir, local_dir, library_name, library_version, user_agent, proxies, etag_timeout, force_download, token, local_files_only, allow_patterns, ignore_patterns, max_workers, tqdm_class, headers, endpoint, local_dir_use_symlinks, resume_download)\u001b[39m\n\u001b[32m    330\u001b[39m         _inner_hf_hub_download(file)\n\u001b[32m    331\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m332\u001b[39m     \u001b[43mthread_map\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    333\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_inner_hf_hub_download\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    334\u001b[39m \u001b[43m        \u001b[49m\u001b[43mfiltered_repo_files\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    335\u001b[39m \u001b[43m        \u001b[49m\u001b[43mdesc\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtqdm_desc\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    336\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmax_workers\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmax_workers\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    337\u001b[39m \u001b[43m        \u001b[49m\u001b[38;5;66;43;03m# User can use its own tqdm class or the default one from `huggingface_hub.utils`\u001b[39;49;00m\n\u001b[32m    338\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtqdm_class\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtqdm_class\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mhf_tqdm\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    339\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    341\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m local_dir \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[32m    342\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mstr\u001b[39m(os.path.realpath(local_dir))\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\tqdm\\contrib\\concurrent.py:69\u001b[39m, in \u001b[36mthread_map\u001b[39m\u001b[34m(fn, *iterables, **tqdm_kwargs)\u001b[39m\n\u001b[32m     55\u001b[39m \u001b[38;5;250m\u001b[39m\u001b[33;03m\"\"\"\u001b[39;00m\n\u001b[32m     56\u001b[39m \u001b[33;03mEquivalent of `list(map(fn, *iterables))`\u001b[39;00m\n\u001b[32m     57\u001b[39m \u001b[33;03mdriven by `concurrent.futures.ThreadPoolExecutor`.\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m     66\u001b[39m \u001b[33;03m    [default: max(32, cpu_count() + 4)].\u001b[39;00m\n\u001b[32m     67\u001b[39m \u001b[33;03m\"\"\"\u001b[39;00m\n\u001b[32m     68\u001b[39m \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34;01mconcurrent\u001b[39;00m\u001b[34;01m.\u001b[39;00m\u001b[34;01mfutures\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mimport\u001b[39;00m ThreadPoolExecutor\n\u001b[32m---> \u001b[39m\u001b[32m69\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43m_executor_map\u001b[49m\u001b[43m(\u001b[49m\u001b[43mThreadPoolExecutor\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mfn\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43miterables\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mtqdm_kwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\tqdm\\contrib\\concurrent.py:51\u001b[39m, in \u001b[36m_executor_map\u001b[39m\u001b[34m(PoolExecutor, fn, *iterables, **tqdm_kwargs)\u001b[39m\n\u001b[32m     47\u001b[39m \u001b[38;5;28;01mwith\u001b[39;00m ensure_lock(tqdm_class, lock_name=lock_name) \u001b[38;5;28;01mas\u001b[39;00m lk:\n\u001b[32m     48\u001b[39m     \u001b[38;5;66;03m# share lock in case workers are already using `tqdm`\u001b[39;00m\n\u001b[32m     49\u001b[39m     \u001b[38;5;28;01mwith\u001b[39;00m PoolExecutor(max_workers=max_workers, initializer=tqdm_class.set_lock,\n\u001b[32m     50\u001b[39m                       initargs=(lk,)) \u001b[38;5;28;01mas\u001b[39;00m ex:\n\u001b[32m---> \u001b[39m\u001b[32m51\u001b[39m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mlist\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mtqdm_class\u001b[49m\u001b[43m(\u001b[49m\u001b[43mex\u001b[49m\u001b[43m.\u001b[49m\u001b[43mmap\u001b[49m\u001b[43m(\u001b[49m\u001b[43mfn\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43miterables\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mchunksize\u001b[49m\u001b[43m=\u001b[49m\u001b[43mchunksize\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\tqdm\\std.py:1169\u001b[39m, in \u001b[36mtqdm.__iter__\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m   1166\u001b[39m \u001b[38;5;66;03m# If the bar is disabled, then just walk the iterable\u001b[39;00m\n\u001b[32m   1167\u001b[39m \u001b[38;5;66;03m# (note: keep this check outside the loop for performance)\u001b[39;00m\n\u001b[32m   1168\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m.disable:\n\u001b[32m-> \u001b[39m\u001b[32m1169\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mobj\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43miterable\u001b[49m\u001b[43m:\u001b[49m\n\u001b[32m   1170\u001b[39m \u001b[43m        \u001b[49m\u001b[38;5;28;43;01myield\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mobj\u001b[49m\n\u001b[32m   1171\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mC:\\Program Files\\Python313\\Lib\\concurrent\\futures\\_base.py:619\u001b[39m, in \u001b[36mExecutor.map.<locals>.result_iterator\u001b[39m\u001b[34m()\u001b[39m\n\u001b[32m    616\u001b[39m \u001b[38;5;28;01mwhile\u001b[39;00m fs:\n\u001b[32m    617\u001b[39m     \u001b[38;5;66;03m# Careful not to keep a reference to the popped future\u001b[39;00m\n\u001b[32m    618\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m timeout \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m619\u001b[39m         \u001b[38;5;28;01myield\u001b[39;00m \u001b[43m_result_or_cancel\u001b[49m\u001b[43m(\u001b[49m\u001b[43mfs\u001b[49m\u001b[43m.\u001b[49m\u001b[43mpop\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    620\u001b[39m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m    621\u001b[39m         \u001b[38;5;28;01myield\u001b[39;00m _result_or_cancel(fs.pop(), end_time - time.monotonic())\n",
      "\u001b[36mFile \u001b[39m\u001b[32mC:\\Program Files\\Python313\\Lib\\concurrent\\futures\\_base.py:317\u001b[39m, in \u001b[36m_result_or_cancel\u001b[39m\u001b[34m(***failed resolving arguments***)\u001b[39m\n\u001b[32m    315\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m    316\u001b[39m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m317\u001b[39m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfut\u001b[49m\u001b[43m.\u001b[49m\u001b[43mresult\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    318\u001b[39m     \u001b[38;5;28;01mfinally\u001b[39;00m:\n\u001b[32m    319\u001b[39m         fut.cancel()\n",
      "\u001b[36mFile \u001b[39m\u001b[32mC:\\Program Files\\Python313\\Lib\\concurrent\\futures\\_base.py:456\u001b[39m, in \u001b[36mFuture.result\u001b[39m\u001b[34m(self, timeout)\u001b[39m\n\u001b[32m    454\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m CancelledError()\n\u001b[32m    455\u001b[39m \u001b[38;5;28;01melif\u001b[39;00m \u001b[38;5;28mself\u001b[39m._state == FINISHED:\n\u001b[32m--> \u001b[39m\u001b[32m456\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m__get_result\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    457\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m    458\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTimeoutError\u001b[39;00m()\n",
      "\u001b[36mFile \u001b[39m\u001b[32mC:\\Program Files\\Python313\\Lib\\concurrent\\futures\\_base.py:401\u001b[39m, in \u001b[36mFuture.__get_result\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m    399\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m._exception \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[32m    400\u001b[39m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m401\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m._exception\n\u001b[32m    402\u001b[39m     \u001b[38;5;28;01mfinally\u001b[39;00m:\n\u001b[32m    403\u001b[39m         \u001b[38;5;66;03m# Break a reference cycle with the exception in self._exception\u001b[39;00m\n\u001b[32m    404\u001b[39m         \u001b[38;5;28mself\u001b[39m = \u001b[38;5;28;01mNone\u001b[39;00m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mC:\\Program Files\\Python313\\Lib\\concurrent\\futures\\thread.py:59\u001b[39m, in \u001b[36m_WorkItem.run\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m     56\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m\n\u001b[32m     58\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m---> \u001b[39m\u001b[32m59\u001b[39m     result = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mfn\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     60\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m exc:\n\u001b[32m     61\u001b[39m     \u001b[38;5;28mself\u001b[39m.future.set_exception(exc)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\huggingface_hub\\_snapshot_download.py:306\u001b[39m, in \u001b[36msnapshot_download.<locals>._inner_hf_hub_download\u001b[39m\u001b[34m(repo_file)\u001b[39m\n\u001b[32m    305\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m_inner_hf_hub_download\u001b[39m(repo_file: \u001b[38;5;28mstr\u001b[39m):\n\u001b[32m--> \u001b[39m\u001b[32m306\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mhf_hub_download\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    307\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrepo_id\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    308\u001b[39m \u001b[43m        \u001b[49m\u001b[43mfilename\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrepo_file\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    309\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrepo_type\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrepo_type\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    310\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrevision\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcommit_hash\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    311\u001b[39m \u001b[43m        \u001b[49m\u001b[43mendpoint\u001b[49m\u001b[43m=\u001b[49m\u001b[43mendpoint\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    312\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcache_dir\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcache_dir\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    313\u001b[39m \u001b[43m        \u001b[49m\u001b[43mlocal_dir\u001b[49m\u001b[43m=\u001b[49m\u001b[43mlocal_dir\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    314\u001b[39m \u001b[43m        \u001b[49m\u001b[43mlocal_dir_use_symlinks\u001b[49m\u001b[43m=\u001b[49m\u001b[43mlocal_dir_use_symlinks\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    315\u001b[39m \u001b[43m        \u001b[49m\u001b[43mlibrary_name\u001b[49m\u001b[43m=\u001b[49m\u001b[43mlibrary_name\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    316\u001b[39m \u001b[43m        \u001b[49m\u001b[43mlibrary_version\u001b[49m\u001b[43m=\u001b[49m\u001b[43mlibrary_version\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    317\u001b[39m \u001b[43m        \u001b[49m\u001b[43muser_agent\u001b[49m\u001b[43m=\u001b[49m\u001b[43muser_agent\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    318\u001b[39m \u001b[43m        \u001b[49m\u001b[43mproxies\u001b[49m\u001b[43m=\u001b[49m\u001b[43mproxies\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    319\u001b[39m \u001b[43m        \u001b[49m\u001b[43metag_timeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43metag_timeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    320\u001b[39m \u001b[43m        \u001b[49m\u001b[43mresume_download\u001b[49m\u001b[43m=\u001b[49m\u001b[43mresume_download\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    321\u001b[39m \u001b[43m        \u001b[49m\u001b[43mforce_download\u001b[49m\u001b[43m=\u001b[49m\u001b[43mforce_download\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    322\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtoken\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtoken\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    323\u001b[39m \u001b[43m        \u001b[49m\u001b[43mheaders\u001b[49m\u001b[43m=\u001b[49m\u001b[43mheaders\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    324\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\huggingface_hub\\utils\\_validators.py:114\u001b[39m, in \u001b[36mvalidate_hf_hub_args.<locals>._inner_fn\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    111\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m check_use_auth_token:\n\u001b[32m    112\u001b[39m     kwargs = smoothly_deprecate_use_auth_token(fn_name=fn.\u001b[34m__name__\u001b[39m, has_token=has_token, kwargs=kwargs)\n\u001b[32m--> \u001b[39m\u001b[32m114\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfn\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\huggingface_hub\\file_download.py:1007\u001b[39m, in \u001b[36mhf_hub_download\u001b[39m\u001b[34m(repo_id, filename, subfolder, repo_type, revision, library_name, library_version, cache_dir, local_dir, user_agent, force_download, proxies, etag_timeout, token, local_files_only, headers, endpoint, resume_download, force_filename, local_dir_use_symlinks)\u001b[39m\n\u001b[32m    987\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m _hf_hub_download_to_local_dir(\n\u001b[32m    988\u001b[39m         \u001b[38;5;66;03m# Destination\u001b[39;00m\n\u001b[32m    989\u001b[39m         local_dir=local_dir,\n\u001b[32m   (...)\u001b[39m\u001b[32m   1004\u001b[39m         local_files_only=local_files_only,\n\u001b[32m   1005\u001b[39m     )\n\u001b[32m   1006\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m-> \u001b[39m\u001b[32m1007\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43m_hf_hub_download_to_cache_dir\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1008\u001b[39m \u001b[43m        \u001b[49m\u001b[38;5;66;43;03m# Destination\u001b[39;49;00m\n\u001b[32m   1009\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcache_dir\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcache_dir\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1010\u001b[39m \u001b[43m        \u001b[49m\u001b[38;5;66;43;03m# File info\u001b[39;49;00m\n\u001b[32m   1011\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrepo_id\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrepo_id\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1012\u001b[39m \u001b[43m        \u001b[49m\u001b[43mfilename\u001b[49m\u001b[43m=\u001b[49m\u001b[43mfilename\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1013\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrepo_type\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrepo_type\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1014\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrevision\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrevision\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1015\u001b[39m \u001b[43m        \u001b[49m\u001b[38;5;66;43;03m# HTTP info\u001b[39;49;00m\n\u001b[32m   1016\u001b[39m \u001b[43m        \u001b[49m\u001b[43mendpoint\u001b[49m\u001b[43m=\u001b[49m\u001b[43mendpoint\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1017\u001b[39m \u001b[43m        \u001b[49m\u001b[43metag_timeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43metag_timeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1018\u001b[39m \u001b[43m        \u001b[49m\u001b[43mheaders\u001b[49m\u001b[43m=\u001b[49m\u001b[43mhf_headers\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1019\u001b[39m \u001b[43m        \u001b[49m\u001b[43mproxies\u001b[49m\u001b[43m=\u001b[49m\u001b[43mproxies\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1020\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtoken\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtoken\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1021\u001b[39m \u001b[43m        \u001b[49m\u001b[38;5;66;43;03m# Additional options\u001b[39;49;00m\n\u001b[32m   1022\u001b[39m \u001b[43m        \u001b[49m\u001b[43mlocal_files_only\u001b[49m\u001b[43m=\u001b[49m\u001b[43mlocal_files_only\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1023\u001b[39m \u001b[43m        \u001b[49m\u001b[43mforce_download\u001b[49m\u001b[43m=\u001b[49m\u001b[43mforce_download\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1024\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\huggingface_hub\\file_download.py:1181\u001b[39m, in \u001b[36m_hf_hub_download_to_cache_dir\u001b[39m\u001b[34m(cache_dir, repo_id, filename, repo_type, revision, endpoint, etag_timeout, headers, proxies, token, local_files_only, force_download)\u001b[39m\n\u001b[32m   1168\u001b[39m     _download_to_tmp_and_move(\n\u001b[32m   1169\u001b[39m         incomplete_path=Path(blob_path + \u001b[33m\"\u001b[39m\u001b[33m.incomplete\u001b[39m\u001b[33m\"\u001b[39m),\n\u001b[32m   1170\u001b[39m         destination_path=Path(blob_path),\n\u001b[32m   (...)\u001b[39m\u001b[32m   1178\u001b[39m         xet_file_data=xet_file_data,\n\u001b[32m   1179\u001b[39m     )\n\u001b[32m   1180\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m os.path.exists(pointer_path):\n\u001b[32m-> \u001b[39m\u001b[32m1181\u001b[39m         \u001b[43m_create_symlink\u001b[49m\u001b[43m(\u001b[49m\u001b[43mblob_path\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mpointer_path\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mnew_blob\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43;01mTrue\u001b[39;49;00m\u001b[43m)\u001b[49m\n\u001b[32m   1183\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m pointer_path\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\huggingface_hub\\file_download.py:731\u001b[39m, in \u001b[36m_create_symlink\u001b[39m\u001b[34m(src, dst, new_blob)\u001b[39m\n\u001b[32m    729\u001b[39m logger.debug(\u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33mCreating pointer from \u001b[39m\u001b[38;5;132;01m{\u001b[39;00msrc_rel_or_abs\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m to \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mabs_dst\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m\"\u001b[39m)\n\u001b[32m    730\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m731\u001b[39m     \u001b[43mos\u001b[49m\u001b[43m.\u001b[49m\u001b[43msymlink\u001b[49m\u001b[43m(\u001b[49m\u001b[43msrc_rel_or_abs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mabs_dst\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    732\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m\n\u001b[32m    733\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mFileExistsError\u001b[39;00m:\n",
      "\u001b[31mOSError\u001b[39m: [WinError 1314] A required privilege is not held by the client: '..\\\\..\\\\blobs\\\\a6344aac8c09253b3b630fb776ae94478aa0275b' -> 'C:\\\\Users\\\\DevanshUpadhyay\\\\.cache\\\\huggingface\\\\hub\\\\models--docling-project--CodeFormulaV2\\\\snapshots\\\\ecedbe111d15c2dc60bfd4a823cbe80127b58af4\\\\.gitattributes'"
     ]
    }
   ],
   "source": [
    "doc = converter.convert(file)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3f402faf",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "MAR (3.13.11)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
